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Chapter 1 
GENERAL INTRODUCTION 
AND OUTLINE OF THE THESIS 
1 
1. CHOLECYSTOKININ 
History 
In 1928, Ivy and Oldberg observed that an extract of the proximal small 
intestinal mucosa induced gallbladder contraction when administered intravenously 
to dogs.1 Because of this property the substance was named cholecystokinin, i.e. 
"that which excites or moves the gallbladder". Using comparable techniques, 
Harper and Raper discovered in 1943 that an extract of the intestinal mucosa was 
able to stimulate secretion of enzymes from the pancreas.2 They named this 
substance pancreozymin (PZ). With the purification of a peptide that possessed 
both cholecystokinin and pancreozymin activities by Jorpes and Mutt in 1968, it 
became clear that cholecystokinin and pancreozymin were in fact the same hor-
mone.3·4 The combined name "cholecystokinin-pancreozymin" (CCK-PZ) was 
subsequently used to describe this hormone with dual activities. In 1970, Grossman 
suggested to use the name cholecystokinin (CCK) instead of CCK-PZ.5 Subse-
quently, the development of specific and sensitive radioimmunoassays made it 
possible to measure CCK in tissue and plasma and to study its relevance in 
humans.6,7 
Molecular forms of CCK 
Multiple molecular forms of CCK (CCK58, CCK39, CCK33, CCK22 and 
CCKg) are present in human plasma.8 All these molecular forms are derived from 
the same prepro-peptide of 115 amino acids by posttranslational processing.9 The 
human gene, that encodes for this prepro-CCK is located on chromosome-3.lu 
CCK58 is presenüy the longest biologically active molecular form of CCK known. 
Smaller molecular forms are the result of further cleavage of CCK58." Following a 
meal, the most important molecular forms present in plasma include CCK58, 
CCK39/33 and intermediate forms between CCK33 and CCK8, whereas CCK„ is 
probably not an important circulating molecular form, since this peptide is effec-
tively extracted from the circulation by the liver. 
The 5 most common CCK-forms all possess the same amidated C-terminal 
pentapeptide (Gly-Trp-Met-Asp-Phe-NH2), a pentapeptide that is the same in both 
CCK and gastrin. The pentapeptide is preceded by a sulfated (*) tyrosine region (-
Tyr*-Met-). This sulfated Tyr at position 7 from the C-terminus is essential for 
binding to specific CCK receptors on gallbladder and pancreas. Desulfation 
decreases CCK-bioactivity a 100-fold and results in gastrin like activity of the CCK 
molecule.6·712 
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Distribution in tissue 
CCK is released from I-cells present in the mucosa of the small intestine.13 
The number of CCK producing cells is the highest in the duodenum and proximal 
jejunum but gradually decreases towards the ileum.14 Within these I-cells CCK is 
present in secretory granules.15 In small intestinal tissue, large molecular forms 
(CCK33, CCK39, CCKjg) and intermediate molecular forms of CCK (between 
CCK33 and CCKg) predominate.7 '6 CCK is not only present in I-cells in the small 
intestine, but also in neurons throughout the nervous system.7 In brain tissue CCK„ 
predominates, but other forms are also present.718 There are no CCK containing 
neurons in stomach, duodenum and jejunum, but the colon and ileum contain a 
major part of the CCK-neurons present in the Gl-tract. Neuronal CCK in the GI-
tract is believed to stimulate acetylcholine release, causing smooth muscle contrac-
tion. '9 Therefore, CCK not only acts as a hormone, but also as a neurotransmitter. 
Furthermore, CCK has also been demonstrated in other cells like in the pituitary 
and adrenal glands. The relevance of CCK in these cells has yet to be determined.17 
CCK receptors 
CCK receptors are mainly present in pancreas, gallbladder, stomach, ileum, 
lower esophageal sphincter and colon.20'23 Furthermore, CCK receptors have been 
identified in the brain and on periferal nerves.20,24 
In general 2 types of CCK receptors can be distinguished, type A(limentary) 
and type B(rain). The type-A receptor has a high affinity for molecular forms of 
CCK that contain at least 8 amino-acids including sulfated tyrosine. This receptor is 
present throughout the Gl-tract but predominantly in gallbladder and pancreas.25 
Type B-receptors are predominantly found in the brain and in the stomach and 
nearly have equal affinity for CCK-8, desulfated CCK-8, CCK-4 and gastrin.24 
Physiological actions in the gut 
Effects of CCK on the gastrointestinal tract are numerous. Because of the 
availability of sensitive and specific radioimmunoassays for CCK and specific CCK 
receptor antagonists for use in humans, much insight into the physiological 
relevance of this peptide has been gained in recent years. 
Gallbladder motility 
It is generally accepted thet CCK is the most important hormonal regulator 
of gallbladder motility.26"28 Studies with specific CCK-receptor antagonists have 
provided final evidence for the important regulatory role of CCK in gallbladder 
motility.29,30'32 The effect of CCK on gallbladder motility is mediated by type-A 
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receptors 2 I ? 3 33 34 During infusion or synthetic CCK, causing plasma CCK levels as 
found after a meal, or during infusion of bombesin (BBS), comparable effects on 
gallbladder contraction were observed as during meal- and BBS stimulation 31 " 3 6 
In addition, the correlation between plasma CCK levels and gallbladder contraction 
is excellent2 8 3 1 3 2 3 7 
Although a direct effect of CCK on gallbladder motility has been demon 
strated in vitro, the effect of CCK on gallbladder motility in vivo is at least in part 
explained by the presence of CCK receptors on cholinergic nerve endings in the 
gallbladder 38 39 
Next to gallbladder motility, sphincter of Oddi pressure is probably also 
regulated by CCK Physiological amounts of CCK cause the spincler to relax as 
was demonstrated by several studies performed in different speciesi0A1 The 
physiological effect of CCK on sphincter of Oddi pressure is probably also 
explained by the presence of specific CCK receptors on cholinergic nerve fibers 
within the sphincter Specific receptors for CCK have also been demonstrated on 
muscle cells in the sphincter, but these receptors are only activated by high, 
probably supraphysiological concentrations of CCK 
Pancreatic exocrine and endocrine secretion 
Postprandial plasma CCK levels effectively stimulate pancreatic exocrine 
secretion 43 However, regulation of pancreatic enzyme secretion after a meal is a 
combined effect of both humoral and neural stimulation (see chapter on the 
pancreas) 
CCK is only a weak effector of bicarbonate release, but has a potentiating 
effect on secretin stimulated pancreatic bicarbonate secretion 46 "7 
CCK also stimulates the release of insulin,48 although the insulin stimulating 
effect could not be blocked by specific CCK-A receptor antagonists,4950 indicating 
that other receptors, probably the type-B receptor, are of importance for this effect 
Pancreatic polypeptide (PP) release is also enhanced by CCK 49 " CCK is 
believed to be responsible for an important part of PP release during the intestinal 
phase of a meal 
There is some evidence in animal studies for an inhibiting effect of somatos 
tatui (released by D-cells) on CCK release Intravenous infusion of ССК
Я
 into rats 
caused a rise m somatostatin levels in the portal vein and decreased gastric acid 
secretion 53 The decrease in gastric acid secretion could be blocked by infusion of a 
somatostatin antibody Furthermore, CCK is able to release somatostatin from the 
isolated perfused canine pancreas/4 whereas canine D-cells release somatostatin in 
response to low concentrations of CCK m vitro 55 The release of SST may suppress 
further CCK release, since SST has been demonstrated to inhibit CCK release and 
the effect of CCK on target organs 
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Effects on pancreatic growth and cell proliferation 
In rats, repeated injections of CCK analogues or feeding of trypsin inhibitors 
stimulates pancreatic growth.56 This growth stimulating effect includes both 
hypertrophy and hyperplasia and can be prevented by CCK-A receptor antagonists 
in the mouse and rat.57,58 Administration of higher doses of CCK in these animals 
causes pancreatitis, which can also be prevented by CCK receptor antagonists.5960 
Presently, no data are available on the effect of CCK on human pancreatic cell 
growth in vivo. Indirect evidence for a trophic effect of CCK on the human 
pancreas comes from studies in coeliac disease, where it has been demonstrated 
that postprandial CCK release is attenuated and where pancreatic atrophy has been 
observed. 
Trophic effects of CCK have been shown on human cancer cell lines derived 
from pancreatic exocrine glands or ducts.61 In rats CCK also seems to stimulate 
pancreatic acinar cell growth.62 These stimulating effects of CCK can be blocked 
by specific type-A receptor antagonists.63 
Effects on gastric emptying and intestinal motility 
In several species including man, CCK is known to inhibit gastric emptying 
by both relaxation of the proximal part of the stomach and contraction of the 
pyloric sphincter.6467 Even low circulating levels of CCK have been shown to be 
effective.68 Although CCK receptors have been identified in the human pyloric 
sphincter,69 conflicting results emerged from studies using CCK receptor an-
tagonists. Either an accelerated gastric emptying rate3068 or no effect32 was ob-
served following CCK receptor blockage after a test meal. Therefore, factors other 
than CCK also participate in the regulation of gastric emptying. Nevertheless, 
circulating CCK levels probably inhibit gastric emptying of a test meal, which may 
contribute to attenuation of postprandial CCK release. In studies on the effect of a 
test meal on gastrointestinal functions like gallbladder contraction and pancreatic 
enzyme secretion, variability in gastric emptying rates might therefore act as a 
confounding factor. By administering a meal intraduodenal I y at the same rate of 
undisturbed gastric emptying (3-5 mL/min), this confounding factor can be 
excluded. 
CCK probably affects intestinal motility through different pathways. Firstly, 
CCK may act through neural pathways (release of acetylcholine by parasympathetic 
nerves) and secondly, CCK might bind directly to specific receptors on the 
intestinal muscle.1970 Under physiological conditions these effects result in a 
decreased transit time and attenuated contraction of intestinal muscles. 
Satiety effects 
In rats it was found that both peripheral and intracerebral administration of 
CCK decreases food intake.71 The ability of peripherally administered CCK to 
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induce satiety is at least partly mediated through the vagal nerve, since vagotomy 
attenuated satiety after food intake in animals 72 Pathways from the nucleus tractus 
solitanus in the area postrema to the hypothalamus seem to be involved in the 
central effects of CCK on satiety 73 
Studies in humans during infusion of various doses of CCK showed diver 
gent results,7476 but specific CCK type-Α receptor antagonists decreased satiety 77 
Yet, the exact role of CCK in the induction of satiety in humans remains to be 
determined, but an exclusive role for this peptide in the induction of satiety is 
illusive Satiety is likely to be a concerted action of multiple endocrine, paracrine 
and neurocrine mechanisms influencing the brain-gut axis 
Regulation of CCK release 
In recent years sensitive and specific radioimmunoassays for CCK have 
become available 6 Basal plasma CCK levels fluctuate between 1 and 3 pM and 
increase to about 5 10 pM after a meal, dependent on the type of RIA used 6 8 ? 8 7 8 7 9 
Fat and proteins,80 but not carbohydrates are the most potent stimuli for 
CCK release 2 6 2 7 In contrast to rodents, hydrolysis of fat and protein seems to be 
crucial for CCK release in humans Not all amino acids and fatty acids are equally 
effective in stimulating CCK release Especially essential amino acids like phenyl­
alanine, tryptophan, methionine and valine are known to be effective, while others 
are not or less effective 81 Also, only fatty acids containing more than 8 carbon 
atoms are able to stimulate CCK m humans 
In rats it is known that proteins but not amino acids are effective in 
stimulating CCK release,82 M whereas medium chain triglycerides are more 
effective than long chain triglycerides 
Feedback regulation of CCK release 
In previous studies it became clear that CCK is responsible for gallbladder 
contraction and pancreatic exocrine secretion With that, the question ansed 
whether the effects of CCK on gallbladder contraction and pancreatic exocrine 
secretion on their turn, might inhibit further gallbladder contraction and pancreatic 
secretion through a negative feedback mechanism It is not yet fully understood it 
such feedback mechanism exists in humans and whether it is mediated by CCK In 
rats a CCK mediated feedback mechanism between pancreatic enzyme secretion 
and intraduodenal protease activity has clearly been demonstrated under basal as 
well as under stimulated conditions (see chapter on the pancreas) Since CCK is 
believed to play an important role in the regulation of gallbladder motility and 
pancreatic enzyme secretion, knowledge of the release of CCK in response to bile 
salts or proteases and their inhibitors will increase our insight in the precise 
regulation of pancreaticobiliary function This might have clinical implications for 
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instance for the management of patients with exocrine pancreatic insufficiency or 
biliary diseases 
The effect of pancreatic proteases on plasma CCK release 
In the rat, protease inhibitors or diversion of pancreaticobiliary juice from 
the lumen of the gastrointestinal tract, potently stimulates the release of CCK 85 " 
In humans however, this phenomenon is presently largely speculative Several 
studies have demonstrated that fatty acid or amino acid stimulated plasma CCK 
could be suppressed by the administration of proteases,9092 suggesting that CCK 
mediated feedback regulation between protease activity in the lumen of the 
intestinal tract and pancreatic exocrine secretion is also operative in man However, 
many other studies do not support this concept,9396 which has only been observed 
durmg perfusion of high concentrations of proteases into the human duodenum 
Furthermore, studies performed with the synthetic protease inhibitor camostate 
(ΓΟΥ 305) clearly showed that inhibition of (chymo)trypsin activity resulted in 
stimulation of pancreatic enzyme secretion, but failed to increase plasma CCK 
levels97 " Since atropine but not CCK receptor antagonists inhibit basal and 
camostate induced pancreatic enzyme secretion, a minor role for CCK in feedback 
regulation of pancreatic enzyme secretion in humans is expected 10° 
An important pitfall in some studies is that experiments were only performed 
under unstimulated conditions Theorethically, the observation that protease 
inactivation does not stimulate CCK release can be attributed to the fact that only 
under nutrient stimulated conditions proteases affect CCK release, rendering 
evidence for an indirect effect of proteases on plasma CCK release In order to 
deal with this possible pitfall, the effect of protease inactivation on pancreatico­
biliary function and CCK release is best studied durmg stimulation with fat or 
protein Again, if nutrient stimulation in humans is necessary for trypsin-mediated 
feedback regulation of plasma CCK release, this would be different from rats, since 
it has clearly been demonstrated that diversion of pancreatic juice alone or ad­
ministration of trypsin inhibitors under unstimulated conditions stimulates 
CCK85101 '°2 in these animals, where two CCK releasing peptides have recently 
been detected 87 ю з l04 The one, "monitor peptide" is produced by the pancreas and 
the other, ' CCK releasing peptide" is released from the intestine Both peptides are 
sensitive to trypsin 
Another pittall in previous studies is the use of protease inhibitors that are 
not effective against all proteases trypsin, chymotrypsin and elastase '°5 The 
soybean inhibitor Bowman-Birk tor instance inactivates (chymo)trypsin (>95%), 
but failed to abolish elastase activity (>50%) More recently, a protease resistant 
variant ot trypsin was detected in human pancreatic juice that may account for the 
prevention of a feedback response on CCK release by trypsin inhibitors in hu-
7 
In addition, the absence of elevated plasma CCK levels in patients with 
exocrine pancreatic insufficiency does not favor the idea of proteases being the key-
processor in the regulation of plasma CCK release in humans.79107108 
The effect of bile salts on plasma CCK release 
The possible effects of bile salts on CCK release have been the subject of 
many studies, performed over the last decades. Supraphysiological amounts of bile 
salts are able to stimulate exocrine pancreatic secretion in man,109110 suggesting a 
stimulating effect on plasma CCK release. However, several studies perfusing bile 
or bile salts at more physiological concentrations into the duodenum support an 
inhibitory role on plasma CCK release, gallbladder motility and pancreatic enzyme 
secretion in humans.93"96"1 "4 
Different techniques were used to study the role of bile salts in the regula-
tion of CCK release. Cholestyramine, a bile salt binding resin, used by Gomez and 
Koop in separately performed studies, increased CCK levels and further reduced 
gallbladder volumes following amino acid or meal-stimulation in dogs and humans, 
whereas this effect could be reversed by the addition of taurocholate93 or 
chenodeoxycholic acid to the stimulus.9495 Studies with cholestyramine performed 
in rats also showed an increase in pancreatic size, an effect that is believed to be 
mediated by CCK.115 
Studies with CCK receptor antagonists like Loxiglumide and MK-329 further 
support the importance of bile salts in the regulation of CCK release and 
pancreaticobiliary function. The administration of a CCK receptor antagonist 
invariably caused an increase in meal or bombesin stimulated CCK 
release,2932"3"6'"8 increased basal gallbladder volume and inhibited gallbladder 
contraction, and to a lesser extend also pancreatic enzyme secretion. The latter 
observation again suggests a more important role for CCK in the regulation of 
gallbladder motility when compared to pancreatic function. The effect of CCK 
receptor antagonists on CCK plasma levels is explained by the lower concentration 
of bile salts in the duodenum due to a diminished gallbladder motility and not 
through a reduced trypsin output."8 
Other interesting studies on this topic were performed in the early and mid 
seventies when Malagelada and coworkers showed that duodenal perfusion of 
sodium taurocholate inhibited amino acid stimulated bilirubin and trypsin output, 
whereas cessation of bile salt perfusion again increased bilirubin and trypsin output. 
Perfusion with mono-oleate, instead of amino acids, showed the same effects.I"·"2 
The effects were restricted to the duodenum since jejunal perfusion with bile salts 
was without effect and since bile salts were ineffective when exogenous CCK was 
used as a stimulus. 
Unfortunately, plasma CCK levels were not determined in these studies, since 
specific and sensitive radioimmunoassays were not available at that time. 
With the results of the different experiments described above, the question 
remains through which inhibiting mechanisms bile salts affect pancreaticobiliary 
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secretion and whether effects of bile salts on pancreaticobiliary secretion and CCK 
release are not only observed in acute experiments but also in chronic studies One 
possible mechanism was suggested by Malagelada "2 He showed that inhibition of 
gallbladder contraction by bile salts was maximal when the ratio fatty acid bile 
salt was 1 1 He suggested that in this situation the absorbtion of fatty acids was 
maximal and thus a "CCK releasing peptide" was no longer able to stimulate CCK 
and gallbladder motility The fact that both higher and lower bile salt perfusates 
were unable to decrease bilirubin output, further strenghtens this hypothesis 
However, the described mechanism might not be effective in case of amino acid 
stimulation 
Therefore, other explanations for the suggested action of bile salts on CCK 
release are possible One explanation might be that bile salts act through the release 
of other hormones Somatostatin and PYY are possible candidates93 Direct effects 
of bile salts on the CCK releasing I cell also belong to the possible explanations "9 
Furthermore, as mentioned before, two CCK releasing peptides have been detected 
in animals,87 '°31M and both are trypsin sensitive Therefore, bile salts might also 
influence the metabolism of these peptides and thus CCK release by affecting 
trypsin activity 
2. BOMBESIN 
Molecular forms of BBS 
Bombesin (BBS), is a 14 amino-acid peptide originally isolated from the skin 
of the amphibian "Bombina Bombina" 12° Its mammalian counterpart is gastrin 
releasing peptide (GRP), a 27 amino acid containing peptide of which the last 7 
amino acids in the biologically active C-terminal part of the molecule are identical 
tho those in BBS p ' Both BBS and GRP are described as mammalian peptides and 
are only present in neuronal cells in mammals 
Distribution in alimentary tract 
BBS-like immunoreactivity is widely distributed in nerve fibers and cell 
bodies in the myenteric plexus of the human gastrointestinal tract and in the 
pancreas 122l24 BBS-like immunoreactivity is also abundantly present in the 
stomach '>s '26 The myenteric plexus of the small and large intestine also contain 
nerve fibers and cell bodies with BBS/GRP immunoreactivity l27,2S 
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BBS receptors 
The shortest fragment of GRP which is biologically active is the C-terminal 
pentapeptide '29 Binding sites for GRP have been located on many cells, including 
pancreatic acinar cells,130 gastrin producing cells,131 132 gastrointestinal smooth 
muscle cells,132 neuronal parts of the myenteric plexus132 and brain cells l33 Untili 
now, two different receptors for BBS/GRP have been identified, one preferring 
GRP (situated on pancreatic acinar cells), the other neuromedin-B 134 
Physiological actions of BBS 
Bombesin has a wide variety of actions in the human gastrointestinal tract 
including stimulation of gastrin release,135 gastric acid secretion,135 cholecystokinin 
release,29 gallbladder contraction35 and pancreatic enzyme secretion 136138 In the rat 
BBS also stimulates somatostatin release 139 
Effect on gastrin release and gastric acid secretion 
Both GRP and BBS are potent stimuli of gastrin release in various species 
including humans ,35 '3Ä ш142 It is presently believed that GRP is the neuro 
transmitter involved in non cholinergic, non adrenergic vagal stimulation of gastrin 
release 143 '46 BBS does not have a direct effect on parietal cells in humans, since 
gastric acid secretion is not stimulated by BBS in antrectomized patients This 
suggests that the release of gastrin from the antrum is responsible for the observed 
gastric acid secretion during BBS infusion in healthy subjects 
Effect on hormonal secretion 
BBS/GRP stimulates the release of somatostatin (SST) which effectively 
inhibits gastric acid secretion and gastrin release ,47 Simultaneous release of SST 
probably blunts the effect of BBS on gastric acid secretion and gastrin release, and 
possibly also on other effector organs, like the pancreas Hormones that have also 
been demonstrated to be released by BBS/GRP, include cholecystokinin (CCK), 
pancreatic polypeptide (PP), glucagon, insulin and gastric inhibitory peptide 
(ΤΊΡΊ 2 9 " 3 1 3 6 1 4 8 1 5 6 
Effect on smooth muscle contraction 
BBS/GRP is known to be a potent stimulus for smooth muscle contraction in 
the GI-tract BBS infusion results in gallbladder emptying and stimulates small 
intestinal motor activity resulting m a decreased transit time l 3 9 1 5 3 ' " Gastric 
motility is inhibited, resulting in delayed gastric emptying 15816° Gallbladder 
motility in humans is probably an indirect effect of BBS, through the release of 
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CCK, since there are no BBS receptors on human gallbladder muscle.161162 In dogs, 
the gallbladder muscle contains BBS receptors Therefore gallbladder contraction in 
this species might be a direct effect of BBS 163 
Effect on pancreatic secretion 
Intravenous administration of BBS potently stimulates CCK release and 
exocrine pancreatic secretion in man ш m The same effects were also observed in 
the rat, dog and guinea pig pancreas.164166 However, contrary to gallbladder 
muscle, human pancreatic cell membranes contain specific receptors for bom­
besin161 1 6 2 1 6 7 and studies have shown that BBS stimulated exocrine pancreatic 
secretion is not totally inhibited by the CCK receptor antagonist loxiglumide,U6 
suggesting that BBS also stimulates pancreatic exocrine secretion directly in 
humans 
Points of interest for further studies with BBS 
Despite continuous infusion of BBS, plasma CCK levels decrease after an 
initial rise 2 9 1 3 6 The mechanism of this phenomenon is presently not known The 
decrease in CCK during continuous infusion of BBS may be explained by con­
comittant release of an inhibitor of CCK, like SST However, since BBS also 
stimulates gallbladder contraction and pancreatic enzyme secretion, either bile or 
pancreatic enzymes may also be involved in feedback regulation of CCK release In 
previous studies, BBS was used in a wide variety of doses given, ranging from 
0 02 to 16 0 ng«kg '«min ',13513613915415616° It is not yet known whether or not the 
infusion of BBS results in physiologic concentrations at receptor sides for BBS, 
since BBS/GRP has only been demonstrated in neurons and not in endocrine cells 
in humans. 
3. GALLBLADDER MOTILITY 
Composition of gallbladder bile 
Absorption of water concentrates gallbladder bile by a factor 10 when 
compared to hepatic bile Concentrations of bile acids are thus increased Glycrne-
conjugated bile acids predominate over taurine-conjugates by a factor 2 to 3, with 
cholic and chenodeoxycholic acid accounting for approximately 80% of the bile 
acids present The remainder part of bile acids is deoxycholic acid 
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Pattern of gallbladder emptying 
Gallbladder volume and its emptying rate constantly fluctuate under un­
stimulated conditions and after feeding.168 In the interdigestive state, gallbladder 
motility follows the MMC complex.169 After a meal, gallbladder emptying follows 
gastric emptying, while refilling starts when gastric emptying is nearly comple­
ted.170 Through the development of ultrasonography, changes in gallbladder volume 
can be measured accurately.171172 
Regulation of gallbladder motility 
Gallbladder motility is regulated by both neural and humoral factors. Neural 
control of gallbladder volume consists of an intrinsic and extrinsic part.m 
Hormonal regulation of gallbladder motility has been the subject of many 
studies performed in the last decade, especially since the development of reliable 
and specific radioimmunoassays for the measurement of CCK. Except CCK, 
motilin, pancreatic polypeptide (PP), somatostatin, and to a lesser extent neuroten­
sin and peptide YY (PYY) are also involved in the regulation of gallbladder 
motility. 
Neural control 
A subserosal and submucosal ganglionated plexus containing acetylcholine 
(Ach), vasoactive intestinal peptide (VIP), somatostatin, substance Ρ and neuropep­
tide Y, together form the intrinsic part of neural gallbladder regulation.173175 In 
animal studies it was shown that these neurons are under control of CCK and are 
able to release Ach.176177 
Not only in animals but also in man, the extrinsic vagal system plays an 
important role in the regulation of basal gallbladder volume. Cholinergic 
stimulation through modified sham feeding, insulin induced hypoglycemia, or 
stimulation with Ach exerts gallbladder contraction.176178"180 This response is 
successfully blocked by infusion of atropine.178180 Even more, the cholinergic 
system also participates in the regulation of meal or CCK stimulated gallbladder 
contraction.181184 Apparently, CCK regulated gallbladder contraction needs an intact 
vagal system. 
In contrast to an important parasympathic regulatory role for gallbladder 
dynamics, the sympathetic regulatory role seems to be of minor importance. 
Stimulation of sympathetic nerves or injection of (nor)adrenaline relaxes the 
gallbladder only after previous CCK infusion or vagal stimulation,176185 due to the 
larger amount of inhibitory /3-adrenergic receptors when compared to the amount of 
α-excitatory adrenergic receptors.186 The significance of the sympathetic system in 
the regulation of gallbladder motility awaits further studies. 
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In studies with guinea pigs, a non-adrenergic non-cholinergic (NANC) 
inhibitory mechanism on gallbladder motility, especially in the interdigestive period 
has been proposed 187 Vasoactive intestinal peptide (VIP), identified on human 
gallbladder nerve fibers188 is thought to be related with NANC mechanism 
Finally, opiate receptors have been identified on gallbladder muscle 189 An 
earlier study allready pomted out that loperamide is able to inhibit CCK stimulated 
gallbladder contraction in healthy volunteers190 and meal stimulated pancreatico 
biliary secretion in patients with short bowel 191 At present, it is not known whether 
loperamide also affects basal and meal-stimulated pancreaticobiliary secretion in 
healthy volunteers 192 
Hormonal control 
It is well documentated that infusion of CCK or the ingestion of a meal 
(causing a rise m endogenous CCK released by I-cells in duodenum and jejunum) 
stimulates gallbladder contraction 26 " 3 1 % CCK type-Α receptors are located on 
gallbladder smooth muscle as well as on intramural pre and postganglionic 
nerves
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 In animal studies, it is suggested that physiological doses of CCK act 
through activation of receptors located on parasympathetic nerve fibres, whereas in 
higher doses CCK directly acts on gallbladder smooth muscle 1 8 3 1 9 7 1 9 t ! In studies 
with specific CCK-A receptor antagonists, the final part of the prove that gallblad 
der contraction is regulated by CCK release was found " 
The effect of motilin on gallbladder motility is much more controversial 
when compared to CCK Motilin is released after oral and ι ν nutrients, intra 
duodenal acidification and presence of ι d bile ' " 2 0 1 Different effects of vagal 
stimuli on motilin release have been reported202 and the effect of motilin on basal 
gallbladder motility is controversial 2 0 3 2 W However, a relation between motilin and 
phase III MMC activity is apparent 1692tM 
The role of pancreatic polypeptide (PP), a pancreatic hormone released 
during cholinergic stimulation,205 in the regulation of gallbladder motility is thought 
to be inhibitory, since an increase in PP levels following CCK infusion relaxes the 
gallbladder, inhibits intraduodenal output of amylase and bilirubin, and decreases 
intraluminal pressure 206 im 
Due to an identical C-terminal pentapeptide with CCK,209 gastrin could be a 
candidate for gallbladder stimulation However, concentrations needed for com­
parable effects with CCK on gallbladder contraction are far beyond physiological 
plasma gastrin concentrations,210 indicating that gallbladder contraction is regulated 
through activation of specific type A receptors, which do not bind gastrins 
Somatostatin is a potent inhibitor of CCK-stimulated and postprandial 
gallbladder contraction in humans2"2 1 2 Basal gallbladder volume is increased 
following somatostatin (analogue) infusion212 In patients with somatostatin 
producing endocrine tumours, gallstones and giant gallbladder volumes are 
frequently observed 213 The increase of basal gallbladder volume and reduction in 
stimulated gallbladder contraction after somatostatin infusion are partly explained 
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by direct effect of somatostatin on gallbladder muscle and partly by a reduction in 
plasma CCK levels.214 
Bombesin is a well known stimulator of gallbladder contraction (see 
paragraph on bombesin). BBS stimulates gallbladder contraction in humans through 
the release of CCK, and has no direct effect on gallbladder muscle. 
Several other hormones like secretin,215 substance P,216 VIP,217 neuroten-
sin,218 peptide YY,219 neuropeptide Y,220 and calcitonin-gene related peptide221 have 
been reported to affect gallbladder motility, but their relevancy for gastrointestinal 
physiology is not yet fully understood. 
In conclusion, basal as wel as stimulated gallbladder motiliy is importantly 
affected by the vagal nerve system. The major regulatory mechanism, however, is 
mediated by the hormone CCK. It appears that the vagal nerve is important to 
maintain a basal tone for the gallbladder, necessary for an adequate reaction 
following a meal or CCK infusion. 
Feedback regulation of gallbladder motility 
Feedback regulation of gallbladder motility is generally described in the 
context of the regulation of CCK release. Since CCK is the most important 
regulator for gallbladder motility (and to a lesser extend also for pancreatic enzyme 
secretion), changes in plasma CCK levels will affect changes in gallbladder motility 
(see paragraph on cholecyslokinin and the pancreas). Presently, our understanding 
of feedback regulation of gallbladder motility originates from studies with the bile 
salt binding resin cholestyramine and from experiments with ursodeoxycholic acid 
(UDCA). 
Role of bile salts 
Several studies have been performed with cholestyramine. The bile salt 
binding capacity of the resin is 2.6 mmol bile salts/gram cholestyramine.222 
Therefore, administration of 6 g of cholestyramine would be enough to bind all 
available bile salts intraduodenally, assuming an average physiological bile salt 
excretion of 30 mmol per day.223 Several studies clearly showed that choles-
tyramine augmented meal stimulated gallbladder contraction,93 95·224 and all studies 
concluded that bile salt depletion resulted in higher plasma CCK levels, due to a 
bile salt mediated feedback system. However, the resin itself is also able to 
stimulate basal gallbladder motility without affecting plasma CCK levels,224 also 
suggesting a direct effect of bile salts on gallbladder motility. Furthermore, the fact 
that loxiglumide administration submaximally inhibits CCK stimulated gallbladder 
motility,33·224 points to an effect of mechanisms other than CCK. Beside bile salts 
and cholinergic acitvity, pancreatic polypeptide (PP) is suggested to enhance 
postcontractile gallbladder filling, at least in the prairy dog model.225 
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Several other studies were performed with bile salts226 229 It was shown that 
UDCA or CDCA increased basal gallbladder volume without affecting plasma 
CCK levels, whereas stimulated gallbladder motility was unaffected in gallstone 
patients,226227 as well as in healthy humans226 Others however, found decreased 
gallbladder emptying in response to UDCA therapy in gallstone patients 22'229 
Perfusion of single bile salts like tCA111 or CDCA95 was without effect on basal 
bilirubin output, whereas during stimulated conditions, intraduodenal or intrajejunal 
perfusion with tC, tCDCA or tDCA reduced amino acid stimulated bilirubin 
output1" and prevented meal stimulated bilirubin output,95 with tC being the most 
effective 
In conclusion, bile salt depletion by cholestyramine stimulates basal and 
meal stimulated gallbladder motility, possibly due to a feedback mechanism of bile 
salts on gallbladder motility, either through effects on plasma CCK release (during 
stimulated conditions) or through other, probably cholinergic, mechanisms (under 
basal conditions) The question whether cholestyramine also affects plasma CCK 
release and gallbladder motility in the interdigestive state remains to be established 
4. BILE SALTS 
Introduction 
Human bile contains bile salts (±67%), phospholipids (±22%), cholesterol 
(±4%), electrolytes, glycoproteins (±4%), bile pigments and water 22J23° Further-
more, commonly used drugs like cardiac glycosides, antibiotics, morphine, 
radiocontrast material and heavy metals can also be secreted into bile 
Bile salts are amphipathic molecules secreted by the liver after formation 
trom cholesterol Above a critical micellar concentration, bile salts are able to form 
micelles Most of the time bile salts in human duodenal bile are in the micellar 
form in order to enhance their availability for fat digestion Bile salts are usually 
conjugated by the liver to glycine or taurine (ratio 2-3 1) Under physiologic 
conditions all bile salts are present in bile as conjugates, making them more water 
soluble at physiological biliary pH 231 About 10% of taurine conjugates and 20% of 
glycine conjugates are deconjugated by colonic bacteria and returned to the liver 
where reconjugation occurs 232 
The most common bile salts are conjugates of cholic acid (CA) and 
chenodeoxycholic acid (CDCA), both formed from cholesterol in the liver 233 After 
secretion into the intestine, the major part of these two is reabsorbed in the 
terminal ileum About 30% of these primairy bile salts are converted into secon-
dary bile salts by bacterial deconjugation in the colon Hereby CA is converted into 
deoxycholic acid (DCA) and CDCA into lithocholic acid (LCA) Furthermore, 
ursodeoxycholic acid (UDCA) is formed in the liver after reuptake from LCA The 
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average values for CA, CDC A and DCA approximate 40, 40 and 20% of the 
amount of bile salts present in human bile. 
The relevancy of the enterohepatic circulation is the elimination of excess of 
cholesterol from the body. Cholesterol is a major fuell for the cells in the human 
body, but excess of cholesterol can be the cause of diseases, like coronary heart 
disease as the most important. Also, bile salts participate in the absorption of 
dietary fatty products,234 they are the major osmotic driving force to promote water 
movement from liver cells into bile and absorption of intraduodenal water235'236 and 
they regulate their own synthesis from cholesterol by returning to the liver.237 
Regulation of enterohepatic circulation 
The secretion of bile into the intestine, the re-uptake of bile salts in the 
ileum and reformation of bile salts in the liver is known as the "entero-hepatic 
circulation". 
During fasting conditions most of the bile salts are stored in the gallbladder 
after their formation in hepatocytes. The filling of the gallbladder in the interdiges-
tive state is possibly due to contraction of the sphincter of Oddi, negative ab-
dominal pressure and continuous flow of bile from the liver into the biliary tree. 
Duodenal concentrations of bile salts vary from 0.1 to 4.0 mmol/L.238 The gallblad-
der is not necessary for bile secretion but facilitates its storage. Even more, 
following cholecystectomy digestion and absorption of fat is not importantly 
affected.223 
During a meal resulting in gallbladder contraction, bile is secreted into the 
intestine in order to facilitate food digestion (see section on gallbladder motility). 
Following a meal, large variations of intraduodenal total bile salt concentrations 
(5.8-39.6 itiM) are seen, resulting in an average concentration of about 15 mM in 
duodenal aspirate during the first 30 min postprandially238 and a total output of ± 
2.3 mmol/h.239 Although duodenal bile is diluted 5- to 10-fold as compared with 
gallbladder bile, it is quantitatively similar to gallbladder bile.240 
The loss of bile salts is prevented by reabsorbtion at the terminal ileum. This 
enterohepatic circulation of bile salts results in a total bile salt pool of only 1.5-4 g 
with cycle frequency of 6-10 times a day.223 Only 2-5% (+ 0.5 g/day) is excreted 
in the feces and estimated to be the daily synthesis under normal conditions.230233 
Bile salt pool seems to be determined in part by its recycling frequency. Thus a 
relative small bile salt pool results in a high recycling frequency to maintain a 
steady state enterohepatic circulation.239 Reabsorption of bile salts occurs passively 
and actively. Passive absorption occurs throughout the whole intestinal tract,241 
whereas active absorption occurs in the ileum.242 The active transport system is 
capable to transport up to 98% of the bile salts during the enterohepatic cycle and 
is the major quantitative site of bile salt reabsorption in humans.243 Passive 
absorption occurs through (non)ionic diffusion and is dependent on intraluminal and 
membrane pH. Non-ionic diffusion (bile acids) is 10 times greater than ionic (bile 
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salts) diffusion 241 So the mam determinant for passive absorption is the polarity of 
the bile salt Glycine conjugates of CDCA and DCA are absorbed passively in 
contrast to glycine conjugates of CA, while taurine conjugates are almost totally 
dependent on active transport241 The most polar bile salts, which are absorbed 
poorly by passive diffusion in the upper intestine, have the highest maximal 
transport rates in the ileum In contrast, less polar bile salts have lower rates of 
transport in the ileum Approximally 60% of free bile salts, 25% of glycine 
conjugates and less than 4% of taurine conjugates may be absorbed passively in 
ileum and colon 1M 245 These percentages may increase in case of ileal disease when 
the glycine-conjugated fraction of bile salts is increased due to loss of taurine 
conjugates245 
After reabsorption, bile salts are bound to serum albumin and transported in 
the portal blood to the liver Therefore plasma levels in portal venous blood are 6 
times higher when compared to peripheral venous blood (appr 3-4 μΜ) Starvation 
has no influence on bile salt levels in peripheral venous blood 246 The existence of 
constant basal plasma bile salt levels renders evidence for a continuous or intermit 
tent secretion ot bile into the intestine which occurs with interdigestive gallbladder 
contraction 24? Most of the peripheral blood bile salts are conjugated The small 
unconjugated part m blood originates from colonic absorption Eating results in a 
two to six-fold increase in total bile salt levels in penferal blood2 3 9 2 4 8 CDCA 
conjugates rise higher and faster when compared to CA conjugates, possibly due to 
more rapid proximal intestinal absorption of CDCA and less hepatic clearance of 
CA M925° Cholecystectomy reduces the maximal level of postprandial plasma bile 
salts but compensatory, a higher constant plateau level is observed " ' 
In conclusion, the enterohepatic circulation of bile salts results m a bile salt 
pool of only several grams This bile salt pool is of high importance in the 
regulation ot pancreaticobiliary secretion Effects of bile salts in the regulation of 
gallbladder motility and pancreatic enzyme secretion are described m the chapters 2 
and 5 of this introduction 
5. THE PANCREAS 
Introduction 
Due to its localisation, the pancreas is one of the most difficult organs to 
study in humans The gland can roughly be divided into two different regions252 
One part, the exocrine pancreas (formation and secretion of bicarbonate and 
digestive enzymes) consist of clusters of acini forming lobules Each acinus 
contains pyramidal acinar cells with their broad bases at the circumference and 
their apexes pointmg towards the center of the lobulus, the luminal side Each 
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acinus is drained through a ductule, intra- and interlobular ducts mto the major 
pancreatic duct (duct of Wirsung) 
The pancreatic lobules are separated from each other by loose connective 
tissue Within this connective tissue the islets of Langerhans are situated, which 
form the endocrine part of the gland (formation and secretion of glucagon and 
insulin) 
Composition of pancreatic juice 
Pancreatic juice, which is iso-osmolar to extracellular fluid, mainly consists 
of electrolytes and proteins The main electrolytes are CI, HC03 ,Na+ and K+ To 
a lesser content, Ca2+, Mg2+, Zn2+, HP042 and SO/ are also present Proteins 
secreted by the pancreas mainly ( + 90%) include digestive (pro)enzymes and to a 
lesser part trypsin inhibitors, plasma proteins and mucoproteins 253 
On the one hand, pancreatic proteases are secreted as inactive proenzymes 
(tripsinogen), which are subsequently converted by enterokinases from the 
intestinal mucosa into active trypsin Subsequently, trypsin activates all other 
pancreatic proteases On the other hand, pancreatic lipase, amylase and 
ribonuclease are already secreted from the pancreas in the active form. Inhibition 
of pancreatic lipase activity by bile salts is prevented by the concomittant secretion 
of co-lipase 254 Amylase (alpha-1,4-glycosidase) only splits straight-chain glucose 
polysaccharides, which have 1,4 linkages, into maltose and maltotnose, and as a 
result dextrins containing the 1,6 glycosidic bonds 255 Lipase splits fatty acids from 
triglycerides, thus forming free fatty acid and monoglycendes These products of 
hpolysis inhibit the action of lipase The pancreas also secretes phosphohpase A2, 
cleaving lecithin into lysolecithin, and cholesterolesterase, hydrolyzing cholesterol 
and other lipids 252 Pancreatic enzymes are secreted in parallel while the relative 
amount of each enzyme remains constant both during basal and stimulated con-
ditions255 257 In humans, protein malnutrition results in a reversible fall in 
pancreatic secretory activity followed by acinar cell atrophy when malnutrition is 
continued.258259 In patients with celiac disease elevated serum amylase activity is 
observed, declining to normal values after gluten withdrawal 26° 
Regulation of pancreatic enzyme secretion (PES) 
As mentioned before, pancreatic exocrine function is difficult to test in vivo 
Nevertheless, many studies have investigated various aspects of exocrine pancreatic 
function in the past Several phases of pancreatic exocrine secretion before and 
during a meal can be distinguished 
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Basal secretion 
Basal PES shows the same cyclic variation as gastric and biliary secretion, 
following the migrating motor complex (MMC), reaching a maximum (about 10-
15% of maximal postprandial secretion) during phase III of the MMC. Both 
atropine and ganglionic blockage are known to abolish this cyclic pattern, in-
dicating that basal PES is mainly regulated by vagal nerve activity.261'263. Basal PES 
may probably be enough for adequate digestion of a normal meal, since maldiges-
tion only occurs when pancreatic secretory activity drops below 10% of normal.264 
Whether basal levels of cholecystokinin (CCK) or other hormones participate 
in the regulation of basal PES is presently not known. The cyclic pattern of PES is 
thought to be an element of the housekeeping function of the human digestive 
system in the interdigestive state, which prevents accumulation of digestive 
products and bacteria in the lumen of the intestinal tract.263 
Cephalic phase 
It is well known that the sight, smell and taste of food,266 or sham feeding267 
stimulate PES up to 50% of responses following exogenous CCK secretion.268 
Sham feeding activates the brain stem of the central nervous system which subse-
quently stimulates exocrine pancreatic secretion through the vagal nerve. Vagotomy 
abolishes the effect of sham feeding on exocrine pancreatic function. These 
responses are under cholinergic control since they are also abolished by atropine, 
whereas the increase in PES following sham feeding is not accompanied by an 
increase in plasma CCK levels.77·268 
Gastric phase 
Gastric distension increases pancreatic enzyme output.269 Intragastric 
dextrose with or without amino acids equally stimulate PES, accompanied only by 
a small release of plasma CCK in the amino acid experiment.270 These effects are 
also explained by gastric distension. The effect of antral distension on exocrine 
pancreatic function can be blocked by atropine or truncal vagotomy.271 Gastrin is 
released by protein in the stomach but tends to be of minor importance in the 
stimulation of PES when compared to CCK.272 
Another important factor in the stimulation of PES is the rate of gastric 
emptying, since it is known that PES is dependent on gastric emptying as demon-
strated in patients following gastric surgery.273 
Intestinal phase 
The contact of digestive products with the duodenal mucosa accounts for 
most of the (about 70% of maximal) increase of PES.26' Low intraduodenal pH is, 
an effective stimulus for pancreatic bicarbonate secretion through the release of 
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secretin.274276 However, the physiological significance of free acid seems to be 
small since gastric acid present in the duodenum is largely buffered by meal 
components.253 
The effect of digestive products on pancreatic enzyme output is mediated via 
both CCK release and cholinergic pathways since: 
1) maximal CCK secretion only exerts submaximal PES,263 
2) the specific CCK antagonist loxiglumide (CR-1505) is only able to partially 
block meal-stimulated PES,116 and is without effect on BBS stimulated PES,136 
3) CCK or meal-stimulated PES is virtually abolished by atropine."6 
A concerted action between CCK and the cholinergic system explains almost all 
secretory enzyme activity in response to a meal. CCK probably stimulates exocrine 
pancreatic secretion through activation of specific type A-CCK receptors present on 
the periferal cholinergic system and probably not by binding to these receptors on 
acinar cells. Binding to specific type-Α receptors on acinar cells probably only 
occurs with supraphysiologic concentrations of CCK. 
Studies performed with mixtures of amino acids have demonstrated that not 
all amino acids are effective in stimulating PES.2 7 7 2 7 8 Mainly phenylalanine, 
methionine, valine and tryptophane drive PES. The part of the intestine were these 
amino acids preferably stimulate PES reaches from 10 cm into the duodenum till 
the jejunum, about 230 cm from the pylorus.279 Furthermore PES elicited by 
essential amino acids is only submaximal.111 Another interesting fact concerning the 
effect of protein on PES is that in rats mainly intact protein but not amino acids 
stimulates PES. 8 2" 2 It is presently not known whether whole protein or the 
digestive products of protein are able to induce PES in humans. This is one of the 
topics of this thesis. 
PES is also effectively stimulated by intestinal perfusion of fatty acids 
containing at least 8 C-atoms.112 The number of carbon atoms seems to be related 
to the rate of stimulation (C18>C12>C8). 
Intestinal perfusion of glucose is without significant effect on PES.277 The 
small effects of carbohydrate perfusion into the duodenum on PES is probably 
largely explained by distension and osmolality, since the rate of perfusion and the 
osmolality of the perfusate have been demonstrated to stimulate PES.280 It is 
therefore of importance to keep the infusion rate and the osmolality at a constant 
level when studying the effects of a stimulus on PES, in order to prevent that 
infusion rate and osmolality will become confounding factors. Under physiological 
conditions, gastric emptying is approximately 3-5 mL/min and the osmolality of the 
chyme entering the duodenum reaches values of approximately 300 mOsmol/L. 
Whether these factors are independent variables for the stimulation of PES during 
fat or protein perfusion still is speculative. 
Finally it is known that intestinal perfusion of CaCl2, MgS04, or MgCl2 
stimulates PES in humans to levels as seen after exogenous CCK.280"283 
In conclusion, pancreatic enzyme secretion is dependent on cholinergic 
activity upon which CCK is able to exert further effects. 
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Feedback regulation of pancreatic enzyme secretion 
Proteases and pancreatic enzyme secretion 
Feedback regulation of pancreatic secretion is well established in the rat. 
The diversion of pancreaticobiliary secretory products from the lumen of the 
intestinal tract or the administration of trypsin inhibitors increases pancreatic 
secretion. Subsequently, intraduodenal administration of proteases into rats 
abolishes the rise in pancreatic secretion after diversion of pancreaticobiliary juice 
from the .^»•«.».юі.км.гмдаі
 I n m e r a t m i s feedback regulation is 
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 Also in the chicken,285286 
pjg 287.28«
 a n (j dog,289·290 proteases exert feedback control of pancreatic exocrine 
secretion. In the latter species feedback regulation of pancreatic secretion is 
mediated by secretin instead of CCK and only effective after intraduodenal 
stimulation with oleic acid.289290 
In humans, it is still controversial whether feedback control of pancreatic 
secretion is operative90,294 and through which mechanisms it is regulated. Several 
studies point to an effect of proteases inhibiting pancreatic secretion,&8a9,91,2932% 
several other studies showed no effect,297'298 while again other studies suggest a 
stimulatory effect on pancreatic secretion after protease inhibition.97 i0° Whether or 
not a protease-mediated feedback mechanism in man is mediated by CCK, also is 
highly controversial.90,291293 
Effect of bile salts on pancreatic secretion 
In the past, the rat has also been extensively studied for the effect of bile or 
bile salts on pancreatic secretion. It is generally accepted that biliopancreatic 
diversion from the gut increases basal pancreatic output of bicarbonate and 
protein.86284·299301 Not only reinfusion of proteases, but also reinfusion of bile 
inhibits the stimulatory effect of biliopancreatic diversion.299·302-303 Additional 
exclusion of endogenous bile potentiated the stimulatory effect on pancreatic 
volume, bicarbonate and protein secretion and again this effect was blocked by 
reinfusion of bile or bile salts.86299302 The only exception was that perfusion with 
ursodeoxycholic acid invariably stimulated pancreatic secretion of bicarbonate and 
protein under unstimulated conditions.304 Bile acid depletion, induced by the 
feeding of cholestyramine increased basal and CCK-stimulated pancreatic enzyme 
secretion in rats, and also increased pancreatic weight.305 In conclusion, in the rat 
not only diversion of proteases from the gut, but also diversion of bile stimulates 
pancreatic enzyme, bicarbonate and volume secretion, and the effect is blocked by 
(re)perfusion of bile intraduodenally. 
In anesthetized cats however, duodenal perfusion with Na-taurocholate, which 
constitutes approx. 90% of cat bile salt pool, increased basal and secretin 
stimulated volume and bicarbonate secretion whereas enzyme secretion was 
unaffected.306307 Furthermore, jejunal perfusion was less effective in stimulating 
21 
pancreatic secretion when compared to duodenal perfusion,306 while ileal perfusion 
of bile salts was without effect 
In dogs, the effects of bile salt perfusion are also not equivocal It is 
reported that the absence or presence of bile was without effect on amino acid, 
secretin, HCL or caerulein stimulated pancreatic enzyme secretion,308 while 
intraduodenally administered bile was also without effect * ° m Cholestyramine 
feeding enhanced amino acid stimulated protein secretion Taurocholate, which 
constitutes about 100% of dog bile salt pool, perfusion blocked this effect93 In 
dogs with biliary pancreatic-fistulas however, perfusion of taurocholic acid 
increased pancreatic protein secretion ш 3 W It seems that basal pancreatic secretion 
is unaffected by bile salts in dogs, whereas bile salt depletion durmg nutrient 
stimulated conditions increases pancreatic secretion, indicating that bile salts might 
inhibit pancreatic function after feeding 
Several studies concerning the effect of bile or bile salts on pancreatic 
secretion have also been performed in humans However, in most studies supra-
physiological concentrations (120-480 mmol/L) of single bile salts,3"312 cattle bile 
(6-26 g/h),312 315 or human bile (20-40 mL)316 were used and able to stimulate basal 
pancreatic secretion 3 I 7 Perfusion of taurocholate (tCA) in lower concentrations, 
comparable to those seen after a meal (10-30 mmol/L), was without effect on basal 
enzyme secretion in some studies,"'3'6 whereas others reported a dose response 
relationship between taurodeoxycholate (tDCA) and basal pancreatic enzyme 
secretion 312 Glycine conjugated296 and unconjugated DCA were also able to evoke 
pancreatic enzyme secretion 318 Furthermore the site of administration appears to be 
of importance since intrajejunally perfused bile was without effect on pancreatic 
enzyme secretion during secretin background infusion ' " 
During stimulation, ι d administration of 5, 10, 15 and 30 mmol/L of tCA, 
10 mmol/L of tDCA or tCDCA reduced pancreatic enzyme secretion,111313 whereas 
ι d perfusion with 4 or 6 g of cattle bile318320 or 200,400 and 600 mg of sodium 
tDCA320 increased secretin stimulated pancreatic enzyme secretion Perfusion of 50-
1800 mg tCA was without effect320321 
Administration of cholestyramine increased Lundh meal stimulated lipase 
output but amylase and trypsin output were unaffected during bile salt precipitation 
with oral cholestyramine9495 However, when CDCA was administered, stimulated 
pancreatic enzyme output was not decreased when compared to the test meal alone 
Even more, CDCA perfusion stimulated basal outputs of pancreatic enzymes 
without affecting bilirubin output or CCK levels, suggesting a dissociation between 
biliary output and CCK release on the one hand and pancreatic secretion on the 
other hand 
One important observation by Malagelada seems to elucidate through which 
mechanism bile salts (BA) exert their effect on pancreatic secretion " 2 As described 
in the paragraph on CCK, the rate in which fatty acids (FA) are absorbed seems to 
be inversely correlated with the effect on pancreatic secretion When the con­
centrations FA BA are m the range of 1 1, intraduodenal FA concentrations were 
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low and stimulated pancreatic enzyme secretion was inhibited when compared to 
FA:BA concentrations either > 1 or < 1. 
Another possible mediator for bile action on the exocrine pancreas is 
secretin, which is the most important hormonal mediator of pancreatic volume and 
bicarbonate secretion.253 However, controversy exists whether plasma levels of 
secretin are increased postprandially263·317 or not.312315,322 Several bile salts have 
been shown to stimulate secretin levels under basal conditions,323,324 whereas this 
effect was abolished during meal stimulation.323 This might be in accordance to the 
stimulatory effect of bile salts on pancreatic secretion in the basal state without 
effect postprandially. 
In conclusion, perfusion studies with bile salts performed in humans over the 
last decades show a large variety of results on pancreatic secretion, ranging from a 
decrease in PES, no effect, to an enhanced PES. When an enhanced pancreatic 
secretion was seen, DCA seemed to account for this effect, whereas CA was only 
weakly or not effective. An explanation for these contradictory results might be the 
use of suprafysiological concentrations of bile salts, the use of cattle bile, the 
osmolality, solubility318 or site of administration."1-323 Thus, it seems that beside the 
amount of bile salts, bile salt composition is of influence on pancreatic enzyme 
secretion. The stimulatory effect of bile and bile salts seems to be restricted to 
basal or unstimulated conditions, since bile or bile salts are without effect or even 
reduce meal stimulated pancreatic enzyme secetion in man. 
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6. AIMS AND OUTLINE OF THE STUDY 
Up to now it is unclear whether trypsin activity or bile salts regulate 
feedback control of pancreaticobiliary secretion, and whether feedback control is 
mediated by CCK M " *>91 "9Î136 It is also questionable whether such a feedback 
mechanism is also operative when there are no nutrients in the gut, for instance 
during intravenous stimulation with BBS To further examine feedback regulation 
of CCK release, several tools are available 
* Bile salt séquestrants like cholestyramine or colestipol can be used to mimic 
büe diversion 93 95 326 
* The protease inhibitor camostate can be used to mimic protease diver-
sion97327 
* Bombesin (BBS) is another potent stimulus of plasma CCK release in 
humans 8 328 Furthermore, gallbladder emptying and pancreatic enzyme secretion 
are also effectively stimulated by BBS 137329 Thus BBS can be used to mimic the 
effects of a meal 
* The infusion of atropine causes a delay in the increase of CCK after a 
meal 33c In vagotomized patients plasma CCK release following a liquid fat meal, is 
enhanced when compared to non operated persons These effects of atropine and 
vagotomy on CCK release are probably explained by the effects of atropine and 
vagotomy on gastric emptying 331 Therefore, the role of the cholinergic system in 
the release of CCK can be studied by infusing atropine together with an intra-
venous stimulus rather than an oral stimulus 
So the aim of this thesis is to leam more about feedback regulation of 
plasma cholecystokinin release and the regulation of gallbladder motility and 
pancreatic enzyme secretion For this purpose, studies were performed in healthy 
subjects using duodenal stimulation with protein, ammo acids and perfusion of bile 
salts, bile salt inhibitors and protease inhibitors Furthermore, stimulation of 
pancreaticobiliary function was also induced by intravenous administration of CCK 
or BBS 
In chapter 2, the effects of intraduodenal perfusion of bile salt séquestrants 
or a protease inhibitor was studied m order to determine if a feedback mechanism, 
mediated by bile salts or proteolytic enzymes, exists in bombesin-stimulated plasma 
CCK and gallbladder contraction In previous studies it was observed that gallblad-
der contraction, plasma CCK levels and, to a lesser extent also pancreatic enzyme 
secretion decrease after an initial rise despite continuous infusion of BBS 29ri "3136 
In chapter 3, the effects of bile salt precipitation on plasma CCK release and 
gallbladder motility, during stimulation with amino acids was studied In order to 
rule out possible effects of bile salt precipitation on food digestion or gastric 
emptying, ammo acids instead of whole proteins were given intraduodenal 1 y 
At present, it is not known whether undigested products of food are able to 
stimulate gallbladder contraction or if digestion is necessary to cause these effects 
In rats whole protein is known to be an effective stimulator of pancreaticobiliary 
secretion, whereas amino acids are not82 In order to study the importance of 
24 
protease activity in the regulation of pancreaticobiliary function a study was 
performed in which albumin or amino acids, together with or without a protease 
inhibitor was administered intraduodenally. The results of these experiments are 
described in chapter 4. 
Chapter 5 describes the effect of duodenal perfusion with chenodeoxycholic 
acid on BBS-stimulated pancreaticobiliary function and CCK release. 
The effect of the cholinergic system on gallbladder motility is suggested to 
be of major importance in the cephalic phase of a meal. We studied whether the 
cholinergic system is also importantly involved in regulating gallbladder motility 
during intravenous stimulation with bombesin. Chapter 6 deals with this topic. 
The importance of opioid receptors, present on gallbladder smooth muscle, 
in the regulation of basal and meal-stimulated gallbladder motility is not yet 
established, although its effect on gastrointestinal motility is well documented. In 
chapter 7 we have studied the effects of an opioid receptor agonist on amino acid 
stimulated PES and CCK release to see whether, next to motility effects secretory 
effects of the gastrointestinal system are also regulated by opioid receptors. 
Chapter 8 describes a study in patients with coeliac disease. In these 
patients, it is known that postprandial gallbladder contraction is impaired.332 
However, it is not known whether a reduced CCK producing capacity of the gut 
causes this phenomenon. In this study we describe the effect of increasing doses of 
bombesin on plasma CCK release and gallbladder motility. 
Finally, a summary of the conclusions reached in the studies that were 
performed is given. 
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ABSTRACT 
Background/Aims: Bombesin-stimulated plasma cholecystokinin levels 
decline after an initial increase despite continuous infusion of bombesin. The aim 
of this study was to determine if a feedback mechanism, mediated by bile salts or 
proteolytic enzymes, is responsible for this decline. Methods: Bombesin (1.0 
ngmkg'*min ') was infused into volunteers for 180 minutes on separate occasions 
Cholestyramine, colestipol, camostate or saline were perfused intraduodenally 
during the second hour of the tests. Cholestyramine was also administered 
without infusion of bombesin. Results: Colestipol and cholestyramine, dependent 
on their bile salt-binding capacity, markedly (P<0.05) enhanced bombesin-
sümulated plasma cholecystokinin from 2.1 ±0.5 pmol/L to 6.4±2.2 pmol/L and 
12.1 ±3.3 pmol/L (P<0.05 vs colestipol), respectively, and further decreased 
gallbladder volume (P<0.05) from 9.4±1.6 mL to 2.0±0.4 mL and 2.2±0.5 
mL, respectively. The protease inhibitor camostate had no effect. Bile salt 
precipitation also enhanced plasma pancreatic polypeptide responses (P < 0.01), 
but did not alter gastrin responses. Plasma cholecystokinin responses to choles-
tyramine without bombesin infusion varied considerably, but increments were 
highly correlated to decreases in gallbladder volume (r=0.91; Ρ<0.005). 
Conclusions: Bile salt sequestration but not protease inactivation enhances 
plasma cholecystokinin and gallbladder responses to bombesin infusion in man 
INTRODUCTION 
Bombesin (BBS) stimulates plasma cholecystokinin (CCK), gallbladder 
emptying and pancreatic enzyme secretion in man M In previous studies, we have 
noticed that plasma CCK levels decrease after an initial increase despite continuous 
infusion of BBS ' 7 The mechanism of this phenomenon might be related to 
feedback inhibition induced by increasing amounts of pancreatic enzymes or bile in 
the intestinal lumen Indeed, several studies have shown that CCK release, in 
response to stimulation with nutrients, is controlled by a feedback mechanism 
involving pancreaticobiliary products in the lumen of the small intestine 7 '4 
However, controversy exists as to whether bile salts1214 '6 or protease activity9 " '7 
regulate this feedback control m humans Furthermore, it is not known if this 
feedback mechanism persists when nutrients are absent from the gut, e g , during 
intravenous stimulation of pancreaticobiliary secretion by BBS 
To determine if a feedback mechanism, mediated by bile salts or proteolytic 
enzymes, exists in BBS-stimulated plasma CCK and gallbladder contraction, the 
effects of intraduodenal perfusion with the bile salt séquestrants cholestyramine or 
colestipol1416""9 (study 1) and the protease inhibitor camostate2021 (study 2) were 
studied The effect of intraduodenal cholestyramine without infusion of BBS (study 
44 
3) was also studied. Furthermore, the effect of camostate or cholestyramine on 
plasma CCK release in response to an intraduodenally administered amino acid 
mixture (study 4) was investigated. In addition, plasma pancreatic polypeptide (PP) 
and gastrin were determined in study 1 because CCK stimulates PP22 but may 
inhibit gastrin release.23 
MATERIALS AND METHODS 
Subjects 
Ten healthy female and 8 healthy male volunteers (mean age, 26 years; 
range 20-46 years) participated in the studies. Non of the volunteers was taking any 
medication or had a history of gastrointestinal symptoms or surgery. The study 
protocol was approved by the ethical committee of the University Hospital Nij­
megen, and all subjects gave their written informed consent before entering the 
study. 
Materials 
Camostate was a gift from Professor Guido Adler (University of Ulm, Ulm, 
Germany). Purchased materials included BBS from UCB (Brussels, Belgium): 
cholestyramine (Questran) from Bristol-Myers Squibb (Woerden, The Netherlands); 
colestipol (Colestid) from Upjohn (Ede, The Netherlands); amino acids from Sigma 
(St. Louis, MO); radioiodinated porcine PP (125I-PPP) from Novo Nordisk AS 
(Bagsvaerd, Denmark); synthetic CCK-33 from Peninsula Laboratories (St. Helens, 
UK); Pharmacia Decanting Suspension #3 and sheep anti rabbit antibody from 
Pharmacia Diagnostics AB (Uppsala, Sweden); synthetic human nonsulfated gastrin 
17 from Cambridge Research Biochemicals Ltd (Cambridge, England); CCK-8-
nonsulfated and ССК-8-sulfated from Neosystem (Strassbourg, France); human 
nonsulfated gastrin 34, human sulfated gastrin 17, human non-sulfated fragment 
gastrin 1-14 and human PP from Sigma (St. Louis, MO, U.S.A.); and human 
nonsulfated gastrin 5-17 from Bachern (Bubendorf, Switzerland); and human 
nonsulfated radioiodinated gastrin 17 from Amersham (Buckinghamshire, England). 
Study Protocols 
After an overnight fast, the volunteers presented at the laboratory at 7:30 
AM. A double-lumen polyvinyl tube was positioned in the duodenum with its 
proximal lumen at the level of the papilla Vateri and its tip positioned 25 cm 
distally. The position of the tube was verified by fluoroscopy. Two indwelling 
intravenous catheters were placed with one in each forearm. The catheters were 
kept patent by a heparine-saline solution. One catheter was used for infusion of 
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BBS, whereas the other catheter was used for the collection of blood samples for 
measurements of CCK, gastrin and PP The following tests, were performed 
Study 1. Seven of the volunteers (3 woman and 4 men, age 21-46 years) 
participated in three experiments performed in random order on different days and 
separated by at least 1 week After the collection of two blood samples under 
unstimulated conditions, 1 0 ng«kg '»mm1 BBS was infused tor 3 hours in each of 
the tests During the second hour of each test, either 12 g/h of cholestyramine or 
12 g/h of colestipol dissolved in 330 itiL of water was administered intraduodenally 
through the proximal lumen of the tube In the third experiment, 330 mL of saline 
was administered m the second hour Blood was collected in ice-chilled glass tubes 
containing 2 g/L of ethylenediammetetraacetate at regular intervals (Figure 1A) 
After the experiments, the blood samples were centnfuged at 4 °C for 10 min at 
3000g The plasma was stored at 20 °C until assayed for CCK, PP or gastrin 
Each time that a blood sample was drawn, two longitudinal and two transverse 
images of the gallbladder were obtained by real time ultrasonography 24 
Study 2. About 2 months after study I, four of the volunteers from study I 
and three other subjects (4 woman and 3 men age, 21-25 years) participated in two 
experiments according to the same protocol as for study 1 However, instead of 
bile salt séquestrants, 1 2 g camostate dissolved in 330 mL of saline or 330 ml of 
saline was perfused intraduodenally during the second hour of the test (Figure 1 A) 
During and at the end of the camostate or saline perfusion period, two duodenal 
juice samples were collected via the distal lumen of the tube for determination ot 
trypsin and chymotrypsin activity 
Study 3. Four of the volunteers from study 2 and three other subjects (3 
women and 4 men, age, 20-27 years) participated in a third experiment that was 
performed according to the same protocol as described for study 1 However, 
instead of BBS, saline was infused intravenously for 3 hours During the second 
hour of the test, 12 g/h of cholestyramine dissolved in 330 mL of water was 
administered intraduodenally at the papilla Vaten level (Figure 1A) 
Study 4. Five volunteers who did not take part in any of the other studies (2 
woman and 3 men, age 21-28 years) participated in 3 experiments in which saline 
(330 mL), cholestyramine (6 g in 330 mL of water/h) or camostate (0 6 g in 330 
mL of saline/h) was constantly perfused intraduodenally for 2 hours During the 
last hour of the tests, 15 g of an amino acid mixture was added to the perfusion 
solutions (Figure IB) On a molecular base, the composition of the amino acid 
mixture was comparable with albumin Blood for measurement of CCK was drawn 
two times before and at 15-minute intervals during intraduodenal perfusion of the 
solutions The solutions were administered intraduodenally to avoid errors in the 
interpretation of the results caused by possible differences m gastric emptying 
between the various experiments 
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Figure 1. (A) Study protocol for the different experiments m studies 1-3. In study 1 (seven 
subjects), 1 0 ng»kg '»mm ' BBS was administered intravenously from 0 to 180 minutes, 
whereas 330 mL saline (sal), 12g/330 mL water cholestyramine (ch) or 12 g/330 mL 
water colestipol (col) were perfused mtraduodenally from 60 to 120 minutes In study 2 
(seven subjects), 1 0 ng*kg '*min ' BBS was administered intravenously from 0 to 180 
minutes, whereas 330 mL saline or 1 2 g/330 mL saline and camostate were perfused 
mtraduodenally from 60 to 120 minutes In study 3, saline was administered intravenously 
from 0 to 180 minutes, whereas 12 g/330 mL water and cholestyramine was perfused 
mtraduodenally from 60 to 120 minutes Plasma samples and gallbladder measurements 
were taken at time intervals indicated by asterisks (B) Study protocol for the two 
experiments in study 4 In both experiments, saline was continuously perfused intra 
duodenallv together with the recovery marker polyethylene glycol 4000 for 3 hours In one 
study, cholestyramine (6 g/h) was added to the saline for the last 2 hours of the ex­
periment In both experiments, 15 g of an amino acid mixture, in the same molecular 
composition as albumin, was perfused mtraduodenally during the last hour of the 
experiments Asterisks denote time points m which blood was drawn for measurement of 
plasma CCK 
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Plasma Samples 
Plasma CCK was measured by a sensitive and specific radioimmunoassay as 
previously described.25-26 The antibody used (T204) binds to biologically active 
CCK peptides containing the sulfated tyrosine region.27 On a molar base, sulphated 
gastrins cross-reacted <2% in the assay, whereas no cross-reactivity with unsul-
phated gastrins or structurally unrelated peptides was found. The detection limit of 
the assay was between 0.5 and 1.0 pmol/L CCK in plasma. The intra-assay 
precision ranged from 4.6% to 11.5% in the steep part of the standard curve, while 
the interassay precision ranged from 11.3% to 26.1 %. 
Plasma PP levels were also determined by radioimmunoassay.28 The 
antibody used showed no cross-reactivity with structurally related gastrointestinal 
regulatory peptides, such as peptide YY or neuropeptide Y, or with structurally 
unrelated gastrointestinal peptides. The intra-assay variation ranged from 4% to 7% 
in the steep part of the standard curve, whereas the inter-assay variation ranged 
from 6% to 12%. The detection limit of the assay was 0.5 pmol/L of incubation 
mixture. 
Plasma gastrin was also measured by radioimmunoassay. The antiserum 
(Gl42-08) was raised against synthetic nonsulphated gastrin 17 coupled to bovine 
serum albumin. The antibody was directed towards the biologically active carboxy-
terminus of gastrin. The antibody has almost equal affinity for sulphated and 
nonsulfated forms of gastrin 34, gastrin 17 and gastrin 5-17. The cross-reactivity of 
these peptides, relative to nonsulfated gastrin 17, ranged between 70% and 110% 
on a molar base. The antibody did not cross-react with the amino-terminal frag­
ment gastrin 1-14, whereas cross-reactivity with sulphated CCK-8 and CCK-33 was 
negligible (<5% on a molar base). No cross-reactivity was observed with struc­
turally unrelated regulatory peptides. Synthetic nonsulphated gastrin 17 was used as 
standard and after coupling to '25I by the chloramine-T method also as label. 
Incubation conditions of anti-serum, labelled gastrin and 50 μ ι of sample or 
standard were chosen as previously described.29 Separation of free and antibody-
bound gastrin was performed by a double antibody technique using Pharmacia 
decanting suspension #3. The ratio of bound- to free-labelled gastrin was inhibited 
by 50% at a concentration of 0.3 pmol/L of incubation mixture. The intra-assay 
variation ranged from 4.5% to 8.4% in the steep part of the standard curve, 
whereas the interassay variation was 7.9% at 34 pmol/L and 8.5% at a con­
centration of 95 pmol/L gastrin in plasma (n=7). The detection limit of the assay 
was 0.1 pmol/L of incubation mixture. 
Protease activity 
In study 2, duodenal juice (5 mL) was collected during two 10-minute 
periods in the second hour of the test (80-90 min and 110-120 min) for deter­
mination of trypsin and chymotrypsin concentrations.жз' 
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Gallbladder Ultrasonography 
Longitudinal and transverse images of the gallbladder were obtained by real­
time ultrasonography (Diasonic RA-1, Siemens [Munich, Germany] or Sonolayer 
Sal 77-B, Toshiba [Tokyo, Japan]) with a 3.5 or 3.75-MHz transducer.2432 
Gallbladder volume was calculated from these images by the sum of cylinders 
method using a computer system.24 The variation of volume measurements ranged 
from 6.0% to 22.4%. 
Statistical Analysis 
All measurements were performed in duplicate, and the mean of these two 
measurements was used for further analysis of results. Gallbladder volume was 
expressed in milliliters and as a percentage of basal volume. Integrated gallbladder 
and plasma CCK responses were determined by calculating the area under the 
gallbladder contraction or CCK concentration time curves after subtraction of basal 
values. Results are expressed as mean ± SEM. Statistical analysis was performed 
by Friedman's two-way analysis of variance and subsequently by Wilcoxon's test 
for paired data (study 1) or by Wilcoxon's test for paired data (study 2-4). Dif­
ferences with a two-tailed Ρ < 0.05 were considered significant. The correlation 
between decreases of gallbladder volumes and increases of plasma CCK in study 3 
was calculated by linear regression analysis. 
RESULTS 
Study 1 
After an initial increase in the first hour of the control experiment to 
126 + 53.4 pmol»L'·60ιτιίη, integrated BBS-stimulated plasma CCK concentrations 
significantly decreased (/><0.05) to 31.0±9.8 pmol#L'»60min in the second and 
to 48.5 + 13.3 pmol«L '«60min in the third hour (Figure 2). In the first hour of 
BBS infusion, integrated plasma CCK responses were not significantly different 
between the control experiment, the colestipol experiment (60.4+21.0 pmol*L ' 
•60min) and the cholestyramine experiment (86.9+29.9 pmol«L'»60min). In the 
second and third hour of BBS infusion, integrated plasma CCK responses sig­
nificantly (P<0.005) increased in the colestipol (191.7+79.2 and 140.6+57.2 
pmol»L'»60min, respectively) and cholestyramine (418.2+113.8 and 337.5 + 86.3 
pmohL'^Omin, respectively) experiments, when compared with the control 
experiment (Figure 2). Integrated plasma CCK responses to cholestyramine were 
significantly (Я < 0.05) higher than the responses to colestipol in the second and 
third hour of BBS infusion. 
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Figure 2. BBS (1.0 ng*kg''min' from 0-180 minutes) stimulated plasma CCK con­
centrations in three experiments performed in random order on different days in which 
either cholestyramine (Ф; 12 g/330 mL water), colestipol (*•; 12 g/330 mL water), or 
saline (O; 330 mL) was administered intraduodenally from 60-120 minutes. Seven healths 
subjects were studied. Values are expressed as mean ± SEM. 
In parallel to the increase of plasma CCK concentration, gallbladder volumes 
decreased (Figure 3). Integrated gallbladder responses were not significantly 
different in the first hour of BBS infusion between the control experiment (2812+ 
236 %«60min), the colestipol experiment (1656 ±641 %#60min) and the choles­
tyramine experiment (1964+736 %»60min). In the second hour of BBS infusion, 
when the anion exchangers or saline were administered, gallbladder volume further 
decreased (P<0.05) in the colestipol and cholestyramine but not in the control 
experiment (Figure 3). In the third hour of BBS infusion, integrated gallbladder 
contraction in the colestipol experiment (4946 ±256 %·60 min) and cholestyramine 
experiment (4869±290 %«60min) was significantly larger (P< 0.005) than that in 
the control experiment (2581 ±679 %«60min). No significant differences in 
gallbladder responses were found between the colestipol and cholestyramine 
experiments. 
Similar to CCK, integrated plasma PP responses to both bile salt seques-
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Figure 3. BBS (1 0 ng*kg ''mm ' from 0-180 minutes) stimulated gallbladder volumes in 
three experiments performed in random order on different days in which either choies 
tyramme f · , 12 g/330 mL water), colestipol (A, 12 g/330 mL water), or saline CO, 330 
mL) was administered intraduodenally from 60-120 minutes Seven healthy subjects were 
studied Values are expressed as mean ± SEM 
trants were significantly enhanced {P<0 01) in the second and third hour of the 
experiment But in contrast to CCK, integrated PP values to cholestyramine and to 
colestipol did not differ (Figure 4) 
Plasma gastrin responses to BBS infusion were not significantly different 
between the control, colestipol, and the cholestyramine experiments (Figure 5) 
Study 2 
Intraduodenal administration of camostate in the second hour of BBS 
infusion did not significantly modify the plasma CCK and gallbladder responses to 
BBS (Figures 6 and 7) 
Trypsin and chymotrypsin activity in the control BBS infusion experiment 
where 5 3 + 17 and 3 5 ± 1 1 kU/L, respectively In the camostate experiment, 
trypsin and chymotrypsin activity were below the detection limit of the assays 
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Figure 4. BBS stimulated (1.0 ng*kg'*min' from 0-180 minutes) plasma PP concen­
trations in three experiments performed in random order on different days in which either 
cholestyramine (Ф; 12 g/330 mL water), colestipol (Ά; 12 gl330 mL water), or saline 
(O; 330 mL) was administered intraduodenally from 60-120 minutes. Seven healthy 
subjects were studied. Values are expressed as mean ± SEM. 
Study 3 
Integrated plasma CCK concentration (2.0±12.2 pmol«L'«óOrnin) in the 
first hour of the experiment increased to 66.4+23.9 pmol'L '»бОтіп (P=0.05) in 
the second hour of the test, when cholestyramine was administered, and to 56.9± 
34.8 pmol»L'*60min (not significant) in the third hour of the test. Integrated 
gallbladder contraction (391 + 152 %«60min) in the first hour of the test increased 
to 1445+644 %«60min (not significant) in the second hour and to 2984 + 890 
%»60min (P=0.05) in the third hour of the test. 
Gallbladder responses to cholestyramine against background infusion of 
saline were somewhat unpredictable but highly correlated (r=0.91; P<0.005) to 
the release of CCK (Figure 8). 
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Figure 5. BBS stimulated (1.0 ng»kg '· min' from 0-180 minutes) plasma gastrin concen­
trations in three experiments performed in random order on different days in which either 
cholestyramine (9; 12 g/330 mL water), colestipol (A; 12 g/330 mL water), or saline 
(O; 330 mL) was administered intraduodenally from 60-120 minutes. Seven healthy 
subjects were studied. Values are expressed as mean ± SEM. 
Study 4 
Integrated plasma CCK concentration during intraduodenal perfusion of 
amino acids was 56±20 pmoleL l#60min. Addition of camostate to amino acids did 
not significantly affect integrated plasma CCK (48 + 11 pmoleL1#60min). 
However, addition of cholestyramine markedly enhanced (Ж0.05) the plasma 
CCK response to amino acids (90+13 pmol#L'»60min). 
DISCUSSION 
The present study shows that both colestipol and cholestyramine augment 
BBS-stimulated plasma CCK concentrations and gallbladder contraction in humans. 
Cholestyramine and colestipol have molecular structures that are chemically not 
53 
11 
^ . 9 
_ l 
Ö 
E 
S 7 
υ 
υ 
ra 5 
E 
w 
_ra 
°- 3-
1 
0 3 0 60 90 120 150 180 
Time (min) 
Figure 6. BBS (1.0 ng»kg '»min' from 0-180 minutes) stimulated plasma CCK concen­
trations in two experiments performed in random order on different days in which either 
camostate (Ш; 1.2 g/330mL saline) or saline (Ώ; 330 mL) was administered intra-
duodenally from 60-120 minutes. Seven healthy subjects were studied. Values are 
expressed as mean ± SEM. 
related to each other.18 However, both substances are anion exchangers that 
precipitate bile salts. Therefore, the data suggest that precipitation of bile salts in 
the lumen of the small intestine is responsible for the augmented effect of colestipol 
or cholestyramine on BBS-stimulated plasma CCK release. On a weight base, 
colestipol augmented BBS-stimulated plasma CCK concentrations significantly less 
than cholestyramine. This reflects the weaker bile salt-precipitating capacity of 
colestipol.18 Despite significantly higher plasma CCK levels when compared to 
colestipol, cholestyramine was not able to further increase BBS-stimulated gallblad­
der contraction, simply because maximal contraction was already achieved by 
colestipol. 
Colestipol and cholestyramine were administered to the subjects at a moment 
that BBS-stimulated plasma CCK concentrations had decreased, despite continuous 
infusion of BBS. The decrease of plasma CCK after an initial rise during con­
tinuous infusion of BBS, which we have observed in several studies before,57 is 
therefore explained by inhibition of CCK release caused by an increased bile salt 
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Figure 7. BBS (1 0 ng*kg '»min ' from 0 180 minutes) stimulated gallbladder volumes in 
two experiments performed in random order on different days in which either camostate 
(Ш, 1 2 g/330 mL saline) or saline (D, 330 mL) was administered intraduodenally from 
60-120 minutes Seven healthy subjects were studied Values are expressed as mean ± 
SEM 
input into the lumen of the small intestine as a result of gallbladder contraction 
This hypothesis is supported by the finding that abolishment of gallbladder 
emptying by the specific CCK receptor antagonist loxiglumide also enhances BBS 
stimulated plasma CCK 5 7 The percentage increase of BBS-stimulated plasma CCK 
in response to cholestyramine was comparable with that in response to loxiglumide 
and a higher dose (2 5 ng«kg '«min ') of BBS 6 7 
Like others,3335 we have also shown that intraduodenal perfusion of saline 
(330 mL/h) against background infusion of saline did not influence plasma CCK 
and gallbladder motility in healthy subjects (data not shown) In the present study, 
a trend for higher CCK levels and stimulation of gallbladder contraction in 
response to 330 mL saline containing the bile salt séquestrant cholestyramine was 
observed (study 3), which may have failed to reach statistical significance because 
the responses were variable and the group of subjects relatively small It is 
interesting to note that in the two subjects without significant (< 10% of basal 
volume) gallbladder emptying in response to cholestyramine, plasma CCK 
55 
Increase In plasma CCK 
(pmol/L) 
5 -
4 " 
3 
2 " 
1 
0 
0 5 10 15 20 25 30 35 
Decrease in gallbladder 
volume (mL) 
Figure 8. Correlation (r=0.9l; Ρ<0.005) between plasma CCK concentrations and 
gallbladder volumes in the interdigestive state in response to intraduodenal administration 
of cholestyramine (12 g/330 mL water administered during a period of 60 minutes) to 
seven healthy volunteers (study 3). 
increments were below the threshold level for gallbladder contraction as previously 
determined.36 On the other hand, in the four subjects with a marked decrease of 
gallbladder volume (>40% of basal volume), plasma CCK increments exceeded 
this threshold level. The excellent correlation between plasma CCK increments and 
decreases of gallbladder volume suggests that CCK not only regulates gallbladder 
motility in response to bile salt precipitating agents under stimulated conditions, but 
also during the interdigestive phase.19 The data on the effect of precipitation of bile 
salts under basal conditions on CCK release in man are different from those 
reported in dogs,15 perhaps because basal secretion of bile salts in dogs may be 
different or because bile salt profiles in dogs are different from man.37 38 
Administration of the protease inhibitor camostate did not affect BBS-
stimulated plasma CCK concentrations or gallbladder volumes. The amount of 
camostate administered in the present study was twice as high as the amount that 
has been shown to eliminate trypsin and chymotrypsin activity in the lumen of the 
small intestine.20-39"" Spot sampling of duodenal contents in the present study also 
showed that chymotrypsin and trypsin activity were eliminated. Therefore, the data 
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show that in humans, protease activity in the lumen of the small intestine is not 
responsible for the decrease of BBS stimulated plasma CCK levels after its initial 
rise. These data are in line with our previous observations that the pancreatic 
enzyme response to BBS is not significantly inhibited by specific CCK receptor 
blockage.6 Pancreatic enzyme activity in the lumen of the small intestine is 
therefore not involved in the augmented CCK response to BBS during loxiglumide 
infusion in humans. 
Our data suggest that bile salts, but not protease activity, mediate a negative 
feedback control of CCK release in humans. This mechanism is different in rats, in 
which a negative feedback control of CCK release is mainly mediated by intra­
luminal protease activity.8A0-42-43 Based on the presented data, however, we can only 
speculate about the possible physiological relevance of our findings because the 
role of BBS in the regulation of CCK release under physiological conditions is 
presently not known and awaits studies with specific BBS receptor antagonists in 
vivo. So far, several indirect arguments can be put foreward in favour of a 
physiological role for BBS in the regulation of CCK release. First, the mammalian 
counterpart of BBS, gastrin-releasing peptide, is present in nerve fibers in the 
vicinity of CCK-producing cells in the mucosa of the human upper gastrointestinal 
tract.44 Thus, gastrin-releasing peptide is an important candidate to stimulate CCK 
release by neurocrine mechanisms. Second, there is evidence that BBS is of 
physiological importance in the regulation of other regulatory peptides, such as 
gastrin4547 and substance P.48 Third, the dose of BBS used in the present study 
stimulates plasma CCK to values in the physiological range comparable with those 
obtained after a meal.5 The data on the effects of camostate and cholestyramine on 
amino acid stimulated CCK release reinforce our hypothesis that bile acids rather 
than protease activity are involved in a negative feedback control between gallblad­
der contraction and CCK release under physiological conditions. These data are in 
line with other studies on the effects of cholestyramine1214"16 and camostate2l'39"41 on 
meal-stimulated plasma CCK release. Inhibition of protease activity under basal 
conditions has indeed been demonstrated to augment basal pancreatic exocrine 
secretion in humans,414950 but this effect is probably not mediated by CCK414Ч but 
by cholinergic mechanisms.41 Like CCK, plasma PP decreases in response to 
continuous infusion of BBS after its initial rise. This decrease is subsequently also 
reverted into an augmented response by the bile salt séquestrants, but in contrast to 
CCK, plasma PP was similarly stimulated by colestipol and cholestyramine. 
Because CCK may be responsible for PP release,5153 our data suggest that the 
augmented BBS-stimulated CCK response to colestipol was already maximally 
effective on the release of PP. 
Neither colestipol nor cholestyramine significantly enhanced the gastrin 
response to BBS. A decrease in gastrin release rather than an increase was ex-
pected because we have previously shown that the specific CCK receptor antagonist 
loxiglumide augmented BBS-stimulated serum gastrin concentrations. Therefore, 
the present results suggest that high circulating concentrations of CCK are probably 
not as powerful in inhibiting plasma gastrin as previously thought.23 
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In conclusion, we have demonstrated that after an initial increase, plasma 
CCK and PP concentrations decrease in response to continuous intravenous 
administration of BBS This decrease of PP and CCK is probably induced by an 
increase of bile salt concentrations in the lumen of the small intestine as a conse­
quence of gallbladder contraction because precipitation of bile salts significantly 
enhances BBS-stimulated CCK and PP concentrations Inhibition of protease 
activity has no effect on BBS-stimulated CCK release and gallbladder contraction 
Therefore, our data suggest that bile salts but not protease activity in the lumen ot 
the small intestine are involved in feedback control of BBS-stimulated CCK release 
in humans 
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ABSTRACT 
Background/Aims: Cholestyramine enhances gallbladder emptying and 
plasma cholecystokinin responses to oral ingestion of a mixed meal. This study 
was performed to determine if this effect occurs independently of alterations in 
gastric emptying or maldigestion of nutrients. Methods: 15 gram of an amino 
acid meal was perfused intraduodenally for 60 min in 7 healthy volunteers, once 
with and once without cholestyramine. Intraduodenal perfusion of saline with or 
without cholestyramine (6 g/h) was started 60 min before the amino acid meal 
and continued for 2 hours. Results: Cholestyramine markedly enhanced 
incremental plasma cholecystokinin response to the meal from 36±12 to 139±25 
pmol*L'*60тіп, (P<0.005), incremental amylase output from 2.4±0.7 to 
5.7±0.7 kU/h, (P<0.05) and incremental integrated gallbladder contraction 
from 1948±235 to 2840±189 %*60min, (P<0.05). Conclusion: The enhancing 
effect of cholestyramine on postprandial gallbladder contraction, pancreatic 
enzyme secretion and plasma cholecystokinin release is not dependent on gastric 
emptying rates or appropriate digestion of nutrients. 
INTRODUCTION 
The anion exchanger cholestyramine precipitates bile salts and is frequently 
used in patients to lower plasma cholesterol levels, to treat obstructive liver 
diseases or to decrease diarrhea induced by bile salt overflow into the colon 
Recently, cholestyramine has also been used to investigate the role of bile salts in 
the regulation of plasma cholecystokinin (CCK) release and pancreaticobiliary 
secretion ' s From these studies it was concluded that bile salt depletion enhances 
plasma CCK levels and gallbladder responses to an orally or intraduodenally (ι d ) 
administered mixed mealM and to bombesin infusion 5 Direct effects of choies 
tyramine on these functions are unlikely, since colestipol, a bile salt binding resin 
with a different molecular structure from cholestyramine, has comparable effects 
on CCK release and gallbladder motility s Nevertheless, cholestyramine may in 
directly affect gallbladder motility and plasma CCK release by enhancing gastric 
emptying6 or by delaying the digestion of fatty nutrients ' To investigate these 
possibilities, we have studied the effect of cholestyramine on plasma CCK and PP 
levels, gallbladder motility and pancreatic enzyme secretion in response to a meal 
stimulus In order to avoid indirect effects induced by gastric emptying, both 
cholestyramine and the meal stimulus were administered intraduodenally To avoid 
effects of cholestyramine on the hydrolysis of nutrients induced by bile salt 
precipitation, an amino acid mixture was used as meal stimulus 
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MATERIALS AND METHODS 
Subjects 
Seven healthy volunteers (3 woman and 4 men, median age 23 years, range 
19 26 years), participated in the studies None of the volunteers was taking any 
medication or had a history of gastrointestinal symptoms or surgery The study 
protocol was approved by the ethical committee of the University Hospital Nij-
megen, and all subjects gave their written informed consent before entering the 
study 
Reagents 
Cholestyramine (Questran*) was obtained from Bristol Myers Squibb (Woerden, 
The Netherlands) as packets containing 4g of the resin, radioiodinated porcine pan-
creatic polypeptide (P,I-PPP) was obtained from Novo Nordisk AS (Bagsvaerd, 
Denmark), synthetic CCK,, from Peninsula Laboratories Europe, Ltd (St Helens, 
England). [i2Sl] hydroxyphenylpropiomc acid-succinimide ester (Bolton Hunter 
reagent) from New England Nuclear (Boston, MA, USA), Pharmacia Decanting 
Suspension #3 from Pharmacia Diagnostics, AB (Uppsala, Sweden), human 
pancreatic polypeptide, L-amino acids from Sigma Chemical Co , St Louis (MO, 
USA), polyethylene glycol 4000 from BDH, Ltd (Poole, England), all other 
materials were obtained from Merck (Amsterdam, The Netherlands) 
Study protocol 
After a 12 hour fasting period, the volunteers presented at the laboratory at 
7 30 hours In random order, 2 experiments were performed separated from each 
other by at least one week At the beginning ot each test a double-lumen polyvinyl 
tube with an outer diameter of 5 7 mm, was positioned in the duodenum The 
proximal lumen of the lube was positioned at the level of the papilla Vaten and the 
distal lumen at the ligament of Treitz The position of the tube was verified by 
fluoroscopy In addition, an indwelling intravenous catheter was placed, in a fore 
arm The catheter was kept patent by a héparine saline solution and was used for 
the collection of blood samples The following tests were performed 
Study 1. Saline (300 mOsmol/L) was continuously perfused intraduodenally 
(i d ) tor three hours (300 mL/h) together with the recovery marker polyethylene 
glycol 4000 (PEG 4000, 6g/L) During the third test hour, 15 g of an amino acid 
solution in the same molecular composition as albumin7 was perfused intra 
duodenally, together with saline (Hgure 1) 
Study 2. Study 2 was performed according to the same protocol as study 1 
However, one hour after the start of saline perfusion, cholestyramine (6 g/h) was 
perlused ι d during the last two test hours (Figure 1) Five-milliliter samples of 
duodenal contents were taken from the tip of the tube during 15 minutes periods by 
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spot-sampling,8 and kept on ice Blood samples were taken every 30 minutes 
during the first hour and subsequently every 15 minutes until the end of the test 
period (Figure 1) 
300 mL/h saline + 1 8 g/h polyethylene glycol 
c h o l e s t y r a m i n e or s a l i n e 
amino acids 
* * * * * * * * * * * 
+ + + + + + + + + + + + + 
I I I Ι ι Ι ι Ι ι Ι ι I 
60 -30 0 30 60 90 120 
Time (mm) 
Figure 1. Studv protocol for the two experiments performed in random order on different 
days In both experiments, saline was continuously perfused intraduodenalh (id) 
together with the recovery marker polyethylene glycol 4000 for 3 hours In one e\ 
périment, cholestyramine (6 g/h) was added to the saline during the last two hours In 
both experiments, 15 g of an ammo acid mixture, m the same molecular composition as 
albumin, was perfused ι d during the last test hour Asterisks denote time points when 
blood was drawn for measurement of plasma CCK and PP, and gallbladder volume was 
measured with ultrasonography Crosses denote time points when duodenal juice WÖ5 
sampled for the determination of amylase output 
Blood was collected in ice-chilled glass tubes containing 2 g/L of ethylene-
diaminetetraacetate (EDTA) After the experiments, the blood samples were 
centrifuged at 4 CC for 10 min at 3000*- Plasma and duodenal samples were stored 
at -20 °C until assayed for CCK, PP, PEG-4000 and amylase Each time that a 
blood sample was drawn, two longitudinal and two transverse images of the 
gallbladder were obtained by real-time ultrasonography 
Plasma Samples 
Plasma CCK was measured by a sensitive and specific radioimmunoassay 
(RIA) as described previously 910 The antibody used (T204) binds to biologically 
active CCK peptides containing the sulfated tyrosine region On a molar base, sul-
fated gastrins cross-reacted <2% in the assay, while no cross-reactivity with 
unsulfated gastrins or structurally unrelated peptides was found The detection limit 
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of the assay was between 0 5 and 1 0 pmol/L CCK in plasma The intra-assay 
precision ranged from 4 6% to 115% in the steep part of the standard curve All 
measurements ot plasma CCK levels were performed in the same run Plasma PP 
levels were also determined by RIA " The antibody used showed no cross-reac 
tivity with structurally related gastrointestinal regulatory peptides, such as peptide 
Y Y or neuropeptide Y, nor with structurally unrelated peptides The detection limit 
of the assay was 0 5 pmol/L of incubation mixture The intra-assay variation 
ranged from 4% to 7% in the steep part of the standard curve All measurements 
of plasma PP levels were performed in one run 
Duodenal Samples 
Duodenal samples were analyzed tor PEG-400012 and amylase activity " 
riow rates passing the distal duodenal sampling site were calculated based on 
known perfusion rates and PEG 4000 concentrations at the perfusion and sampling 
ports я Outputs of amylase were calculated from the product of enzyme activity and 
flow rates Furthermore, in order to exclude a possible direct effect of choles­
tyramine on the amount of free ammo acid concentrations, duodenal samples taken 
during the last test hour were analysed for the amount of free amino acids by ion 
exchange chromatography 7 '4 
Gallbladder Ultrasonography 
I ongitudinal and transverse images of the gallbladder were obtained by real 
time ultrasonography (Sonolayer Sal 77-B, Toshiba, Japan) using a 3 75-MHz 
transducer и | 6 Gallbladder volume was calculated from these images by the sum of 
cylinders method using a computer system 17 The variation of volume measure­
ments ranged from 6% to 22% 
Statistical Analysis 
All measurements were performed in duplicate and the mean of these two 
measurements was used for further analysis of results Gallbladder volume was 
expressed in mL and as a percentage (%) of the mean volume obtained in the first 
hour of the experiment (-60 to 0 minutes) Integrated plasma CCK, PP and 
gallbladder responses were determined by calculating the area under the CCK, PP 
or gallbladder contraction time curves after subtraction of the mean of the values 
obtained in the first 60 mm period ( 60 to 0 minutes) Subsequently, incremental 
integrated CCK, PP and gallbladder contraction to the amino acid meal was 
calculated by subtracting the integrated response in the basal period (0 60 minutes) 
from the integrated response in the period of stimulation (60 120 minutes) in each 
experiment Similarly, incremental amylase outputs were calculated by subtraction 
of the total output in the basal period (0-60 minutes) from the total output in the 
period of stimulation (60 120 minutes) Results are expressed as mean ± SEM 
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Statistical analysis was performed by Student's t test for paired results. Differences 
with a two tailed Ρ value < 0.05 were considered significant.18 
RESULTS 
Plasma Concentrations of CCK 
Basal plasma CCK levels were unaffected by saline perfusion with or 
without cholestyramine and varied between 2.4 and 3.0 pmol/L during the first two 
hours in both experiments (Figure 2). Perfusion of the amino acid solution caused a 
rise in plasma CCK levels from 2.9±0.2 to a maximum of 3.6±0.5 pmol/L, 
achieved 15 min after the start of amino acid perfusion. Thereafter plasma CCK 
levels declined to 3.1+0.3 pmol/L during the last 45 min of the third test hour. 
Perfusion of cholestyramine markedly enhanced amino acid stimulated CCK levels 
to 5.2+0.7 pmol/L, 15 min after the start of amino acid perfusion. Furthermore 
plasma CCK levels did not decline in the last 45 min of the test hour but even 
tended to increase (Figure 2). As a result, incremental integrated levels (Table 1) 
during amino acid perfusion differed between the test without and with choles­
tyramine (36+12 vs. 139 + 25 pmol'L'»60min, P<0.01). 
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Figure 2. Basai and amino acid stimulated (60-120 minutes) plasma CCK concentrations 
(pmol/L) in 7 healthy subjects either with (Ш) or without (О) intraduodenal admi­
nistration (0-120 minutes) of cholestyramine at a dose of 6 g/h. Values are expressed as 
mean ± SEM. 
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Plasma Concentrations of Pancreatic Polypeptide 
Basal plasma pancreatic polypeptide (PP) levels were not affected by saline 
perfusion with or without cholestyramine (Figure 3) and varied between 17 and 22 
pmol/L Perfusion of amino acids caused small increases (P<0 05) of PP from 
18 + 2 to a maximum ot 37+7 pmol/L, 30 min after the start of amino acid perfu­
sion Ingestion of cholestyramine markedly increased plasma PP levels to a maxi­
mum ot 90+22 pmol/L, 45 min after the start of amino acid perfusion As a 
result, incremental integrated plasma PP levels (Table 1) during amino acid perfu­
sion were enhanced by cholestyramine (669±216 vs 3169 + 982 pmol»L'·60ιηιη, 
P<0 05) 
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Figure 3. Basal and amino acid stimulated (60 120 minutes) plasma PP concentrations 
(pmol/L) in 7 healthy subjects either with (Ф) or without (O) intraduodenal admi 
lustration (0-120 minutes) of cholestyramine at a dose of 6 g/h Values are expressed as 
mean ± SEM 
Gallbladder Volume 
Perfusion of saline did not affect basal gallbladder volume (37+4 niL, 
Tigure 4) Mean basal gallbladder volume decreased (P<0 05) from 35 + 3 mL at 
the start to 25+4 mL one hour after perfusion of cholestyramine ( Ж 0 05 vs 
saline), while integrated gallbladder contraction increased (P<0 05) trom 121 + 
121 %»60min to 748 + 352 %«60min (Table 1) Amino acid perfusion resulted in 
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gallbladder contraction from 35+3 niL to a minimum of 19±2 mL, 45 min after 
the start of amino acid perfusion. Cholestyramine further decreased gallbladder 
volume to a minimum of 7±2 mL, 60 min after the start of amino acid perfusion. 
Incremental integrated gallbladder contraction following amino acid perfusion 
(Table 1) was markedly enhanced by cholestyramine (1948 + 235 vs. 2840+189 
%»60min, P<0.05). 
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Figure 4. Basal and amino acid stimulated (60-120 minutes) gallbladder motility (mL) in 
7 healthy subjects either with (%) or without (O) intraduodenal administration (0-120 
minutes) of cholestyramine at a dose of 6 glh. Values are expressed as mean ± SEM. 
Pancreatic Enzyme Output 
Basal amylase output (Figure 5) during saline perfusion was not significantly 
changed by cholestyramine (2.8+0.9 vs. 4.0+1.3 kll/h). Amino acid stimulated 
amylase output was enhanced by cholestyramine (5.2+0.7 vs. 9.7 + 1.6 kU/h, 
Ж0.05). As a result, incremental amylase output was also enhanced (P<0.05) in 
the cholestyramine experiment when compared to amino acid perfusion alone 
(Table 1). 
Amino Acid Analysis 
Perfusion of cholestyramine together with amino acids did not affect free 
amino acid concentrations in duodenal juice at 90 min (Table 2). Furthermore, 
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similar amounts of free amino acids were found in the amino acid meal with and 
without cholestyramine at all other time points during the last test hour (60,75,105 
and 120 minutes, data not shown) 
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Figure 5. Basal and amino acid stimulated (60-120 minutes) amylase output (kU/15min) 
in 7 healthy subjects either with (Ш) or without (O) intraduodenal administration (0-120 
minutes) of cholestyramine at a dose of 6 g/h Values are expressed as mean ± SEM. 
DISCUSSION 
The present study shows that pancreatic enzyme secretion and gallbladder 
contraction as well as plasma CCK and PP release in response to an intraduodenal-
ly administered ammo acid meal are enhanced by duodenal perfusion of choles­
tyramine in humans This is in line with previous studies ' 3 However, the ex­
perimental protocol of the present study differed m several aspects from those of 
previous studies 
Firstly, a basal period of 60 minutes with or without intraduodenal ad­
ministration of cholestyramine preceeded the meal-stimulation period. Therefore, in 
contrast with previous studies this protocol allows us to differentiate between 
effects of cholestyramine on unstimulated and on meal-stimulated functions The 
results demonstrate that cholestyramine significantly induces gallbladder contraction 
under unstimulated conditions and tends to evoke pancreatic enzyme secretion 
without affectmg plasma CCK and PP release. Therefore, the enhancing effect of 
cholestyramine on meal-stimulated gallbladder contraction and pancreatic enzyme 
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Table 1. Integrated responses to i.d. perfusion of saline (sal) with and without choles­
tyramine (CH) in the basal period (0-60 minutes) and to i.d. perfusion of amino acids 
with or without cholestyramine (60-120 minutes). 
test 0-60 min 60-120 min incremental 
сек 
(prnol'L '»60min) 
PP 
(pmol»L l#60min) 
GBCT 
(% «60min) 
sal 
sal + CH 
sal 
sal + CH 
sal 
sal + CH 
-9 + 6 
-6 + 8 
-20 + 90 
3 + 140 
-121 + 121 
748 + 352* 
27+1Г 
133 + 30+'* 
648+143+ 
3172+ 1006t-h 
1827 + 217* 
3589 + 3741'-* 
36+12 
139 + 25* 
669 + 216 
3169 + 982* 
1948 + 235 
2840+189* 
Amylase sal 2.8+0.9 5.2+0.7+ 2.4+0.7 
( k U )
 sal + CH 4.0+1.3 9.7+1.6'* 5.7 + 0.7* 
Data are mean ± SEM from 7 healthy subjects; incremental responses were obtained by 
subtraction of integrated values in the basal period (0-60 minutes) from integrated values 
in the period of stimulation (60-120 minutes), i GBC = gallbladder contraction; 
* = Ρ< 0.05 vs. saline perfusion; t = Ρ<0.05 vs. 0-60 minutes. 
secretion, but not on CCK and PP release, might in part be explained by the effect 
of cholestyramine on these parameters in the basal state. 
Secondly, the meal and the cholestyramine were administered intraduodenal-
ly in this study. Intraduodenal administration excludes possible effects of choles­
tyramine on gastric factors like gastric emptying, which may interfere with the 
ultimate results.14 The persistence of the enhancing effects of cholestyramine after 
intraduodenal administration indicates that cholestyramine can exert its effects 
independent of gastric factors. Only one other study in humans investigated 
intraduodenal administration of a meal.3 However, in that study a mixed meal 
containing whole protein and fat was used. 
Finally, in our study an amino acid mixture was perfused i.d. This elemental 
meal has the advantage that cholestyramine can not interfere with the digestion of 
fat or protein, which is essential for stimulation of gallbladder contraction and CCK 
release."1 This is important, because it has been suggested that the effect of 
cholestyramine is mediated by insufficient formation of micelles as a result of 
intraluminal bile salt sequestration or by binding of fatty acids.' This may result in 
malabsorption of fat and subsequently lead to the exposure of an increased surface 
area of the proximal intestinal mucosa to CCK-stimulating fatty nutrients for a 
prolonged period of time.1 The present data indicate that the enhancing effect of 
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cholestyramine is not necessarilly related to fatty nutrients, but persists with an 
amino acid mixture and therefore indicates that other mechanisms are involved. 
Theoretically, cholestyramine may bind amino acids and thereby delay the 
absorption of CCK stimulating substances which may in tum trigger CCK cells to 
increased secretion. This possibility was excluded by the presence of similar 
concentrations of free amino acids in both the study with and without choles-
tyramine. 
In conclusion, the present study demonstrates that the enhancing effect of 
cholestyramine on meal-stimulated gallbladder contraction, pancreatic enzyme 
secretion, CCK and PP release is independent of gastric emptying and the 
hydrolysis of nutrients. 
Table 2. Free essential amino acids present in duodenal juice (mmol/L) at 90 
minutes when either amino acids without or with cholestyramine were perfused 
(data are mean ± SEM from 7 healthy subjects). 
VALINE 
METHIONINE 
PHENYLALANINE 
LEUCINE 
ISOLEUCINE 
TYROSINE 
LYSINE 
HLSTIDINE 
AMINO ACIDS 
7.6+0.8 
0.6±0.1 
6.5+0.6 
13.3 + 1.5 
2.6+0.3 
2.1+0.1 
18.8+1.5 
4.4+0.4 
AMINO ACIDS + 
CHOLESTYRAMINE 
7.5+0.8 
0.6+0.1 
6.3+0.5 
12.7 + 1.2 
2.6+0.2 
2.3+0.2 
16.8 + 3.5 
4.6+0.3 
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ABSTRACT 
Background & Aims: The role of small intestinal proteolytic activity in the 
regulation of upper gastrointestinal function in humans is poorly under stood. 
The aim of this study was to determine the importance of proteolytic activity for 
protein- or amino acid-induced cholecystokinin release and pancreaticobiliary 
secretion. Methods: In 9 healthy subjects, saline was perfused intraduodenally for 
3 hours either with or without the synthetic protease inhibitor camostate. During 
the last hour, albumin or amino acids, in the same molecular composition as 
albumin, were also perfused. Results: Perfusion with camostate, in con-
centrations that abolished intraduodenal proteolytic activity, had no effect on 
unstimulated plasma cholecystokinin concentrations or gallbladder emptying, but 
markedly (P < 0.05) increased unstimulated pancreatic enzyme output. Perfusion 
with protein, distinctly stimulated cholecystokinin release, gallbladder emptying 
and pancreatic enzyme output (P < 0.05). Perfusion with camostate resulted in 
significantly lower protein-stimulated plasma cholecystokinin, gallbladder and 
pancreatic enzyme responses (P<0.05). Perfusion with amino acids also 
stimulated plasma cholecystokinin, gallbladder emptying, and pancreatic enzyme 
output (P<0.05). Camostate did not inhibit these values. Conclusions: This study 
shows that appropriate digestion of protein is required to stimulate plasma 
cholecystokinin release, gallbladder emptying, and pancreatic enzyme secretion in 
humans. 
INTRODUCTION 
Pancreaticobiliary responses to meals, which are essential for the digestion 
of nutrients, can be classified into (1) cephalic responses, which are mainly 
activated by seeing, smelling, chewing, and swallowing of food, and are primarily 
induced by vagal cholinergic activity,1 (2) gastric responses, which are activated 
when food enters the stomach and are principally dependent on local cholinergic 
activity,2 and (3) intestinal responses, which are activated when food enters the 
duodenum and are not only dependent on cholinergic but also on peptidergic 
activity 3 Intestinal responses are considered to be most important for appropriate 
digestion of nutrients Regulation of pancreaticobiliary secretion at the intestinal 
level is subjected to feedback control, in which protease activity seems to play an 
important role4 7 However, indications accumulate that species differences in 
feedback regulation of pancreaticobiliary secretion complicate extrapolation of 
animal data to humans8 '2 A clear comprehension of feedback regulation of 
pancreaticobiliary secretion in humans is of major importance for the understanding 
of clinical conditions such as exocrine pancreatic insufficiency and gallstone 
disease 
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The aim of the present study was to investigate the importance of protease 
activity in the regulation of cholecystokinin (CCK) release, gallbladder contraction, 
and pancreatic exocrine secretion under both basal conditions and during 
stimulation with protem (albumin) or an amino acid mixture For this purpose, 
protease activity in the lumen of the small intestine was inactivated in some of the 
experiments by perfusing the duodenum with camostate, a synthetic protease 
inhibitor that inactivates proteases including trypsin, chymotrypsin, phospholipase-
A, and pancreatic kalhkrein 8 9 '3 
MATERIALS AND METHODS 
Subjects 
Nine healthy volunteers (1 woman and 8 men, mean age, 24 + 3 years) 
participated in the studies None of the volunteers was taking any medication or 
had a history of gastrointestinal symptoms or surgery The study protocol was 
approved by the ethical committee of the University Hospital Nijmegen, and all 
subjects gave their written informed consent before entering the study 
Reagents 
Camostate was a gift from Professor Guido Adler (University of Ulm, 
Germany) Radioiodinated porcine pancreatic polypeptide (l25I-PPP) was obtained 
from Novo Nordisk AS (Bagsvaerd, Denmark), synthetic CCKj3 from Peninsula 
Laboratories Europe, Ltd (St Helens, England), [l25I]-hydroxyphenylpropionic 
acid-succimmide ester (Bolton-Hunter reagent) from New England Nuclear 
(Boston, MA, USA), Pharmacia Decanting Suspension #3 from Pharmacia 
Diagnostics, AB (Uppsala, Sweden), human pancreatic polypeptide, L amino 
acids, and albumin from Sigma Chemical Co (St Louis, MO, USA), PEG 4000 
from BDH Ltd (Poole, England), and trypsin radioimmunoassay kits from Behring 
Diagnostica (Amsterdam, The Netherlands) All other materials were obtained from 
Merck (Amsterdam, The Netherlands) 
Study Protocol 
After a 12 hour fast, the volunteers presented at the laboratory at 07 30 AM 
In random order, 4 experiments were performed separated from each other by at 
least one week A triple-lumen polyvinyl tube with an outer diameter of 5 7 mm, 
was positioned under fluoroscopic control with the proximal lumen in the stomach, 
the middle lumen at the level of the ampulla ot Vater and the distal lumen at the 
ligament of Treitz In addition, an indwelling intravenous catheter was placed in a 
lorearm for the collection of blood samples After an equilibration period of at 
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least 30 minutes, the following tests were performed 
Study 1. In 9 subjects, polyethylene glycol 4000 (0 6 g/100 mL saline) was 
perfused through the middle opening of the tube at a rate of 5 mL/min during the 
entire 3 hour study period Camostate (0 6 g/h) was added to this solution during 
the last 2 hours of the test During the last hour of the test, albumin (15 g/h, 330 
mOsmol/L) was also perfused intraduodenally through the middle opening of the 
tube (Figure 1) 
saline + PEG-4000 
camostate (test 1 and 3) 
albumin or AA 
* • * * * * * * * * * 
Ι ι Ι ι Ι ι Ι ι I . I I 
60 30 0 30 60 90 120 
Time (mm) 
Figure 1. Study protocol for the different experiments in study 1-4 In study 1 (9 sub­
jects), saline (300 ml/h) was continuously perfused intraduodenally with the recovery 
marker polyethylene glycol 4000 (1 8 g/h) for 3 hours During the last 2 hours of the 
test, the protease inhibitor camostate (0 6 g/h) was added to saline, whereas albumin (15 
g) was added to saline during the last test hour In study 2 (9 subjects), albumin was per­
fused during the last test hour without camostate In studies 3 and 4 (6 subjects), the 
same experiments as in studies I and 2 were performed However instead of albumin 
amino acids were perfused Asterisks denote time points when blood was drawn and 
ultrasonography was performed Duodenal juice was collected over each 15 minute period 
by spot sampling 
Study 2. The protocol of study 2 was comparable with that of study 1, 
however, in this experiment, 15 g of albumin without camostate was perfused 
intraduodenally in the 9 subjects during the last hour of the test (Figure 1) 
Study 3. The protocol of study 3 was also comparable with that of study 1, 
however, instead of albumin, 15 g of an L amino acid solution (330 mOsmol/L) in 
the same molecular composition as in albumin (Table 1) was perfused intra 
duodenally in 6 of the 9 subjects (6 men, 24 ± 1 years of age) during the last hour 
of the test (Figure 1 ) 
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Study 4. The protocol of study 4 was comparable with that of study 3 but, 
ш this experiment, 15 g of the L-amino acid mixture without camostate was 
perfused intraduodenally in the 6 subjects of study 3 during the last hour of the test 
(Figure 1) 
Table 1: Ammo Acid Content of the Albumin Meal 
Amino acid Content (mmol)* 
Alanine 8 9 
Arginine 5 3 
Aspartic acid 10 5 
Cystine 3 3 
Glutamic acid 14 4 
Glycine 3 0 
Histidine 3 3 
Isoleucine 2 5 
Leucine 12 0 
Lysine 14 0 
Methionine 0 7 
Phenylalanine 5 1 
Proline 5 3 
Serine 5 1 
Threonine 6 2 
Tryptophan 0 4 
Tyrosine 3 6 
Valine 6 4 
= amount of amino acids (mmol) in 15 g of the albumin meat 
In all tests, gastric acid was continuously drained through the proximal 
opening of the tube by intermittent negative pressure 
Five milliliter samples of duodenal contents were taken during 15-minute 
periods from the tip of the tube by spotsamplingN and kept on ice Blood samples 
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were taken every 30 minutes during the first hour and subsequently every 15 
minutes until the end of the test period (Figure 1 ). 
Blood was collected in ice-chilled glass tubes containing 2 g/L of ethylene-
diaminetetraacetic acid. After the experiments were performed, the blood samples 
were centrifuged at 4 °C for 10 min at 3000g. 
Plasma and duodenal samples were stored at -20 °C until assayed for CCK, 
pancreatic polypeptide, or polyethylene glycol 4000, bilirubin, amylase, trypsin and 
chymotrypsin. Each time that a blood sample was drawn, two longitudinal and two 
transverse images of the gallbladder were obtained by real-time ultrasonography. 
To determine if camostate affects amylase concentrations in vitro, four 
milliliter of duodenal juice obtained in 5 subjects during amino acid perfusion was 
divided into 2 samples of 2 milliliter each and incubated at 37°C for 30 minutes 
with or without 2 mg/mL of camostate. Subsequently, the samples were put on ice 
for another 60 minutes and frozen until assayed for amylase activity. 
Plasma Samples 
Plasma CCK was measured by a sensitive and specific radioimmunoassay as 
described previously.1316 The antibody used (T204) binds to biologically active 
CCK peptides containing the sulfated tyrosine region with almost equal affinity. On 
a molar base, sulfated gastrins cross-reacted <2% in the assay, whereas no cross-
reactivity with unsulfated gastrins or structurally unrelated peptides was found. The 
detection limit of the assay was between 0.5 and 1.0 pmol/L CCK in plasma. The 
mtra-assay precision ranged from 4.6% to 11.5% in the steep part of the standard 
curve. All measurements of plasma CCK levels were performed in the same run. 
Plasma pancreatic polypeptide levels were also determined by radioimmuno-
assay.17 The antibody used showed no cross-reactivity with structurally related 
gastrointestinal regulatory peptides, such as peptide Y Y or neuropeptide Y, or with 
structurally unrelated peptides. The detection limit of the assay was 0.5 pmol/L of 
incubation mixture. The intra-assay variation ranged from 4% to 7% in the steep 
part of the standard curve. All measurements of plasma PP levels were performed 
in one run. 
Duodenal Samples 
Duodenal samples were analyzed for polyethylene glycol 4000,'8 bilirubin,19 
amylase activity,20 and trypsin concentrations. Trypsin concentrations in the 
duodenal samples were measured by a commercially available radioimmunoassay 
kit.21 For measurement of trypsin concentrations, the duodenal samples were 
diluted with assay buffer finally containing 2 mg/L of camostate. Camostate did not 
displace radiolabelled trypsin from the antibody, and addition of camostate to the 
standard trypsin solution resulted in an identical standard curve as without camos 
late (data not shown). Flow rates passing the distal duodenal sampling site were 
calculated based on known perfusion rates and poyethylene glycol 4000 con-
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centraiions at the perfusion and sampling ports 14 Outputs of bilirubin, trypsin, and 
amylase were calculated from the product of concentrations or activity and flow 
rates In basal duodenal samples taken in the 15-minute period before and from 45 
to 60 minutes after the start ot albumin perfusion with or without camostate, 
trypsin and chymotrypsin activity was determined 2 2 2 3 In these samples, amino acid 
analysis was also performed by ion-exchange chromatography24 on an amino acid 
analyser (Sykam S432) according to the procedure from the manufacturer 
(Analylica bv, Rijswijk, The Netherlands) Ninhydrin reagent was used, and the 
ninhydrm-amino acid adduct was quantified with an absorbence detector (Uvis-205, 
Lineair, Analytica bv, Rijswijk, The Netherlands) 
Gallbladder Ultrasonography 
I ongitudinal and transverse images of the gallbladder were obtained by real­
time ultrasonography (Sonolayer Sal 77-B, Toshiba, Tokyo, Japan) using a 3 75-
MHz transducer 2 5 2 6 Gallbladder volume was calculated from these images by the 
sum of cylinders method using a computer system 27 The variation of volume 
measurements ranged from 6% to 22% 
Statistical Analysis 
All measurements were performed in duplicate, and the mean of these two 
measurements was used for further analysis of results Gallbladder volume was 
expressed in milliliters Integrated plasma CCK, pancreatic polypeptide, and 
gallbladder responses were determined by calculating the area under the CCK, 
pancreatic polypeptide, or gallbladder contraction time curves Subsequently, 
incremental CCK, pancreatic polypeptide, and gallbladder responses to the various 
stimulants were calculated by subtracting the integrated response in the basal period 
(0 60 minutes) from the integrated response in the period of stimulation (60 120 
minutes) in each experiment Similarly, incremental bilirubin, amylase, and trypsin 
outputs were calculated by subtraction of the total output m the basal period (0-60 
minutes) from the total output in the period of stimulation (60-120 minutes) 
Results are expressed as mean ± SEM Statistical analysis was performed 
by two-way analysis of variance (trypsin output after loganthmical transformation) 
and subsequently by least significant difference test or by Student's t test for paired 
results When appropriate, the method of Bonferrom was used to correct for 
multiple testing Differences with a two tailed probability Ρ value of <0 05 were 
considered significant 
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RESULTS 
Plasma Concentrations of CCK and Pancreatic Polypeptide 
Plasma CCK and pancreatic polypeptide time curves are shown in Figures 2 
and 3. Perfusion of camostate did not significantly influence basal CCK (2.3 + 0.3 
pmol/L) and pancreatic polypeptide (20 + 3 pmol/L) levels (Table 2). Both the 
albumin and amino acid meal induced significant (P<0.05) increases of plasma 
CCK to 3.0 + 0.4 pmol/L and 4.1+0.5 pmol/L (Figure 2) and of plasma pancreatic 
polypeptide to 30±3 pmol/L and 44+4 pmol/L (Figure 3), respectively. Camostate 
abolished (P<0.05) incremental plasma CCK and pancreatic polypeptide responses 
to albumin perfusion but was without effect on incremental CCK and pancreatic 
polypeptide responses to the amino acid meal (Table 3). Incremental CCK and 
pancreatic polypeptide values in the amino acid experiments were higher than in the 
albumin experiment, but in case of CCK, this difference failed to reach statistical 
significance. 
Gallbladder Volume and Bilirubin Output 
Camostate did not significantly influence basal gallbladder volume nor 
bilirubin output (Figures 4 and 5 and Table 2). Perfusion of albumin or amino 
acids without camostate induced a statistically significant decrease of gallbladder 
volume (P<0.00\) , which was accompanied by a significant (P<0.05) increase 
of bilirubin output into the duodenum (Figures 4 and 5). Camostate completely 
inhibited incremental gallbladder contraction and bilirubin output in response to 
albumin (P<0.05) but not to amino acids (Table 3). Gallbladder and bilirubin 
responses to amino acids with and without camostate were higher than those to 
albumin with and without camostate, but in case of bilirubin output, this difference 
failed to reach statistical significance. 
Pancreatic Enzyme Output 
Perfusion of camostate markedly (P<0.05) increased basal trypsin and 
amylase output when compared to saline (Figure 6 and Table 2). In the albumin 
experiments, camostate significantly (P<0.05) inhibited incremental trypsin output 
and reduced incremental amylase output when compared with albumin perfusion 
alone (Table 3). Incremental trypsin and amylase outputs during perfusion of amino 
acids were not influenced by camostate. 
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Figure 2. Plasma CCK (pmol/L) in response to intraduodenal perfusion of (A) 15 g of 
albumin in 9 healthy subjects or (B) 15 g of amino acids m 6 healthy subjects with (open 
symbols) or without (closed symbols) the protease inhibitor camostate Results are 
expressed as mean ± SEM 
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Figure 3. Plasma pancreatic polypeptide (pmol/L) in response to intraduodenal perfusion 
of (A) 15 g of albumin in 9 healthy subjects or (B) 15 g of amino acids in 6 healthy 
subjects with (open symbols) or without (closed symbols) the protease inhibitor camostate 
Results are expressed as mean ± SEM 
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Table 2: Integrated responses in the basal period (0 60 Minutes) 
Without camostate With camostate 
CCK 
(pmol/L*60min) 
Pancreatic polypeptide 
(pmol/L»60min) 
Gallbladder contraction 
(mL»60min) 
Bilirubin 
(μΓΠθ1) 
Trypsin 
(Mg) 
137±16 
1246±104 
-34±51 
15 2+4 8 
216+43' 
128+16 
1318+214 
18+55 
16 3±5 0 
633+128 
Amylase 5 1+0 8* 7 2+12 
(kU) 
Integrated responses to intraduodenal perfusion of saline with or without camostate in the 
basal period (0-60 minutes) in 9 subjects Results are expressed as mean ± SEM 
* significantly different (P<0 05) from camostate 
Trypsin and Chymotrypsin Activity 
Trypsin and chymotrypsin at the end of the last test hour (105-120 minutes) 
were 1 13 + 0 62 and 0 34 ± 0 11 kU/L, respectively, during perfusion of 
albumin without camostate, whereas they were below the the detection limit 
(<0 01 kU/L) of the assays (P<0 01) when albumin was perfused with camostate 
Amino acid analysis 
Before and at the end of albumin perfusion experiments, an additional 
duodenal juice sample was obtained for amino acid analysis During albumin 
perfusion, high amounts of free amino acids were detectable, whereas during 
addition of camostate to the albumin solution, almost no free ammo acids were 
present (P<0 001 for all amino acids measured, Table 4) 
In Vitro Amylase Activity 
Amylase activity in the 5 duodenal samples obtained during perfusion of the 
duodenum with amino acids was 38 4±8 4 kU/L Addition of camostate to these 
samples did not significantly affect amylase activity (41 0+8 8 kU/L) 
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Figure 4. Gallbladder volumes (mL) in response to intraduodenal perfusion of (A) 15 g of 
albumin m 9 healthy subjects or (B) 15 g of ammo acids in 6 healthy subjects with (open 
symbols) or without (closed symbols) the protease inhibitor camostate Result ч are 
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Figure 5. Bilirubin output (μ/ηοί/15ηιιη) in response to intraduodenal perfusión of (A) 15 
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Figure 6. (A and B) Trypsin output (μξ/Ιδηιίη) and (C and D) amylase output (kU/15min) 
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DISCUSSION 
In the present study, we have shown that the synthetic protease inhibitor 
camostate inhibits CCK release, pancreatic polypeptide release, gallbladder 
motility, and pancreatic enzyme secretion in response to intraduodenally perfused 
albumin Camostate by itself is not responsible for the observed effects because 
camostate did not affect these parameters in response to an amino acid mixture in 
the same molecular composition as in albumin Camostate almost abolished trypsin 
and chymotrypsin activity in the lumen of the small intestine not only under basal 
conditions but also during perfusion of albumin The very low concentrations of 
free amino acids measured in the duodenal samples during perfusion of albumin 
with camostate are thus explained by impaired proteolysis of albumin We therefore 
conclude that digestion of protein is of crucial importance for stimulation ot CCK 
release, pancreatic polypeptide release, gallbladder contraction, and pancreatic 
enzyme secretion in humans 
Table 3: Incremental integrated responses 
Albumin Albumin Amino acids Amino acids 
+ camostate + camostate 
CCK 
(pmol/L»60min) 
Pancreatic 
polypeptide 
(pmol/L«60min) 
Gallbladder 
contraction 
(ml«60min) 
Bilirubin 
(μΐηοΐ) 
Trypsin 
(Mg) 
27 0 + 6 3* 
245+71* 
504±116* 
32 3 + 9 4* 
903 + 192* 
-184+100 
29 ±66 
110+50 
1 3+4 6 
383 + 123 
58 1 ±17 6* 
978 + 131** 
871±123** 
45 2+17 7* 
836 + 166* 
49 0±6 8* 
1155 + 115*1 
744 + 81* ' 
61 6+12 9* 
876 + 304 
Amylase 3 7 ± 1 7 13+0 8 2 9+0 6 3 9+0 8 
(kU) 
Incremental responses to intraduodenal perfusion of albumin or amino acids with or 
without camostate in 6 subjects Incremental responses were obtained after subtraction of 
integrated values m the basal period (0-60 minutes) from integrated \alues in the period 
of stimulation (60 120 minutes) Results are expressed as mean ± SEM 
* significantly different (P<0 05) from albumin with camostate 
* significantly different (P<0 05) from albumin without camostate 
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Table 4: Increments (Mean ± SEM) of intraduodenal free amino acid concentrations 
(μηιοΙ/L) in response to an albumin meal with or without camostate 
Ammo Acid Albumin Albumin + camostate 
Threonine 
Serme 
Aspartic acid 
Glutamic acid 
Proline 
Glycine 
Alanine 
Valine 
Cystine 
Methionine 
Isoleucine 
Leucine 
Tyrosine 
Phenylalanine 
Lysine 
Histidine 
Argmine 
Tryptophan* 
= not quantitatively tested 
1963±414 
1420 ±303 
708±135 
1599+334 
579 ±145 
226 ±86 
2836+635 
3397+744 
391+79 
612 + 93 
1189+231 
6073 + 1186 
2727 + 809 
4420 ±858 
7108 + 1426 
1248+246 
3664 + 721 
+ + + + 
163 ±62 
144+46 
33+20 
82+36 
150±68 
115+41 
278 ±64 
192+42 
12+6 
37+12 
61 + 18 
302+69 
78 + 23 
154±42 
173 + 32 
54+16 
90 ±20 
+ + 
These findings are in Ime with the observation that inactivation of lipase 
activity m the lumen of the small intestine by the synthetic lipase inhibitor tetra-
hydrohpstatin inhibits CCK release in response to unhydrolysed fat and alters 
biological functions of the hormone, such as biliary output, pancreatic enzyme 
secretion, and gastric emptying 28 In dogs, amino acids or fatty acids were also 
found to be more effective than intact proteins or fat in stimulating pancreatic 
exocrine secretion2930 This mechanism is different in rats, in which only intact 
proteins, but not ammo acids, stimulate the release of CCK and pancreatic exocrine 
secretion'1 " 
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Inactivation of protease activity in the lumen of the human small intestine by 
camostate under basal conditions resulted in a significant increase of amylase and 
trypsin output but did not stimulate gallbladder contraction and plasma CCK 
release. Addition of camostate to duodenal samples did not significantly influence 
amylase concentrations. This excludes the possibility that the increase of amylase 
concentrations during camostate perfusion was the result of impaired autodigestion 
of amylase by inhibition of protease activity.932 This supports the hypothesis that at 
least under unstimulated conditions, feedback regulation between pancreatic enzyme 
secretion and protease activity in the lumen of the small intestine is operative in 
humans8'1033 as well as in other species like rats.73435 However, in contrast with 
rats,735 protease dependent feedback regulation of pancreatic exocrine secretion 
under basal conditions in humans is probably not mediated by CCK, but by 
cholinergic activity.10 
CCK-dependent negative feedback regulation between intraluminal contents 
and pancreatic exocrine secretion has not only been demonstrated under basal 
conditions but also after stimulation with a meal.4735 However, the present study is 
inconsistent with this hypothesis becuase camostate did not enhance albumin- or 
amino acid-stimulated CCK release. Methodological differences between previous 
studies and the present study may have contributed to these conflicting results con-
cerning the role of protease activity in the lumen of the human small intestine and 
CCK release. In contrast with our study, CCK was not measured31 or measured by 
different techniques4 35 or less specific antibodies32 and endogenous protease activity 
was not inactivated by camostate33 34 or suppressed by perfusing bovine trypsin into 
the duodenum.4 The latter study4 shows that proteases can inhibit CCK release, 
whereas the present study shows that inhibition of proteases does not stimulate 
CCK release. 
Because we and others have demonstrated that CCK release and gallbladder 
contraction in response to intraduodenal administration of a meal or bombesin are 
augmented by sequestration of bile acids" ,63Q but not by protease inactivation, we 
believe that CCK-mediated feedback control of pancreaticobiliary secretion in 
humans is principally regulated by bile acids and not by protease activity.10 
Protein and fat are the major constituents of a meal that stimulate CCK 
release, pancreatic exocrine secretion, and gallbladder contraction.3941 In a meal 
that was isonitrogenous to 18 g of beaf hydrolysate, the amount of the individual 
amino acids tryptophan, methionine, phenylalanine, and valine, which were potent 
stimuli of exocrine pancreatic secretion,4243 was 0.8, 3.1, 4.0, and 7.7 mmol/h 
respectively. The amounts of the individual amino acids present in our albumin and 
amino acid meal (0.4, 0.7, 5.1 and 6.4 mmol/h, respectively) were comparable. 
These results confirm that CCK is important for stimulating pancreaticobiliary 
secretion in humans at nutrient quantities comparable with a regular meal.3944 
The present findings, together with the report that lipolysis is essential to 
stimulate CCK release and gallbladder contraction in humans,28 provide an explana-
tion for our findings in patients with exocrine pancreatic insufficiency in which 
impaired postprandial release of CCK and gallbladder motility are restored by 
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supplementation of pancreatic enzymes M The present data also provide an explana­
tion for our experiences in patients with coehac disease and a flat jejunal mucosa in 
which CCK release and gallbladder contraction are also impaired in response to an 
ordinary meal but not to a predigested meal43 "6 
In conclusion, the present study shows that intraduodenal stimulation of 
CCK release, gallbladder contraction, and pancreatic enzyme secretion is dependent 
on digestion of protein Undigested protein only weakly stimulates pancreatic 
enzyme output and does not significantly stimulate CCK release and gallbladder 
contraction, whereas digested protein markedly stimulates the release of CCK, 
gallbladder contraction, and pancreatic enzyme output 
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ABSTRACT 
Background: Bile salts modulate postprandial gallbladder emptying and 
pancreatic enzyme secretion possibly by interfering with plasma cholecystokinin 
responses. The regulatory role of bile salts in the absence of nutrients from the 
gut is poorly understood. Aim: Therefore, we studied the effect of intraduodenal 
sodium chenodeoxycholate on bombesin or cholecystokinin stimulated plasma 
cholecystokinin, plasma pancreatic polypeptide, gallbladder motility and pancrea­
tic enzyme secretion. Methods: In a cross over design saline without or with 
chenodexycholate was perfused intraduodenally for 3 hours in healthy volunteers. 
During the last hour either bombesin (n=9) or cholecystokinin (n=10) was 
infused intravenously. Results: Chenodeoxycholate inhibited bombesin stimulated 
gallbladder contraction from 59±4% to 34+6% (P<0.05), incremental amylase 
output from 27±10 to 21 ±3 kU/h (NS), pancreatic polypeptide release from 
555±201 to 198±98 pM*60min (P=0.08) and bilirubin output from 53±7 to 
34±4 μmol/h (P<0.05), but it increased integrated plasma cholecystokinin levels 
from 157+19 to 184+19 pM»60min (P=0.01). Similarly, chenodeoxycholate 
inhibited gallbladder contraction (P< 0.001), bilirubin output (P=0.08), amylase 
output (P=0.06) and incremental pancreatic polypeptide release (P=0.005) in 
response to intravenous cholecystokinin. Conclusion: Intraduodenal chenodeoxy­
cholate inhibits bombesin and cholecystokinin stimulated gallbladder emptying, 
pancreatic enzyme secretion and pancreatic polypeptide release, most probably by 
diminishing the sensitivity to cholecystokinin. 
INTRODUCTION 
Bile acids are important for appropriate digestion and absorption of fatty 
nutrients. Bile acids are currently used in the treatment of several gastrointestinal 
disorders like primairy biliary cirrhosis, sclerosing cholangitis, dissolution of 
gallstones and cystic fibrosis. Bile acids in the proximal gut also affect gallbladder 
emptying and pancreatic enzyme secretion.1"3 Several studies indicate that bile or 
bile acids in the lumen of the proximal gut induce pancreatic enzyme secretion 
under basal conditions,4 '° while oral treatment with ursodeoxycholic acid increases 
basal gallbladder volume in gallstone patients and in normal subjects." '2 However, 
intraduodenal bile acids reduce pancreaticobiliary secretion in response to stimulati­
on with products of protein or fat digestion in the proximal gut.2-3 Bile acids do not 
modify the effects of intravenous cholecystokinin.2 However, from these studies, it 
was not clear if plasma cholecystokinin levels obtained during i.v. infusion were 
within the physiological range. It was postulated that modification of pancreatic 
enzyme secretion or bilirubin output under stimulated conditions was related to an 
interaction between nutrients and bile acids in the proximal gut, determining the 
amount of cholecystokinin released.2·3 Data obtained from studies using binding of 
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bile acids by cholestyramine indeed suggest that this inhibitory effect of bile acids 
can be attributed at least in part to inhibition of plasma cholecystokinin release ' '3 
Furthermore, it was recently shown that plasma CCK release in response to an 
intraduodenal mixed liquid meal was inhibited when sodium chenodeoxycholic acid 
(CDCA) was given together with the meal 14 
The present study was undertaken to determine the effect of intraluminal 
CDCA on basal and stimulated plasma CCK release and pancreaticobiliary function 
in the absence of nutrients from the gut Plasma CCK and pancreatic polypeptide, 
gallbladder volume, and output of bilirubin and amylase into the duodenum were 
measured under basal conditions and during ι ν stimulation with low doses of 
bombesin inducing plasma CCK levels m the physiological range To further 
elucidate the mechanism by which bile acids affect pancreatic enzyme secretion and 
gallbladder motility, the effect of intraduodenal CDCA was also studied during ι ν 
infusion of cholecystokinin inducing plasma cholecystokinin levels within the 
physiological range The amount of CDCA perfused corresponded to the amounts 
and concentrations as observed intraduodenal 1 y after a meal '5 '6 Since bile salts are 
delivered gradually to the duodenum over a certain period of time, we chose for a 
continuous perfusion rather than instillation of the bile salt in the given concentrati 
on at once 
MATERIALS AND METHODS 
Subjects 
Nineteen healthy volunteers (12 women and 7 men, mean age 25 years, 
range 18-45 years), participated in the studies None of the volunteers was taking 
any medication or had a history of gastrointestinal symptoms or surgery The study 
protocols were approved by the ethical committee of the University Hospital 
Nijmegen, and all subjects gave their written informed consent before entering the 
study 
Reagents 
Bombesin (BBS) was obtained from UCB (Brussels, Belgium) and cholecys­
tokinin (CCK) from Ferring (Malmo, Sweden) Radioiodinated porcine pancreatic 
polypeptide (PT PPP) from Novo Nordisk AS (Bagsvaerd, Denmark), Synthetic 
CCK33 from Peninsula Laboratories Europe, Ltd (St Helens, England), [125I] 
hydroxyphenylpropionic acid-succmimide ester (Bolton-Hunter reagent) from New 
England Nuclear (Boston, MA, USA), Pharmacia Decanting Suspension #3 from 
Pharmacia Diagnostics, AB (Uppsala, Sweden), Human pancreatic polypeptide 
trom Sigma Chemical Co (St Louis, MO, USA), polyethylene glycol 4000 from 
BDH, Ltd (Poole, England), Chenodeoxycholic acid (chenofalk) from Tramedico 
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(Weesp, The Netherlands). All other materials were obtained from Merck, Amster-
dam, The Netherlands. 
Study Protocols 
After a 12 hour fast, the volunteers presented at the laboratory at 7:30 AM. 
A double-lumen polyvinyl tube with an outer diameter of 5.7 mm, was positioned 
under fluoroscopic control with the proximal lumen at the level of the ampulla of 
Vater and the distal lumen at the ligament of Treitz. In addition, an indwelling 
intravenous catheter was placed in each forearm, one for the collection of blood 
samples for measurements of CCK, PP and bile salts, the other for the adminis-
tration of BBS, CCK or saline. After an equilibration period of at least 30 minutes, 
in random order, 2 experiments were performed, separated from each other by at 
least one week. The following tests were performed. 
Study 1. 9 of the volunteers (6 women and 3 men; age 19-45 years) 
participated in two experiments. PEG-4000 (0.6 g/100 mL saline) was perfused 
through the proximal opening of the tube at a rate of 5 mL/min during the entire 3 
hour study period. During the last hour of the test, bombesin 1.0 ng«kg '«min ' was 
infused intravenously. In the other experiment, along with the saline, 0.5 g/h 
unconjugated chenodeoxycholic acid (CDCA) was perfused intraduodenally in the 9 
subjects during the entire test period (Figure la). 
Study 2. 10 other volunteers (6 women and 4 men; age 18-28 years) who 
did not participate in study 1 were studied on two different occasions separated 
from each other by at least one week. The protocol of study 2 was comparable to 
that of study 1. In the first experiment saline and PEG-4000 were perfused 
intraduodenally as in study 1. The second test was performed with perfusion of 0.5 
g/h CDCA and saline during the whole test period. However, instead of BBS, 
cholecystokinin (0.33 I.D.U.»kg '»h ' corresponding to 1.1+0.2 pmol'kg '«h ' as 
measured from the tip of the infusion line was given during the last test hour 
(Figure lb). 
Five-milliliter samples of duodenal contents were taken during 15-minute 
periods from the tip of the tube by spotsampling,17 and kept on ice. Blood samples 
were taken every 30 minutes during the first hour and subsequently every 15 
minutes until the end of the test period. 
Blood was collected in ice-chilled glass tubes containing 2 g/L of ethylene-
diaminetetraacetate (EDTA). After the experiments, the blood samples were 
centrifuged at 4 °C for 10 min at 3000g. 
Plasma and duodenal samples were stored at -20 "C until assayed for CCK, 
PP or PEG-4000, bilirubin, amylase and bile salt concentrations. Each time that a 
blood sample was drawn, two longitudinal and two transverse images of the 
gallbladder were obtained by real-time ultrasonography. 
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Figure 1. (A) Stud\ protocol for the two experiments in study 1 In both experiments, 
saline (300 ml/h) was continuously perfused intraduodenally (id) together with the 
recovery marker PEG-4000 (1 8 g/h) for three hours In one experiment, CDCA (0 5 g/h) 
was also perfused ι d for three hours During the last test hour, 1 0 ng'kg '»min ' BBS 
was administered intravenously (ι ν ) Asterisks denote time points when blood was drawn 
and ultrasonography was performed Crosses denote time points when duodenal juice was 
collet ted b\ spot sampling (B) Study protocol for the two experiments performed in study 
2 In both experiments, saline was continuously perfused ι d for three hours together with 
the recovery marker PEG-4000 (1 8 g/h) In one experiment, CDCA (0 5 g/h) was also 
perfused ι d for three hours During the last test hour 0 33 I D U »kg^h' was adminis 
tered ι ι Asterisks denote time points when blood was drawn and ultrasonography was 
performed Crosses denote time points when duodenal juice was collected by spot 
sampling 
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Plasma Samples 
Plasma CCK and PP were measured by sensitive and specific radioimmuno­
assays as described previously.1820 All measurements of plasma CCK and PP were 
performed in the same run. Conjugated plasma CDCA and total bile salt levels 
were determined gas chromatographically as previously described.21 In the BBS 
test, bile salt levels where also determined in duodenal juice. 
Duodenal Samples 
Duodenal samples were analyzed for PEG-4000,22 bilirubin,23 amylase 
activity,24 and total bile salt concentrations.2' Flow rates passing the distal duodenal 
sampling site were calculated based on known perfusion rates and PEG-4000 
concentrations at the perfusion and sampling ports.17 Outputs of bilirubin and 
amylase were calculated from the product of concentrations or activity and flow 
rates. 
Gallbladder Ultrasonography 
Longitudinal and transverse images of the gallbladder were obtained by real­
time ultrasonography (Sonolayer Sal 77-B, Toshiba; Tokyo, Japan) using a 3.75-
MHz transducer.25 Gallbladder volume was calculated from these images by the 
sum of cylinders method using a computer system.26 
Statistical Analysis 
All measurements were performed in duplicate and the mean of these two 
measurements was used for further analysis of results. Gallbladder volume was 
expressed in milliliter and as a percentage of the mean basal volume at -15 and 0 
minutes. Integrated plasma CCK, PP and gallbladder volume responses were 
determined by calculating the area under the CCK, PP or gallbladder volume time 
curves. Subsequently, incremental CCK, PP and gallbladder volume responses to 
the various stimulants were calculated by subtracting the integrated response in the 
basal period (-60-0 minutes) from the integrated response in the period of 
stimulation (0-60 minutes) in each experiment. Similarly, incremental bilirubin and 
amylase outputs were calculated by subtraction of the total output in the basal 
period (-60-0 minutes) from the total output in the period of stimulation (0-60 
minutes). 
Results are expressed as mean ± SEM. Statistical analysis was performed 
by Student's / test for paired results (amylase output after logarithmical transfor­
mation). Differences with a two-tailed Ρ value of < 0.05 were considered sig­
nificant. 
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RESULTS 
Plasma Concentrations of CCK and Pancreatic Polypeptide 
Plasma CCK significantly ( Ж 0 05) increased from a basal value of 
I 7+0 2 pM (t = 0 minutes) to 4 0±0 7 pM at 20 minutes during ι ν infusion of 
bombesin and from 1 8 + 0 3 pM (t=0 minutes) to 4 6±0 3 pM ( Ж 0 0001) 
during ι ν infusion of CCK (Figure 2) CDCA did not alter basal plasma CCK 
levels (1 9±0 1 pM in the bombesin study and 1 8+0 3 pM in the CCK study) 
Under bombesin stimulated conditions however, perfusion of the duodenum with 
CDCA induced significantly larger (p=0 01) plasma CCK levels when compared to 
the test without CDCA (Figure 2 and Table 1) Plasma CCK levels were not sig­
nificantly altered by CDCA during ι ν infusion of exogenous CCK (Figure 2 and 
Table 2) Bombesin induced a significant increase of plasma PP from 23 + 3 pM to 
35+7 pM (P<0 05) A comparable increase of PP from 23 + 3 pM to 46+12 pM 
was observed in response to exogenous CCK As can be seen in Figure 3 and in 
Table 1 and 2, CDCA inhibited bombesin stimulated plasma PP to 28+5 pM 
(p=0 08) and CCK stimulated PP to 30+6 pM (p=0 08) 
Gallbladder Volume and Bilirubin Output 
After 2 hours of intraduodenal perfusion with CDCA, basal gallbladder 
volume was significantly (P<0 005) larger when compared to the test without 
CDCA (32 + 4 mL vs 25 + 4 mL in the BBS study and 39±5 mL vs 31+5 mL in 
the CCK study, Figure 4) This increase of basal gallbladder volume was not 
accompanied by any change in bilirubin output (Figure 5 and Table 1 and 2) 
neither in the BBS study (14±3 μπιοΐ/h without vs 13 + 3 μιτιοΐ/h with CDCA, 
NS), nor in the CCK study (19±4 μπιοΐ/h without CDCA vs 17 + 3 μπιοΙ/h with 
CDCA, NS) Both lv infusion of BBS (P<0 0001) and of CCK (P<0 005) 
resulted in a significant decrease of gallbladder volume to a residual volume of 
II 7+2 5 mL at 40 minutes in the bombesin study, and of 8 3±0 5 mL at 60 
minutes m the CCK study (Figure 4 and Table 1 and 2) This gallbladder contrac 
tion was accompanied by a significant ( f < 0 005) increase in bilirubin output to 
53 + 7 μΐτιοΐ/h in response to bombesin, and to 69 + 10 μπιοΐ/h in response to CCK 
(Tigure 5) Intraduodenal perfusion of CDCA significantly inhibited maximum 
gallbladder contraction from 59±4% to 34±6% (P<0 005) in the bombesin study, 
and from 70+4% to 42+7% (P<0 001) in the CCK study (Figure 4 and Table 1 
and 2) Similarly, CDCA inhibited incremental bilirubin output into the duodenum 
trom 40 + 9 μηιοΙ/h to 21 +5 μηιοΙ/h (P<0 05) in the BBS study and from 51 + 10 
μΐηοΐ/h to 41 + 10 μΐηοΙ/h (P=0 08) in the CCK study (Figure 5 and Table 1 and 
2) CDCA decreased the ratio of incremental integrated gallbladder contraction to 
incremental integrated plasma CCK from 31 2 + 10 8 mL/pM to 3 6 + 3 1 mL/pM 
during stimulation with BBS (F<0 05), and from 7 3±1 4 mL/pM to 3 8± 1 2 
mL/pM during stimulation with CCK (P<0 05) 
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kg'»min') or (B) CCK (0.33 l.D.U.*kg'*h') was administered intravenously. Results are 
expressed as mean ± SEM. 
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Pancreatic Enzyme Output 
Amylase output into the duodenum in the basal state was larger when the 
duodenum was perfused with CDCA (7.3 + 1.3 kU/h vs 5.5±1.2 kU/h, NS in the 
bombesin study, and 7.0 + 1.6 kU/h vs 3.4 ±1.0 kU/h, P=0.06 in the CCK study; 
Figure 6 and Table 1 and 2). CDCA inhibited incremental amylase output in 
response to bombesin from 27.4±9.6 kU/h to 21.0 + 3.0 kU/h (/>=0.16) and from 
3.1 ± 1.2 kU to 1.9±0.8 kU/h (P=0.06) in response to CCK (Figure 6 and Table 1 
and 2). 
BUe Salt Levels 
Conjugated total bile salt levels in duodenal juice were 2.1+0.6 mmol/L 
after saline perfusion and 2.6+0.3 mmol/L after CDCA perfusion (NS vs saline) 
for two hours. Perfusion of CDCA significantly increased (P<0.05) basal plasma 
total bile salt levels from 1.5±0.2 μπιοΙ/L to 4.9+0.8 μΓηοΙ/L, two hours after the 
start of CDCA (during saline perfusion from 1.4+0.4 μπιοΙ/L to 1.5+0.5 μπιοί/ 
L). BBS stimulated plasma total bile salt levels were increased to 7.0+1.4 μΐτιοΙ/L 
in the CDCA experiment (30 minutes after the start of BBS), and in the saline 
experiment to 1.7+0.4 μπιοΙ/L (P<0.05 vs CDCA). CCK stimulated plasma total 
bile salt levels were increased to 7.8+1.3 μπιοΙ/L (30 minutes after the start of 
CCK), and to 15.1+2.6 μπιοΙ/L (60 minutes after the start of CCK) in the CDCA 
experiment. In the saline experiment, CCK stimulated plasma total bile salt levels 
were increased to 2.7+0.5 μπιοΙ/L (after 30 minutes) and to 6.9+2.1 μηιοΙ/L 
(after 60 minutes) (P<0.05 vs CDCA). The increases in plasma total bile salt 
levels were predominantly caused by increases of plasma CDCA levels. 
DISCUSSION 
The present study shows that gallbladder contraction and bilirubin output in 
response to a low dose of i.v. bombesin was reduced during background perfusion 
of the duodenum with a CDCA dosage that was able to increase circulating plasma 
bile acid levels. Incremental amylase output and PP release were also lower. 
However, this inhibitory action of CDCA on pancreaticobiliary secretion was not 
accompanied by a reduction of plasma cholecystokinin levels. On the contrary, 
plasma CCK levels were even increased. Therefore, the inhibitory action of CDCA 
on pancreaticobiliary function could not be attributed to inhibition of plasma CCK 
release. Because CCK is an important mediator of gallbladder contraction in 
response to bombesin,'7,27 and also potently stimulates pancreatic enzyme 
secretion28 30 and pancreatic polypeptide release,30 31 these data strongly suggest that 
the sensitivity of the gallbladder and pancreas to respond to CCK is diminished by 
intraduodenal administration of CDCA. Indeed, in the present study we showed, 
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Figure 6. Amylase output (kU/I5min) in response to intraduodenal perfusion with CDCA 
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that CDCA inhibited gallbladder contraction, bilirubin and amylase output into the 
duodenum and pancreatic polypeptide release in response to exogenous CCK, 
inducing plasma CCK concentrations comparable to those observed during bom­
besin infusion. 
Conflicting results have been reported on the effects of bile acids on 
gallbladder motility in response to a meal. On the one hand, oral administration of 
ursodeoxycholic acid for 1 to 4 weeks increased absolute and relative gallbladder 
emptying in response to a fatty meal in normal subjects and in gallstone patients,12 
while bilirubin output into the duodenum was markedly enhanced when a mixed 
liquid meal was administered intraduodenally together with CDCA.14 On the other 
hand, Malagelada found that continuous intraduodenal perfusion of the duodenum 
with several bile salts inhibited bilirubin output stimulated by essential amino acids 
or by fatty acids in healthy volunteers.2 3 Similarly, percents of gallbladder empty­
ing as measured with ultrasonography were decreased in gallstone patients who 
Table 1. Basal (-60-0 minutes) and BBS-stimulated (0-60 minutes) integrated responses in 
9 healthy subjects without or with intraduodenal CDCA administration. 
Treatment Basal BBS Incremental 
-60-0 min 0-60 min 
CCK 
(pM«60min) 
PP 
(pM«60min) 
Gallbladder 
volume 
(ml»60min) 
Bilirubin 
(μπιοί) 
- CDCA 
+ CDCA 
- CDCA 
+ CDCA 
-CDCA 
+ CDCA 
- CDCA 
+ CDCA 
111 + 10 
127±9 
1269±148 
1278 ±229 
1496+243 
1763+204a 
14+3 
13+3 
157+19 
184+19a 
1824+265 
1477+228" 
982+184 
1622+ 194a 
53+7 
34+4a 
46+18 
57+18 
555+201 
198 + 98h 
-514±67 
-141 ± 107a 
40 + 9 
21+5a 
Amylase (kU) -CDCA 5.5±1.2 32.9 + 9.9 27.4+9.6 
+ CDCA 7.3±1.3 28.2 + 3.4 21.0 + 3 
Incremental responses were obtained by subtraction of integrated values in the basal 
period (-60-0 minutes) from integrated values during the period of stimulation (0-60 
minutes). Results are expressed as mean ± SEM. 
'" Ρ< 0.05 when compared to test without CDCA. 
ь
 0.05<P<0.1 when compared to test without CDCA. 
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were treated with ursodeoxycholic acid " The reason for these contradictory fin­
dings is not obvious, but may be related to methodological differences between the 
studies including type, time course, dose, and route of administration of the bile 
acid, the technique for measurement of gallbladder motility, the kind of subjects 
studied and the composition of the meal. The present study indicates that continu­
ous intraduodenal infusion of CDCA at a physiological dose, profoundly inhibits 
bombesin stimulated gallbladder motility in the absence of nutrients from the gut, 
when measured with ultrasonography and with bilirubin output into the duodenum 
Furthermore, in line with previous observations, CDCA increased fasting gallblad­
der volumes " '2 This indicates that the inhibitory effect of bile acids on gallbladder 
motility is not dependent on the presence of nutrients in the gut as has been 
suggested previously 2 ' 
Bile acid binding by cholestyramine increased gallbladder emptying respon­
ses to meal ingestion and was associated with an enhanced plasma CCK release ' 
Table 2. Basal (-60-0 minutes) and CCK-stimulated (0-60 minutes) integrated responses in 
10 healthy subjects without or with intraduodenal CDCA administration 
Treatment Basal CCK Incremental 
-60-0 min 0-60 min 
CCK 
(pM«60min) 
PP 
(pM«60min) 
Gallbladder 
volume 
(mL«60min) 
Bilirubin 
(μηιοί) 
- CDCA 
+ CDCA 
- CDCA 
+ CDCA 
CDCA 
+ CDCA 
- CDCA 
+ CDCA 
111+9 
120+14 
1457+203 
1499+240 
1847+261 
2190±323a 
19+4 
17 + 3 
221+8 
239+20 
2169+417 
1621+3I6a 
1041+91 
1739+228" 
69±10 
58 + 11 
110+13 
119+17 
712+227 
123±lll a 
-806+191 
-451 + 149a 
51 + 10 
41 + 10h 
Amylase (kU) -CDCA 3 4 ± 1 0 6 5 + 0 4 3 1 + 1 2 
+ CDCA 7 0+1.6 8 8 + 1 8 1 9 + 0 8b 
incremental responses were obtained by subtraction of integrated values in the basal 
period (-60-0 minutes) from integrated values during the period of stimulation (0-60 
minutes) Results are expressed as mean + SEM. 
a
 P<0 05 when compared to test without CDCA 
ь
 0 05<P<0 I when compared to test without CDCA. 
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Basal and meal stimulated plasma CCK levels were elevated in patients with bile 
diversion from the duodenum,1332 and intraduodenal administration of CDCA 
inhibited plasma CCK response to a mixed liquid meal '4 We recently found that 
bile acid binding by cholestyramine or colestipol markedly enhanced bombesin 
stimulated plasma CCK release and gallbladder contraction.33 All these data support 
the hypothesis that the inhibitory effect of intraduodenal bile acids on gallbladder 
motility is mediated by negative feedback regulation of plasma CCK release 
However, in this study it was shown that plasma CCK responses to bombesin were 
not reduced during perfusion of the duodenum with CDCA. This seems hard to 
explain in view of previous observations. One reason might be that during bom-
besin stimulation the amount of endogenous bile acids delivered into the duodenum 
already exerts a maximal inhibitory effect on CCK release which can only be 
reduced by diversion but not enhanced by addition of bile acids 
The present study shows that continuous intraduodenal perfusion of the 
proximal gut with amounts of CDCA that mimiek the amount of this bile acid 
delivered into the duodenum after a normal meal, stimulates basal pancreatic ezyme 
secretion This observation is in line with several other reports in which a 
stimulatory effect of intraduodenal bolus injection of cattle bile,4 6 9 '° glycocholic 
acid,6 CDCA,514 or tauro deoxycholic acid910 on pancreatic enzyme secretion under 
basal conditions was observed. Pancreatic enzyme secretion in response to intradu-
odenal nutrients including amino acids or products of fat digestion was also 
significantly inhibited by tauro deoxycholate, tauro chenodeoxycholate or tauro 
cholate 2 3 The finding that CDCA tended to inhibit bombesin stimulated incremen-
tal amylase output is in agreement with this obervation but is contrary to the 
observation that intraduodenal administration of a mixed liquid meal with 2 g of 
CDCA resulted in a significantly higher pancreatic enzyme output than a meal 
without addition of bile acids '4 Stimulation of basal pancreatic enzyme secretion 
and a non-specific wash-out effect may have accounted for this elevated pancreatic 
enzyme secretion, because CDCA alone without a meal also potently stimulated 
pancreatic enzyme output.14 Beside this effect on exocrine pancreatic function, 
CDCA also affected the endocrine pancreas as reflected by the inhibition of 
incremental pancreatic polypeptide release 
The mechanism by which CDCA inhibits bombesin stimulated pancreatico 
biliary secretion is not related to inhibition of plasma CCK release Bombesin 
stimulated plasma CCK levels were even higher during CDCA perfusion This 
suggests that CDCA decreases the sensitivity of the target organs to respond to 
endogenous CCK. This hypothesis is supported by the finding that CDCA marked-
ly inhibited CCK induced gallbladder contraction and bilirubin output Further-
more, incremental amylase and pancreatic polypeptide responses to exogenous 
CCK were also significantly reduced The mechanism by which intraduodenal bile 
acid perfusion affects target organ responses to CCK is not known CDCA may 
interact with inhibitory humoral mechanisms like somatostatin or peptide Y Y or it 
may exert its inhibitory effect via the nervous system. CDCA may also down 
regulate CCK receptors at the level of the end organ M The increased circulating 
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plasma bile acid levels during perfusion of the duodenum with CDCA are com 
patible with this hypothesis A direct inhibitory effect of bile salts in a 
physiological dose range on contractility of in vitro human gallbladder strips has 
been demonstrated " 
In conclusion, m the absence of nutrients from the gut, intraduodenal cheno 
deoxycholate inhibits bombesin and cholecystokinin stimulated gallbladder 
emptying, pancreatic enzyme secretion and pancreatic polypeptide release The data 
indicate that this effect is not mediated by suppression of cholecystokinin release, 
but is related to reduced sensitivity of the gallbladder and pancreas to cholecys­
tokinin 
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ABSTRACT 
Background/Aims: To determine the contribution of the cholinergic system 
in the regulation of cholecystokinin (CCK) release, gastrin release and gallblad-
der motility, the effect of atropine infusion prior to, and together with bombesin 
(BBS) infusion was studied in 8 healthy subjects. Methods: After an overnight 
fast atropine (0.015 mg»kg~' as a bolus followed by 0.005 mg»kg~'»h~') or saline 
was infused for 5h on 2 separate occasions. After 2h, BBS (0.1 ng*kg~'*min') 
was infused in both tests. Subsequently, the BBS dose was fourfolded every 45 
min to a maximum of 6.4 ng*kgl»min'. Results: Atropine did not influence 
basal CCK or gastrin levels. Basal gallbladder volume increased from 26 ±3 to 
36±4 mL during atropine (P< 0.001), but was not affected during saline (26±1 
vs 27±1 mL). Increasing dosages of BBS (0.1, 0.4 and 1.6 ng»kg'»min') 
induced a maximum gallbladder contraction of 26±3%, 47+6% and 70±3% 
respectively. Atropine reduced (P<0.05 vs saline) BBS stimulated gallbladder 
contraction to 8+3%, 32±5% and 50+6% respectively. Further increase in BBS 
dosage to 6.4 ng*kg'9min' resulted in gallbladder relaxation in both ex-
periments. BBS induced significant (P<0.05) increments of plasma CCK to a 
maximum of 3.2 + 0.3 pmol/L during saline and to 3.2 + 0.3 pmol/L during 
atropine (NS). Atropine tended to increase plasma gastrin responses to increasing 
doses of bombesin. Conclusions: Atropine increases basal gallbladder volume and 
inhibits gallbladder motility during stimulation with increasing doses of bombesin, 
without significant effects on plasma CCK. This suggests that not only under 
basal conditions, but also during stimulation with bombesin, the cholinergic 
system contributes to the regulation of gallbladder motility. 
INTRODUCTION 
Gallbladder motility is regulated by a combination of humoral and choliner-
gic mechanisms.18 The cephalic phase of gallbladder motility is mediated by 
cholinergic pathways, probably independent of cholecystokinin release,910 whereas 
the intestinal phase of gallbladder contraction is mainly regulated by cholecys-
tokinin (CCK).J'7" However, it is also reported that cholinergic receptor blockage 
with atropine causes reduction of meal or CCK stimulated gallbladder contrac-
tion,4·12 pointing to a combined effect of CCK and the cholinergic system. 
To study the effect of the cholinergic system on gallbladder motility, 
atropine seems to be a good tool,13 when taking into consideration several pitfalls. 
Firstly, infusion of atropine affects basal gallbladder volume lasting for about 2 
hours to reach a steady state of maximum relaxation of gallbladder volume.1" 
Therefore, a basal period of two hours is requested to study the effect of atropine 
on gallbladder contraction during intravenous, oral or intraduodenal stimulation. 
Secondly, atropine is able to delay gastric emptying of food as was previously 
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suggested '5 Therefore intravenous, rather than oral stimulation is preferred when 
determining the role of the cholinergic system on stimulated gallbladder motility 
Bombesin (BBS) is known to stimulate gallbladder contraction through the 
release of CCK,'6 '7 and to stimulate the release ot gastrin 1β " So BBS is an ideal 
tool to mimic a meal and to study the effects of atropine in stimulated hormone 
release and gallbladder motility 
The aim of this study was to determine the role of the cholinergic system in 
the regulation of basal and bombesin-stimulated plasma CCK release, gastrin 
release and gallbladder motility 
MATERIALS AND METHODS 
Subjects 
Four healthy female and four healthy male volunteers, mean age 22+ 1 years 
(range 20-25 years), participated in the studies None of the volunteers was taking 
any medication or had a history of gastrointestinal symptoms or surgery The study 
protocol was approved by the ethical committee of the University Hospital Nij 
megen, and all subjects gave their written informed consent before entering the 
study 
Materials 
Purchased materials included BBS trom UCB (Brussels, Belgium), Synthetic 
CCKjj from Penmsula Laboratories (St Helens, England), Pharmacia Decanting 
Suspension #3, sheep anti rabbit antibody from Pharmacia Diagnostics AB (Upp 
sala, Sweden), Synthetic human nonsulfated gastrin,, from Cambridge Research 
Biochemicals LTD (Cambridge, England), CCK8 non-sulfated and CCK8 sulfated 
trom Neosystem (Strassbourg, France), Human non sulfated gastnn,34 human 
sulfated gastrin,
 17 human non-sulfated fragment gastrin, M from Sigma (St Louis, 
MO, USA) Human non sulfated gastrin,
 l7 from Bachern (Bubendorf, Switzerland), 
Human non sulfated radìoiodmated gastrin,, from Amersham (Buckingham shire, 
England) Atropini sulfas from Pharmachemie BV (Haarlem, The Netherlands) 
Experimental Protocols 
After an overnight fast, the volunteers presented at the laboratory at 7 30 
AM Two indwelling intravenous catheters were placed, one in each forearm The 
catheters were kept patent by a heparine-saline solution One catheter was used for 
infusion of BBS alone or together with atropine, while the other catheter was used 
for the collection of blood samples for measurements of CCK and gastrin 
2 experunents were performed using a cross over design In the first 
121 
experiment atropine (0 015 mg'kg ' as a bolus followed by 0 005 mg«kg '«h ') was 
infused continuously for 5 hours Two hours after the start of atropine, bombesin 
was infused by stepwise increasing doses of 0 1, 0 4, 16 and 6 4 ng»kg'«min' 
every 45 minutes In experiment 2 the same protocol was performed as for 
experiment 1 however, saline instead of atropine was continuously perfused for 5 
hours Blood was collected m ice-chilled glass tubes containing 2 g/L of ethylene 
diaminetetraacetic acid at regular intervals After the experiments, the blood 
samples were centrifuged at 4°C for 15 minutes at 3000g The plasma was stored 
at -20°C until assayed for CCK and gastrin Each time that a blood sample was 
drawn, two longitudinal and two transverse images of the gallbladder were obtained 
by real-time ultrasonography and the heart rate was monitored 
Plasma Samples 
Plasma CCK was measured by a sensitive and specific radioimmunoassay 
(RIA) as described previously ,021 The antibody used (T204) binds to biologically 
active CCK peptides containing the sulfated tyrosine region ~ On a molar base, 
sulphated gastrins cross-reacted <2% in the assay, while no cross-reactivity with 
unsulphated gastrins or structurally unrelated peptides was found The detection 
limit of the assay was between 0 5 and 1 0 pmol/L CCK in plasma The intra-assay 
precision ranged from 4 6% to 11 5% in the steep part of the standard curve 
Plasma gastrin was also measured by radioimmunoassay as described 
previously 162J The antiserum (Gl42 08) was raised against synthetic nonsulphated 
gastrin,, coupled to bovine serum albumin The antibody was directed towards the 
biologically active carboxy-lerminus of gastrin The antibody has almost equal 
affinity for sulphated and nonsulfated forms of gastnn34, gastnn17 and gastnn3,7 
The cross-reactivity of these peptides, relative to nonsulfated gastrin,·,, ranged 
between 70% and 110% on a molar base The antibody did not cross-react with the 
amino terminal fragment gastrin,
 M, while cross-reactivity with sulphated CCKS and 
CCK33 was negligible (<5% on a molar base) The detection limit of the assay was 
0 1 pmol/L of incubation mixture The intra-assay variation ranged from 4 5 % to 
8 4% m the steep part of the standard curve (n=7) 
Plasma levels of conjugated bile salts were determined gaschromato 
graphically as described previously 24 
Gallbladder Ultrasonography 
Longitudinal and transverse images of the gallbladder were obtained by real 
time ultrasonography (Diasonic RA-1, Siemens [Munich, Germany] or Sonolayer 
Sal 77-B, Toshiba [Tokyo, Japan] with a 3 5 or 3 75-MHz transducer ,5 : ' Gall 
bladder volume was calculated from these images by the sum of cylinders method 
using a computer system 2S The variation of volume measurements ranged from 
6 0% to 22 4% 
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Statistical Analysis 
All measurements were performed in duplicate, and the mean of these two 
measurements was used for further analysis of results. Results are expressed as 
mean ± SEM. Basal value was defined as the mean value at -15 and 0 minutes. 
Gallbladder volume was expressed in milliliter and as percentage of basal volume. 
Integrated responses during each infusion period were obtained by calculating the 
area under the curve after subtraction of basal value. The mean value of gallblad­
der volume, plasma gastrin concentration and cholecystokinin concentration at 30 
and 45 minutes during each infusion period was calculated. Incremental responses 
during each infusion period were obtained by subtraction of basal value from these 
values at the end of each infusion period. To determine dose response relations, the 
slope of the linear regression of plasma cholecystokinin increment, plasma gastrin 
increment and gallbladder contraction on log bombesin dose was calculated for 
each individual, and the average slope was compared with zero by means of a 
paired / test.27 The three lower doses of BBS were included in this analysis for 
CCK and gallbladder contraction, because plasma CCK and gallbladder contraction 
in response to the highest BBS dose tended to decrease. Statistical analysis was 
performed by student's t test for paired data. Differences with a two tailed Ρ value 
of < 0.05 were considered significant. 
RESULTS 
Plasma CCK Levels 
Basal plasma CCK levels were comparable in both tests and were not 
significantly influenced by infusion of atropine (Figure 1). Infusion of 0.1, 0.4, 1.6 
and 6.4 ng»kg'#min' BBS without atropine increased plasma CCK from a mean 
basal value of 2.6±0.2 pmol/L to 2.7+0.2 pmol/L (NS), 3.0±0.3 pmol/L 
(/><0.05 vs basal), 3.2+0.4 pmol/L (/><0.05 vs basal) and 3.2+0.3 (P<0.05 vs 
basal; Figure 1) respectively. Similarly, infusion of these stepwise increasing doses 
of BBS with background infusion of atropine induced significant increases of 
plasma CCK from a basal value of 2.6+0.2 pmol/L to 2.8+0.2 pmol/L (Ж0.01 
vs basal), 3.2+0.3 pmol/L (P<0.01 vs basal), 3.2+0.3 pmol/L (P<0.01 vs 
basal) and 3.0+0.3 pmol/L (/><0.05 vs basal: Figure 1). The highest dose of BBS 
did not induce any further increase of plasma CCK levels in both tests. The 
average slope of the linear regression of plasma CCK increment on log BBS-dose 
was 0.38+0.25 (NS vs zero) in the study without atropine, and 0.32+0.18 in the 
study with atropine (NS vs zero; NS vs study with atropine). This indicates that 
there was no clear dose response relationship between the amounts of BBS infused 
and the increments in plasma CCK. The integrated plasma CCK responses to BBS 
with and without atropine were not significantly different (Table I). 
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bombesin ι ν (ng/kg*min) 
ι 1 1 1 1 1 1 1 1 1 1 — 
-120 -90 -60 -30 0 30 60 90 120 150 180 
Time (mm) 
Figure 1. Plasma CCK concentrations (pmoUL) in response to intravenous infusion of 
stepwise increasing doses of bombesin with (9) or without (O) continuous ι ν back­
ground infusion of atropine from -120 to 180 min in 8 healthy subjects Results are 
expressed as mean ± SEM 
Plasma Gastrin Levels 
Basal plasma gastrin levels were comparable in both tests and were not 
significantly influenced by infusion of atropine (Figure 2) Infusion of increasing 
doses of BBS induced significant increases of plasma gastrin from a mean basal 
value of 18 + 1 pmol/L to 28+5 pmol/L (P<0 05 vs basal), 28+5 pmol/L 
(P<0.05 vs basal), 38±7 pmol/L (P<005 vs basal) and 61 ±17 (P<0 05 vs 
basal) respectively in the study without atropine, and from 21+3 pmol/L to 43 + 11 
pmol/L ( P < 0 05 vs basal), 44±9 pmol/L ( P < 0 05 vs basal), 52+11 pmol/L 
( P < 0 05 vs basal) and to 90+23 pmol/L ( P < 0 05 vs basal) in the study with 
atropine (Figure 2) In contrast to plasma CCK and gallbladder contraction, plasma 
gastrin further increased in response to the highest bombesin dose (Figure 2) The 
average slope of the linear regression of plasma gastrin increment on log BBS-dose 
was 18 4+7.1 ( P < 0 05 vs zero) m the study without atropine and 24 9 + 7 9 in the 
study with atropine ( F < 0 05 vs zero, NS vs study with atropine), indicating that 
there were dose response relationships between the increments in plasma gastrin 
and the amounts of BBS infused Integrated plasma gastrin responses to BBS tended 
to be higher in the study with atropine when compared to the study without 
atropine (Table 1) However, these differences reached statistical significance only 
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for the 0 4 and 6 4 ng«kg '»mm ' BBS dose ( Ж 0 05 vs saline) 
bombesin ι ν (ng/kg*min) 
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Figure 2. Plasma gastrin (pmol/L) in response to intravenous infusion of stepwise 
increasing doses of bombesin without (O) or with (9) continuous ι ν background 
infusion of atropine from -120 to 180 mm in 8 healthy subjects Results are expressed as 
mean ± SEM 
Table I. Integrated responses to ι ν infusion of stepwise (0 1, 0 4, 16 and 6 4 ng'kg'· 
mm') increasing doses of bombesin without (SAL=saline) and with (ATR) continuous 
background infusion of atropine Each bombesin dose was infused for 45 mm Data are 
mean ± SEM from 8 healthy subjects 
CCK Gastrin GBC 
Time(min) 
0 45 
45-90 
90 135 
135-180 
(ρΜ·45 
SAL 
2 + 4 
14+5 
33 + 10 
33 + 9 
min) 
ATR 
7 ± 3 
29+7 
32+9 
25 + 8 
(pM· 
SAL 
306 + 107 
550+235 
913 + 282 
1667+529 
45 min) 
ATR 
810+298 
1230+419* 
1353 + 468 
2762 + 869* 
(%« 
SAL 
629 ±94 
1801 + 171 
2715 + 83 
2289 + 315 
45 m in) 
ATR 
176 + 75* 
1089+212* 
2005 + 225* 
1898+239 
GBC = Gallbladder contraction, * = P<0 05 vs saline infusion 
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Gallbladder Volume 
Infusion of atropine increased gallbladder volume from 26 4+3 2 mL at the 
start of the experiment to a mean value of 35 6+3 6 mL at -15 and 0 min 
(Ρ<0 001), whereas basal gallbladder volume did not change in the saline study 
(26 0 + 1 1 vs 26 8 + 1 4 mL, Figure 3) Gallbladder contraction in response to 0 1, 
0 4, 1 6 and 6 4 ng'kg^min 1 without atropine was 26 0 + 3 1% (P<0 001 vs 
basal), 47 2+5 7% ( Ж 0 001 vs basal), 70 1+3 3% (F<0 001 vs basal) and 
38 3 + 11 3% (P<0 05 vs basal, Figure 4) Similarly, ι ν infusion of graded doses 
of BBS with atropine induced significant gallbladder contractions of 8 3 + 3 2% 
(P<0 05 vs basal), 31 9+5 0% ( Ж 0 001), 49 5+5 8% (P<0 001) and 36 5 + 
5 3% (P<0 001 vs basal, Figure 4) During the highest BBS dose, gallbladder 
relaxation was observed in both tests (Figure 4) The average slope of the linear 
regression of gallbladder contraction (%) on log BBS dose was 36 6 + 3 7 
(P<0 0001 vs zero) in the study without atropine, and 34 2+4 7 (P<0 0005 vs 
zero, NS vs the study without atropine) in the study with atropine, indicating that 
there was a dose response relationship between the amounts of BBS infused and the 
bombesin ι ν (ng/kg*min) 
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Figure 3. Gallbladder volume (mL) in response to intravenous infusion of stepwise 
increasing doses of bombesin with (Ш) or without (O) continuous ι ν background 
infusion of atropine from -120 to 180 min in 8 healthy subjects Results are expressed as 
mean ± SEM 
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degree of gallbladder contraction. The integrated gallbladder contractions in 
response to BBS with atropine were significantly smaller than those in response to 
BBS without atropine for the lower BBS doses (Table 1). 
bombesin i.v. (ng/kg*min) 
τ 1 1 1 ' ' 1 1 1 1 1 1 1 
0 45 90 135 1Θ0 
Time (min) 
Figure 4. Gallbladder contraction (%) in response to intravenous infusion of stepwise 
increasing doses of bombesin with (Ш) or without (O)continuous i.v. background infusion 
of atropine from -120 to 180 min in 8 healthy subjects. Results are expressed as mean ± 
SEM. 
Plasma Bile Salt Levels 
Basal plasma bile salt levels did not differ between the two tests. Infusion of 
atropine was without effect on basal bile salt levels (data not shown). Infusion of 
bombesin caused small but significant (P<0.05) increases of plasma bile salt levels 
from a basal value of 1.5+0.2 /¿mol/L to a maximum of 2.4+0.4 μπιοΙ/L, during 
infusion of the highest bombesin dose (Table 2). Bombesin only marginally 
stimulated plasma bile salt levels in the atropine experiment from 1.2+0.2 μηιοΙ/L 
to a maximum of 1.6+0.4 μπιοΙ/L, during infusion of the 1.6 ng^kg'^min"' dose 
(NS vs basal). Plasma CDCA levels during infusion of the highest dose of bom­
besin were significantly lower (P<0.05) in the experiment with atropine when 
compared to the experiment without atropine (Table 2). 
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DISCUSSION 
This study shows that the cholinergic system co-regulates gallbladder 
motility in the interdigestive state as well as during stimulation with bombesin 
(BBS) Several others allready reported that the vagal-cholinergic nerve system 
preserves a basal tone for the gallbladder in the interdigestive state '°14 28 The 
results of the present study demonstrate that atropine decreased basal gallbladder 
volume and that dilatation of the gallbladder reached a steady state after 2 hours of 
atropinization Atropine inhibited gallbladder contraction in response to the 3 
lowest doses of bombesin that induced circulating cholecystokmm levels in the 
lower physiological range This inhibition was not complete and a significant 
gallbladder contraction was preserved in the atropine experiment Previous studies 
have demonstrated that gallbladder contraction in response to bombesin is principal 
ly mediated by cholecystokinin 1 4 1 7 However, the present results cannot be 
explained by suppression of cholecystokinin release because atropine did not affect 
bombesin stimulated plasma cholecystokinin as has been observed previously '8 29 
Table 2. Conjugated plasma bile salt levels and plasma CDCA levels during ι ν infusion 
of stepwise (0 1, 0 4, 16 and 6 4 ng»kg'»min') increasing doses of bombesin without 
(SAL=saline) and with (ATR) continuous background infusion of atropine Each bombesin 
dose was infused for 45 min Data are mean ± SEM from 8 healthy subjects 
bombesin Total plasma bile salts plasma CDCA 
(ng^kg^min1) (μΠΊθΙ/L) (μπιοΙ/L) 
0 
0 1 
0 4 
1 6 
6 4 
* = P<0 05 vs salme 
SAL 
1 5±0 2 
1 5±0 1 
1 7±0 2 
1 9±0 3 
2 4±0 4 
infusion 
ATR 
1 2+0 2 
1 2±0 1 
1 5±0 3 
1 6+0 4 
1 1+0 1* 
SAL 
0 6+0 1 
0 6±0 1 
0 8+0 1 
0 9+0 1 
1 2±0 3 
ATR 
0 5 ± 0 1 
0 5±0 1 
0 6±0 1 
0 7±0 1* 
0 6±0 Γ 
Three distinct mechanisms have been proposed to explain the effect of 
atropine on CCK stimulated gallbladder contraction7 The cholinergic system 
modulates gallbladder tone that may be important for modulation of gallbladder 
responsiveness to cholecystokinin Another hypothesis is that cholecystokinin 
stimulates release of acetylcholine from neurons located in the gallbladder wall 
This hypothesis is supported by the finding that CCK receptors have been located 
on postganglionic cholinergic nerve terminals in the gallbladder wall 3 0 3 ' Finally, 
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atropine may activate an inhibitory neural pathway to the gallbladder that is 
normally blocked by acetylcholine.32 The observation that gallbladder volume 
reached a steady state before the start of stimulation with bombesin is important. 
This makes it highly unlikely that the inhibitory effect of atropine on bombesin 
stimulated gallbladder contraction can be attributed to an on going decrease of 
gallbladder tone. The finding that atropine did not completely block bombesin 
stimulated gallbladder contraction suggests that endogenous CCK, even at very low 
circulating levels induces gallbladder contraction, at least in part by an atropine 
insensitive mechanism. This agrees with the observation that atropine induced only 
a small reduction of gallbladder contraction in response to exogenous cholecys-
tokinin.67 It has been demonstrated that atropine more potently inhibited gallblad-
der contraction in response to lower doses of exogenous CCK than to higher 
doses.633 Unfortunately, circulating plasma CCK levels in the present study 
remained in the lower physiological range even though the highest bombesin dose 
was 64 times higher than the lowest dose. Therefore, it could not be established if 
atropine also less effectively inhibited gallbladder responses to higher levels of 
circulating endogenous CCK. 
Although infusion of increasing doses of bombesin induced increasing levels 
of plasma cholecystokinin, a clear dose response effect could not be established. In 
contrast to cholecystokinin, a clear dose response relationship for gallbladder 
emptying and plasma gastrin responses was found. This absence of a dose response 
relationship between BBS and CCK may be attributed to the delivery of bile salts 
into the duodenum as a result of gallbladder contraction, since we and others 
reported earlier that intraduodenal bile salts are major regulators of a negative 
feedback control of plasma CCK release.1634 In other words, gallbladder contrac-
tion is followed by an increase of intraduodenal bile salt concentrations and 
thereafter a reduction of CCK release. 
It was surprising to note that there was a relaxation of the gallbladder during 
infusion of the highest bombesin dose. A comparable effect has been found for 
gastric acid secretion by Vamer et al, who observed increases of gastrin during 
high doses of bombesin but a fall of gastric acid secretion.19 Relaxation of the 
gallbladder during stimulation with the highest dose of bombesin may be related to 
the stimulation by bombesin of an inhibitory neural or humoral pathway. It may 
also be related to a decreased sensitivity of the gallbladder to CCK resulting from 
increased circulating bile acid levels.35 We have previously demonstrated that an 
increase of plasma bile acids is associated with a decreased sensitivity of the 
gallbladder to respond to endogenous and exogenous CCK.36·37 Indeed, a marked 
increase of plasma bile acid levels was observed during infusion of the highest 
bombesin doses. The finding of lower plasma bile acid levels during the highest 
BBS dose may explain why relaxation in the atropine experiment was less 
pronounced. 
In conclusion, gallbladder contraction in response to bombesin is mediated in 
part by a atropine sensitive mechanism that does not involve suppression of 
bombesin stimulated cholecystokinin release. 
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ABSTRACT 
Background/Aims: Loperamide, a peripherally acting opiate receptor 
agonist with antidiarrhoeal action, inhibits ileal and colonic motor function. We 
determined whether loperamide also affects gallbladder emptying and pancreatic 
enzyme secretion in humans. Methods: We have measured plasma cholecys-
tokinin (RIA), gallbladder volume (ultrasonography) and intraduodenal bilirubin 
and amylase output (spot sampling) at regular intervals before and during 
intraduodenal perfusion of an amino acid meal in 8 healthy subjects, once 
without and once with pretreatment of 8 mg loperamide, ingested 13 and 4 hours 
before the start of the meal. Results: Loperamide decreased basal amylase output 
from 3.2±0.5 to 1.0±0.5 kU/h (P<0.005) and abolished basal bilirubin output 
(21 ±5 vs 0±0 μmol/h;P< 0.005) into the duodenum. Loperamide increased basal 
gallbladder volume from 28±4 to 39±4 mL (P< 0.0001), but was without effect 
on basal plasma cholecystokinin (2.7±0.3 vs 3.0±0.3 pmol/L). During the amino 
acid meal, pretreatment with loperamide inhibited amylase output from 5.1 ±0.8 
to 1.6±0.4 kU/h (P<0.001), bilirubin output from 39±6 to 18±6 ßmol/h 
(P<0.0005), and gallbladder contraction from 47±3% to 26±6% (P<0.05), 
while loperamide enhanced amino acid stimulated plasma cholecystokinin from 
4.5+1.6 to 7.6±1.0 pmol/L (P<0.05). Conclusions: Loperamide inhibits basal 
and amino acid stimulated gallbladder motility and intraduodenal output of 
bilirubin and amylase, despite an enhanced postprandial cholecystokinin release. 
INTRODUCTION 
Loperamide is widely used for the treatment of patients with diarrhoea 
resulting from a variety of diseases '2 Dosages used to treat acute or chronic 
diarrhoea vary from 2 to 16 mg daily ' Recently, even higher dosages have been 
recommended 2 Loperamide probably exerts its antidiarrhoeal action by a change in 
motor function of the intestine resulting in an increased capacitance of the gul and 
a delay in the passage of fluid through the intestine ' 3 Some studies also suggest 
antisecretory effects of the drug at the intestinal level 4 5 The effects of loperamide 
on pancreaticobiliary functions are poorly investigated Inhibition of gallbladder 
emptying or pancreatic enzyme secretion by loperamide may have important 
clinical implications, because stasis of bile is a major factor contributing to the 
formation of gallstones 610 and because impairment of pancreatic enzyme secretion 
may induce or aggravate maldigestion " 13 
Therefore, the aim of this study was to determine the effect of loperamide 
on basal and meal stimulated gallbladder motility and pancreatic enzyme secretion 
in healthy volunteers Gallbladder emptying and pancreatic enzyme secretion was 
studied in response to an intraduodenal amino acid meal, in order to circumvent 
possible influences of loperamide on gastric emptying or on the digestion of 
nutrients '" 
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MATERIALS AND METHODS 
Subjects 
Eight healthy volunteers (3 woman and 5 men; range 19-27 years), par-
ticipated in the studies. None of the volunteers was taking any medication or had a 
history of gastrointestinal symptoms or surgery. The study protocol was approved 
by the ethical committee of the University Hospital Nijmegen, and all subjects gave 
their written informed consent before entering the study. 
Reagents 
Loperamide chloride was obtained from Janssen Pharmaceutica (Beerse, 
Belgium); Radioiodinated porcine pancreatic polypeptide (125I-PPP) from Novo 
Nordisk AS. (Bagsvaerd, Denmark); Synthetic CCK^ from Peninsula Laboratories 
Europe, Ltd. (St. Helens, England); [125I]-hydroxyphenyl propionic acid-suc-
cinimide ester (Bolton-Hunter reagent) from New England Nuclear (Boston, MA, 
USA); Pharmacia Decanting Suspension #3 from Pharmacia Diagnostics, AB. 
(Uppsala, Sweden); Human pancreatic polypeptide and Lamino acids from Sigma 
Chemical Co. (St. Louis, MO, USA); Polyethylene glycol 4000 from BDH, Ltd. 
(Poole, England). All other materials were obtained from Merck (Amsterdam, The 
Netherlands). 
Study Protocol 
After a 12 hour fast, the volunteers presented at the laboratory at 07.30 AM. 
In random order, 2 experiments were performed separated from each other by at 
least one week. At the beginning of each experiment, a double-lumen polyvinyl 
tube with an outer diameter of 5.7 mm, was placed in the duodenum. The proximal 
lumen of the tube was positioned at the level of the papilla Vateri and the distal 
lumen at the ligament of Treitz. The position of the tube was verified by fluoros-
copy. In addition, an indwelling intravenous catheter was placed in a forearm. The 
catheter was kept patent by a heparine-saline solution and was used for the 
collection of blood samples. After an equilibration period of at least 30 minutes, 
the following tests were performed. 
Test 1. Saline (300 mOsmol/L) was continuously perfused intraduodenal 1 y 
(i.d.) for two hours (300 mL/h) together with the recovery marker polyethylene 
glycol (PEG-4000; 6g/L). During the third test hour, an isoosmotic solution (300 
mOsmol/L; Figure 1) of an amino acid mixture,15 containing L-valine (2.17 g), L-
methionine (1.71 g), L-tryptophan (0.67 g) and L-phenylalanine (2.34 g) was 
perfused i.d. together with saline (140 mL) and demineralised water (160 mL). 
Test 2. This test was performed according to the same protocol as test 1. 
However, 13 and 4 hours prior to the start of the amino acid perfusion, 8 mg of 
loperamide was given orally. Five-milliliter samples of duodenal contents were 
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taken during 15-minute periods from the tip of the tube by spotsampling16 and kept 
on ice. Blood samples were taken every 30 minutes during the first hour and 
subsequently every 15 minutes until the end of the test period (Figure 1). 
300 mL/h saline + 1.8 g/h polyethylene glycol 
amino acids 
* * * * * * * * * * * * * * 
+ + + + + + + + + + + + + 
Ι ι Ι ι Ι ι Ι ι Ι ι Ι ι I 
-60 -30 0 30 60 90 120 
Time (min) 
Figure 1. Study protocol for the two tests performed in random order. In both tests, 
saline was continuously perfused intraduodenally (i.d.) together with the recovery marker 
PEG-4000 (Ì.8 g/h) from -60 to 120 minutes, at a constant rate of 5 mL/h. During the 
last test hour, 6.89 g of an amino acid solution was also perfused i.d. In one of the two 
tests loperamide (8 mg) was ingested 13 and 4 hours prior to the start of the amino acid 
perfusion. Asterisks denote time points when blood was drawn for the measurement of 
plasma CCK and PP levels, while gallbladder volume was determined by ultrasono-
graphy. Crosses denote time points when duodenal juice was sampled for the deter-
mination of bilirubin and amylase 
Blood was collected into ice chilled glass tubes containing 2 g/L of ethylene-
diaminetetraacetate (EDTA). After the experiments, the blood samples were 
centrifuged at 4 °C for 15 min at 3000g. In test 2, an additional blood sample was 
taken just before the start of the amino acid perfusion for measurement of plasma 
loperamide levels. Plasma and duodenal samples were stored at -20 °C until 
assayed for CCK, pancreatic polypeptide, loperamide, PEG-4000, bilirubin and 
amylase. Each time that a blood sample was taken, two longitudinal and two 
transverse images of the gallbladder were obtained by real-time ultrasonography. 
Plasma Samples 
Plasma CCK was measured by a sensitive and specific radioimmunoassay 
(RIA) as described previously.1718 The antibody used (T204) binds to biologically 
active CCK peptides containing the sulfated tyrosine region, with almost equal 
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affinity On a molar base, sulfated gastrins cross-reacted <2% in the assay, while 
no cross-reactivity with unsulfated gastrins or structurally unrelated peptides was 
found The detection limit of the assay was between 0 5 and 1 0 pmol/L CCK in 
plasma The intra-assay precision ranged from 4 6% to 11 5% in the steep part of 
the standard curve All measurements of plasma CCK levels were performed in the 
same run Plasma pancreatic polypeptide levels were also determined by RIA '9 
The antibody used showed no cross-reactivity with structurally related gastrointes-
tinal regulatory peptides, like peptide Y Y or neuropeptide Y, nor with structurally 
unrelated peptides The detection limit of the assay was 0 5 pmol/L of incubation 
mixture The intra-assay variation ranged from 4% to 7% in the steep part of the 
standard curve All measurements of plasma pancreatic polypeptide levels were 
performed in one run Plasma loperamide levels were determined at the department 
of Drug, Metabolism and Pharmacokinetics, Jansen Pharmaceutica, Beerse, 
Belgium as previously described 20 
Duodenal Samples 
Duodenal samples were analyzed for PEG 4000,21 bilirubin22 and amylase 
activity 23 Flow rates passing the distal duodenal sampling site were calculated 
based on known perfusion rates and PEG 4000 concentrations at the perfusion and 
sampling ports '6 Outputs of bilirubin and amylase were calculated from the 
product of concentrations or activity and flow rates 
Gallbladder Ultrasonography 
Longitudinal and transverse images of the gallbladder were obtained by real-
time ultrasonography (Sonolayer Sal 77-B, Toshiba, Japan) using a 3 75-MHz 
transducer 24 25 Gallbladder volume was calculated from these images by the sum of 
cylinders method using a computer system26 The variation of volume 
measurements ranged from 6 % to 22% 
Statistical Analysis 
All measurements were performed in duplicate and the mean of these two 
measurements was used for further analysis of results Gallbladder volume was 
expressed in milliliter and as percentage of the mean basal value at 45 and 60 
minutes Integrated plasma CCK, pancreatic polypeptide and gallbladder responses 
were determined by calculating the area under the plasma CCK concenlration-limc 
curves, pancreatic polypeptide concentration-time curves or gallbladder volume 
time curves Subsequently, incremental plasma CCK, pancreatic polypeptide 
concentrations and gallbladder volume responses to the meal were calculated by 
subtracting the integrated response in the basal period (0 60 minutes) trom the in 
tegrated response in the period of stimulation (60 120 minutes), in each ex-
periment Similarly, incremental bilirubin and amylase outputs were calculated by 
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subtraction of the total output in the basal period (0-60 minutes) from the total 
output in the period of stimulation (60-120 minutes). Results are expressed as mean 
± SEM. Statistical analysis was performed by Student's / test for paired results or 
by two way analysis of variance (ANOVA) when appropriate Differences with a 
two tailed (P) value < 0 05 were considered significant 
RESULTS 
Plasma Loperamide Levels 
Plasma levels of loperamide at the start of the amino acid perfusion in test 2 
were 2.5 ±0 3 ng/mL 
Amino acids 
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Figure 2. Basal and ammo acid stimulated plasma CCK concentrations (pmol/L) in 8 
healthv subjects with (9) or without (O) prior ingestion of loperamide Values are 
expressed as mean ± SEM. 
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Figure 3. Basal and amino acid stimulated plasma PP concentrations (pmol/L) in 8 
healthy subjects with (9) or without (O) prior ingestion of loperamide. Values are 
expressed as mean ± SEM. 
Plasma Concentrations of CCK and Pancreatic Polypeptide 
Plasma CCK and pancreatic polypeptide time curves are shown in Figures 2 
and 3. Loperamide significantly (P<0.05) inhibited basal pancreatic polypeptide 
level from 25 ±5 to 20+4 pmol/L (Figure 3, Table 1), but was without significant 
effect on basal CCK (2.7+0.3 pmol/L without loperamide vs 3.0±0.3 pmol/L 
with loperamide; Figure 2, Table 1). Intraduodenal administration of the amino 
acid meal induced a significant (P<0.05) increase of plasma pancreatic polypeptide 
from 25+5 to 36±7 pmol/L (Figure 3), and of plasma CCK from 2.7±0.3 to 
4.5 + 1.6 pmol/L (Figure 2). Loperamide induced a statistically significant 
(P<0.05) enhancement of this amino acid stimulated plasma CCK level from 
4.5 + 1.6 to 7.6+1.0 pmol/L (Figure 2, Table 1), but it inhibited (P<0.05) the 
amino acid stimulated plasma pancreatic polypeptide level from 36 ±7 to 28 + 7 
pmol/L (Figure 3, Table 1). 
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Gallbladder Volume and Bilirubin Output 
After pretreatment with loperamide, basal gallbladder volume was sig­
nificantly larger than in the control experiment (39+4 mL vs 28+4 mL; 
P<0.0001; Figure 4, Table 1). This increase in gallbladder volume was accom­
panied by complete inhibition of bilirubin output into the duodenum under basal 
conditions (Figure 5, Table 1). Intraduodenal perfusion of amino acids resulted in 
significant gallbladder contraction (P<0.0001) and bilirubin output (P<0.01) into 
the duodenum (Figure 4, Table 1). Loperamide significantly (P<0.05) attenuated 
maximum gallbladder contraction in response to the amino acid meal from 4 7 + 3 % 
to 26 + 6% (Figure 4, Table 1) and intraduodenal bilirubin output from 39+6 
μπιοΐ/h to 18 + 6 μπιοΐ/h (P<0.0001; Figure 5, Table 1). 
Amino acids 
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Figure 4. Basal and amino acid stimulated gallbladder volume (mL) in 8 healthy subjects 
with (Ш) or without (O) prior ingestion of loperamide. Values are expressed as mean ± 
SEM. 
Pancreatic Enzyme Output 
Loperamide inhibited basal amylase output from 3.2+0.5 kU/h to 1.0+0.5 
kU/h (P<0.005) and amino acid stimulated output from 5.1+0.8 kU/h to 1.6 + 
0.4 kU/h ( Ж 0 . 0 0 1 ; Figure 6, Table 1). 
<D 
E 
Ъ 
> 
i— 
Φ 
тэ 
•σ 
я 
ω 
CD 
140 
Amino acids 
τ г 1 1 г 
О 30 60 90 120 
Time (mm) 
Figure 5. Basal and amino acid stimulated bilirubin output (ßmol/l5min) in 8 healthy 
subjects with (9) or without (O) prior ingestion of loperamide Values are expressed as 
mean ± SEM 
DISCUSSION 
Loperamide is a synthetic opiate receptor agonist, which selectively interacts 
with peripheral opiate receptors in the digestive tract l2729 Enkephalins are natural 
ligands for these receptors Enkephalins have not only been demonstrated in the 
colon, where loperamide competes with these ligands to inhibit bowel movements, 
but also in other places of the digestive system, like the gastric antrum, duodenum, 
pancreas, cystic duct and bile duct 273° The results of the present study ( with the 
administration of loperamide, causing plasma levels in the therapeutical range' ) 
provide evidence that loperamide not only interacts with peripheral opiate receptors 
in the colon, but also with opiate receptors in the proximal part of the intestinal 
tract, since we have found that loperamide inhibits basal and amino acid stimulated 
gallbladder motility and bilirubin output, as well as amylase output 
In a previous study, it was demonstrated that loperamide inhibited basal and 
meal stimulated trypsin and bilirubin output into the duodenum of patients with a 
short bowel syndrome 3' From that study, it was not clear whether loperamide 
inhibited these functions by inhibition of gastric emptying,32 resulting in a 
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diminished supply of food to stimulating receptors for gallbladder contraction and 
pancreatic enzyme secretion in the duodenum. In order to exclude effects of 
loperamide on gastric emptying, we administered the test meal into the duodenum. 
An elementary test meal was used, in order to exclude possible confounding effects 
of loperamide on nutrient digestion, since we have previously demonstrated that 
appropriate digestion of protein is essential for stimulation of CCK release and 
pancreaticobiliary secretion in humans.14 
Amino acids 
0 30 60 90 120 
Time (min) 
Figure 6. Basal and amino acid stimulated amylase output (kU/15min) in 8 healthy 
subjects with (9) or without (O) prior ingestion of loperamide. Values are expressed as 
mean ± SEM. 
It has been suggested that the inhibitory effect of the opioid peptide 
enkephalin on meal stimulated pancreatic protein secretion in dogs was mediated by 
a reduction in the release of CCK."34 According to our data, the evidence in 
humans is otherwise, since the release of CCK in response to a meal is enhanced 
by loperamide. A prolonged contact time between stimulating nutrients and CCK 
secreting cells, may be responsible for this enhanced release of CCK by 
loperamide, since loperamide delays the passage of fluid through the intestine. In a 
previous study we have demonstrated that loperamide inhibits gallbladder contrac-
tion in response to intravenously administered CCK, resulting in plasma CCK 
concentrations as observed as after a meal.35 We therefore postulate, that the 
sensitivity of the pancreas and gallbladder to respond to an amino acid meal 
(causing increases of CCK in the physiological range as seen postprandial^) is 
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attenuated by loperamide due to interference with opioid receptors on the pancreas 
and gallbladder. Subsequently, according to negative feedback concept between 
Table 1. Integrated responses under basal conditions (0-60 minutes) and in response to 
amino acids (60-120 min) in 8 healthy subjects with (+loperamide) or without (-
loperamide) loperamide pretreatment. Incremental responses were obtained after subtrac­
tion of integrated values in the basal period (0-60 minutes) from integrated values during 
the period of stimulation (60-120 minutes). Results are expressed as mean ± SEM. 
Basal Amino acids 
test 0-60 min 60-120 min Incremental 
сек 
(pM»60min) 
PP 
(pM»60min) 
Gallbladder 
volume 
(mL»60min) 
Bilirubin 
(μπιοί) 
-loperamide 
+ loperamide 
-loperamide 
+ loperamide 
-loperamide 
+ loperamide 
-loperamide 
+ loperamide 
174+24 
181 + 18 
1606+279 
1258+220* 
1619+219 
2209 + 208* 
21+5 
0+0* 
229+55 
411+52* 
1886 + 384 
1446+295* 
1198+193 
2077 + 223* 
39+6 
18+6* 
55 + 35 
230+41* 
280+130 
188+109 
-421 +56 
-132+76* 
18+5 
18+6 
Amylase -loperamide 3.2+0.5 5.1+0.8 1.9+0.6 
( k U )
 +loperamide 1.0+0.5' 1.6+0.4* 0.5+0.3 
* significantly different (P< 0.05) from test without loperamide pretreatment. 
pancreaticobiliary output and CCK release,3639 the diminished output of 
pancreaticobiliary products into the duodenum enhances the release of CCK. 
Recently it was shown that enkephalin attenuates pancreatic enzyme 
secretion in the rat by inhibiting the release of acetylcholine.40 A direct effect of 
opioids on pancreatic acini was unlikely."1 In humans, loperamide may also 
attenuate pancreaticobiliary secretion by inhibiting the release of acetylcholine. The 
finding of decreased pancreatic polypeptide levels, a hormone that is primarily 
controlled cholinergically,42·43 after administration of loperamide, supports the 
hypothesis that loperamide also interferes with the human cholinergic system to 
attenuate pancreaticobiliary secretion. 
The results of the present study may also be explained by an increased 
outflow resistance at the level of the sphincter of Oddi. 4 4 4 3 However, this is 
unlikely, since basal amylase output was not inhibited, and amino acid stimulated 
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amylase and bilirubin output were not abolished. 
Since a diminished gallbladder motility causes bile stasis, which is a major 
factor contributing to the formation of gall stones,610 further studies are needed to 
see whether chronic administration of loperamide contributes to the development of 
gall stones. Since loperamide can impair pancreatic enzyme secretion, this might be 
a relevant side effect in patients who have a (borderline) pancreatic insufficien­
cy12'31 or a short bowel syndrome,31 "6 and therefore should be noticed when 
prescribing loperamide. 
In conclusion, loperamide inhibits basal and amino acid stimulated gallblad­
der motility and pancreatic enzyme secretion in humans, despite an enhanced amino 
acid stimulated CCK release. 
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ABSTRACT 
Background/Aims: Impaired postprandial gallbladder emptying in coeliac 
disease has been attributed to absence of appropriate cholecystokinin (CCK) 
release due to a damaged upper small intestinal mucosa. This study was per­
formed to determine if a flat jejunal mucosa in coeliac patients results in a 
reduced CCK secreting capacity. Methods: Increasing doses of BBS (O.I, 0.4, 
and 1.6 ng*kg'*min '; each dose for 45 min) were infused into 6 patients with 
coeliac disease and a flat jejunal mucosa (group A), in 7 coeliac patients with a 
normal jejunal mucosa while on a gluten free diet (group B) and in 7 healthy 
controls (group C). Results: Infusion of increasing doses of BBS induced 
significant (P<0.05) and dose related increments of plasma CCK to a maximum 
value of 1.0±0.3 pM in group A, to 1.5±0.3 pM in group В and to 1.2±0.3 pM 
in group С (NS between groups). Plasma CCK increments were accompanied by 
significant (P<0.05) and dose related gallbladder emptying responses with a 
maximum value of 70±4% in group A, 47±10% in group В and 65±5% in 
group C. The average slopes of the linear regression of increments in plasma 
CCK and decreases in gallbladder volume on log-BBS dose were not different 
between the groups, indicating similar dose response relationships. Conclusions: 
Plasma CCK release and gallbladder responses to graded doses of BBS are not 
disturbed in coeliac patients with a flat jejunal mucosa, indicating that there is no 
major impairment of the CCK secreting capacity nor in responsiveness of the 
gallbladder to CCK in these patients. 
INTRODUCTION 
Diarrhoea and malnutrition due to gluten sensitive villous atrophy of the 
small intestine are characteristic features of coeliac disease ' 2 Previous studies have 
convincingly shown that postprandial gallbladder responses are also impaired in 
these patients 3 '° A diminished release of endogenous CCK from the inflammed 
intestinal mucosa probably is responsible for these findings, since postprandial 
CCK release is almost abolished in coeliac patients with a flat jejunal mucosa b9 " 
The most obvious conclusion from these findings is that the impaired postprandial 
release of CCK is a consequence of reduced production of this hormone by the 
inflammed intestinal mucosa of coeliacs Indeed, low intestinal concentrations of 
CCK, suggesting an impaired capacity to produce CCK, have been demonstrated m 
coeliacs " 
However, an increased number of CCK producing cells has also been found 
m mucosal biopsies in coeliac patients,1213 suggesting that a reduced feasibility to 
stimulate the release of CCK, rather than a reduced production of CCK by the 
inflammed intestinal mucosa may explain the low postprandial plasma CCK 
concentrations 
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In order to differentiate between these apparently conflicting observations we 
have designed a study protocol to test the hypothesis that the impaired postprandial 
CCK release, consistently found in patients with coeliac disease and a flat jejunal 
mucosa, is not the concequence of an impaired production of CCK by the in 
flammed mucosa, but of an impaired feasibility of the meal to stimulate the release 
of CCK For this purpose, we have stimulated CCK producing cells primarily from 
the vascular site by intravenous administration of BBS, and not from the luminal 
site, where meal components are supposed to act BBS was used since this peptide 
has been shown to stimulate the release of CCK and gallbladder contraction in 
humans after mtravenous administration ы '5 
The study was performed in patients with coeliac disease and a flat jejunal 
mucosa, and the results were compared with those obtained in coeliac patients with 
a normal jejunal mucosa while on a gluten free diet, and in healthy controls 
MATERIALS AND METHODS 
Subjects 
Six patients with coeliac disease and a flat jejunal mucosa (3 woman and 3 
men, mean age 41 years, range 28 55 years), 7 patients with coeliac disease and an 
intact intestinal mucosa while on a gluten free diet (4 woman and 3 men, mean age 
54 years, range 37 72 years) and 7 healthy volunteers (6 woman and 1 man, mean 
age 46 years, range 20 73 years) were studied None of the patients or volunteers 
was taking any medication or had a history of surgery or other gastrointestinal 
diseases The study protocol was approved by the ethical committee of the Univer 
sity Hospital Nijmegen, and all subjects gave their written informed consent before 
entering the study 
Reagents 
BBS was obtained from UCB (Brussels, Belgium), Synthetic CCK33 from 
Peninsula Laboratories Europe, Ltd (St Helens, England), [125I] hydroxyphenyl 
propionic acid succinimide ester (Bolton Hunter reagent) from New England 
Nuclear (Boston, MA, USA), Pharmacia Decanting Suspension #3 trom Pharmacia 
Diagnostics, AB (Uppsala, Sweden), All other materials were obtained from 
Merck (Amsterdam, The Netherlands) 
Study Protocol 
After an overnight fast, the participants presented at the laboratory at 7 30 
AM An indwelling intravenous catheter was placed in each forearm, one for the 
collection of blood samples, the other for the administration of BBS The catheters 
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were kept patent by a hepanne-saline solution After a basal period of 30 minutes, 
BBS was infused by stepwise increasing doses of 0 1, 0 4 and 1 6 ng»kg'»min' 
every 45 minutes Blood samples were taken 3 times before and subsequently every 
15 minutes after the start of BBS infusion until the end of the infusion period 
Blood was collected in ice-chilled glass tubes containing 2 g/L of ethylene-
diaminetetraacetate (EDTA) After the experiments, the blood samples were 
centnfuged at 4 °C for 10 min at 3000g Plasma was stored at 20 °C until assayed 
for CCK Each time that a blood sample was drawn, two longitudinal and two 
transverse images of the gallbladder were obtained by real time ultrasonography 
Plasma Samples 
Plasma CCK was measured by a sensitive and specific radioimmunoassay 
(RIA) as described previously '6 '7 The antibody used (T204) binds to biologically 
active CCK peptides containing the sulfated tyrosine region, with almost equal af 
finity On a molar base, sulfated gastrins cross reacted <2% in the assay, while no 
cross reactivity with unsulfated gastrins or structurally unrelated peptides was 
found The detection limit of the assay was between 0 5 and 1 0 pmol/L CCK in 
plasma The intra assay precision ranged from 4 6% to 11 5% in the steep part of 
the standard curve Measurements of CCK samples were performed in the same 
run 
Gallbladder Ultrasonography 
Longitudinal and transverse images of the gallbladder were obtained by real 
time ultrasonography (Sonolayer Sal 77 B, Toshiba, Tokyo, Japan) using a 3 75 
MHz transducer '8 Gallbladder volume was calculated from these images by the 
sum of cylinders method as previously described 19 The variation of volume 
measurements ranged from 6 % to 22% 
Statistical Analysis 
All measurements were performed in duplicate, and the mean of these two 
measurements was used for further analysis Gallbladder contraction was expressed 
as percent decrease of gallbladder volume at the end of each 45 minute infusion 
period relative to basal volume, which was calculated as the mean of gallbladder 
volumes at 30, 15, and 0 mm Plasma CCK increments for each infusion period 
were obtained by subtracting basal plasma CCK concentrations from the mean of 
plasma CCK concentrations at 30 and 45 minutes of each infusion dose Results are 
expressed as mean ± SEM To determine whether there were dose response 
relations between the doses of BBS infused, plasma CCK increments and gallblad 
der contractions, the average slope of the linear regression for each response 
variable, computed on log dose for each subject, was compared with zero by 
means of a Student's t test20 One way analysis of variance was performed to 
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determine differences between groups Differences with a two tailed Ρ value < 
0 05 were considered significant The relationship between plasma CCK increment 
and gallbladder contraction was determined by linear regression analysis 
RESULTS 
Plasma Concentrations of CCK 
Basal plasma CCK levels in coeliac patients with a flat jejunal mucosa 
(2 8+0 2 pM), in patients with an intact intestinal mucosa while on a gluten free 
diet (3 3+0 2 pM) and in controls (2 8±0 2 pM) were not significantly different 
from each other (Figure 1) Infusion of 0 1, 0 4 and 1 6 ngekg'«min' of BBS, 
significantly (P<0 05) and dose dependently increased plasma CCK at the end of 
each infusion period to 3 1+0 1 pM, 3 4+0 2 pM, and 3 8 + 0 3 pM, respectively 
in the six coeliac patients with a flat jejunal mucosa, to 3 7+0 3 pM, 4 2±0 3 
pM, and 4 8+0 4 pM, respectively in the seven coeliac patients while on a gluten 
free diet, and to 3 1+0 3 pM, 3 3+0 4 pM, and 3 9+0 5 pM, respectively in the 
7 healthy volunteers (Figure 1) Plasma CCK increments m response to these 
stepwise increasing doses of BBS were not significantly different among patients 
and normal subjects (Figure 2) The average slopes of the linear regression of 
plasma CCK increments and logarithmic BBS doses were 0 6+0 2 in patients with 
a flat jejunal mucosa, 1 0+0 2 in patients while on a gluten free diet, and 0 7+0 2 
in healthy controls These slopes were not significantly different among the 3 
groups, indicating similar dose response relationships between healthy subjects and 
patients with coeliac disease 
Gallbladder volume 
Fasting gallbladder volume was 31 1+5 5 mL in untreated patients, 
44 2 + 7 9 mL in treated patients, and 26 5+2 8 mL in healthy volunteers (NS) 
Infusion of graded doses of BBS induced significant and dose related gallbladder 
emptying responses ot 20+9 %, 51+9 %, and 70+4 % respectively in coeliac 
patients with a flat jejunal mucosa, of 9 + 3 %, 34±9 %, and 47 + 10 %, respecti 
vely in coeliac patients while on a gluten tree diet, and of 27±10 %, 41+6 %, 
and 65+5 %, respectively in healthy controls (Figure 3) The degree of gallbladder 
contraction at the end of each BBS dose was not significantly different among 
coeliac patients and healthy controls (Figure 4) The average slopes of the linear 
regression of decreases in gallbladder volume and logarithmic BBS doses were 
41+6 in coeliacs with a flat |ejunal mucosa, 32 + 8 in coehacs on a gluten free 
diet, and 32 + 8 in healthy controls (NS), indicating similar dose response rela 
tionships The average slope of the linear regression of gallbladder contraction 
versus plasma CCK increment was 82±23 %·ρΜ' in patients with a flat jejunal 
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mucosa, 33 + 7 % · ρ Μ ' in patients on a gluten free diet, and 40+24 % · ρ Μ ' in 
healthy controls (NS) 
bombesin ι ν ng/kg*min 
0.1 0.4 1.6 
о 
E 4 
Q. 
ϋ 
ϋ 3 
(0 
Ε 
W (0 ρ 
-45 45 90 135 
Time (mm) 
Figure 1. Plasma cholecystokinin (CCK) m response to intravenous infusion of stepwise 
increasing doses of bombesin m six coehac patients with a flat jejunal mucosa (9), m 
seven healthy volunteers (A), and in seven patients with coehac disease with a normal 
mucosa while on a gluten free diet (O) Results are expressed as mean ± SEM 
DISCUSSION 
The present study shows that intravenous infusion of BBS markedly and dose 
dependently stimulates plasma CCK release and gallbladder contraction in coehac 
patients with a flat jejunal mucosa, comparable to responses found in healthy 
subjects and in coehac patients with a normal intestinal mucosa while on a gluten 
free diet This is in marked contrast with the responses to oral or intestinal 
administration of fat in coehacs with a flat jejunal mucosa, where plasma CCK and 
gallbladder responses are almost abolished 6 9 " Intestinal concentrations of CCK 
have been reported to be lower in patients with coehac disease than in healthy sub 
jects " Therefore, abnormal gallbladder responses to fatty meals have been attribu­
ted to a diminished CCK secreting capacity of the upper small intestinal mucosa in 
coehacs ' " However, immunohistochemical studies have demonstrated that the 
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Figure 2. Effect of increasing doses of intravenously administered bombesin on plasma 
cholecystokinin increments in six coeliac patients with a flat jejunal mucosa (closed bars), 
in seven coeliac patients with a normal mucosa while on a gluten free diet (hatched bars), 
and in seven healthy controls (open bars). Results are expressed as mean + SEM. 
number of CCK-like cells are increased in duodenal biopsies from patients with 
coeliac disease.12·13 These apparently contrasting findings suggest, that the at-
tenuated fat-stimulated release of CCK in coeliacs with a flat jejunal mucosa may 
either result from impaired production of CCK in the inflammed intestinal mucosa, 
or from impaired postprandial stimulation of CCK, despite a normal or even 
increased number of CCK-producing cells in the elongated crypts of the mucosa. 
Our finding that intravenous infusion of BBS dose dependently stimulates the 
release of CCK in patients with a flat jejunal mucosa, comparable to healthy 
volunteers and coeliacs with a normal mucosa while on a gluten free diet, indicates 
that the inflammed mucosa has an undisturbed potential to secrete CCK. 
The discripancy between the effects of meal-stimulation on the one hand and 
BBS-stimulation on the other on CCK release in coeliacs with a flat jejunal mucosa 
indicates that stimulation of CCK-cells from the luminal side is impaired. It might 
be that elongation of the crypts in the inflammed intestinal mucosa may contribute 
to impaired stimulation, rendering the contact between luminal contents and CCK-
producing cells more difficult. It is interesting to note that CCK-cells in coeliac 
patients with a flat jejunal mucosa can be stimulated when predigested nutrients are 
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infusion of stepwise 
increasing doses of bombesin in six coeliac patients with a flat jejunal mucosa (9), in 
seven healthy volunteers (A), and in seven patients with coeliac disease and a normal 
mucosa while on a gluten free diet (O). Results are expressed as mean ± SEM. 
administered iniraduodenally.21 This suggests that maldigestion of nutrients 
contributes to the impaired postprandial CCK release in these patients,22 and that 
the CCK secreting capacity is not disturbed. 
BBS by itself has probably no effect on human gallbladder contraction, since 
no BBS receptors have been demonstrated on human gallbladder muscle in vitro.23 
Therefore, CCK released by BBS is the principal mediator of gallbladder contrac­
tion.24·25 This is supported by the present finding that BBS-infusion dose depen-
dently stimulates CCK release and gallbladder contraction. The extent of gallblad­
der contraction in response to BBS is also not diminished in coeliacs with a flat 
mucosa when compared to coeliacs with a normal mucosa while on a gluten free 
diet and to healthy subjects, demonstrating that gallbladder sensitivity to circulating 
endogenous CCK is not impaired. This is further supported by the observation that 
the slope of the linear regression of gallbladder contraction versus plasma CCK 
increment in untreated coeliacs is not lower but even tends to be higher than the 
slope in healthy volunteers or coeliacs with a normal mucosa. This is an interesting 
observation, since some previous studies have suggested that gallbladder sensitivity 
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Figure 4. Effect of increasing doses of intravenously administered bombesin on gallblad­
der emptying in six coeliac patients with a flat jejunal mucosa (closed bars), in seven 
coeliac patients with a normal mucosa while on a gluten free diet (hatched bars), and in 
seven healthy controls (open bars). Results are expressed as mean ± SEM. 
to circulating CCK is diminished in coeliacs.8·26 The results of the present study are 
more in line with data showing that gallbladder sensitivity to intravenously infused 
CCK analogues in coeliacs with a flat or normal mucosa, is not different from 
gallbladder sensitivity to CCK in controls.3·6·7·27 This strongly suggests that the 
abnormally impaired post-prandial gallbladder response in coeliac patients with a 
flat jejunal mucosa is not related to a lack of end-organ responsiveness to CCK. 
In conclusion, plasma CCK release and gallbladder contraction in response 
to increasing doses of intravenously administered BBS are not reduced in patients 
with coeliac disease and a flat jejunal mucosa when compared to healthy subjects. 
Thus, the impaired postprandial CCK release and gallbladder contraction in these 
patients are not related to abnormalities in CCK secreting capacity, but to impaired 
stimulation by (undigested) nutrients. 
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SUMMARY 
Feedback regulation of cholecystokinin release has been the subject of many 
studies performed in the past, illustrating the importance of this topic. The majority 
of these studies concluded that protease activity in the lumen of the proximal 
gastrointestinal tract regulates the release of CCK. This concept has resulted in the 
general believe that in patients with chronic pancreatitis and exocrine pancreatic 
insufficiency, low protease activity in the lumen of the proximal small intestine 
stimulates CCK which subsequently stimulates pancreatic secretion resulting in 
increased ductal pressure and pain in these patients. However, most of these studies 
were performed in animals, specially in rats. Previous experiments performed in 
our laboratories have casted doubt on the importance of protease activity on CCK 
release in humans. 
The studies presented in this thesis investigate the problem of feedback 
control of CCK release, gallbladder motility, and pancreatic exocrine secretion in 
humans in more detail. Special attention is payed to the role of bile salts and 
protease activity in the lumen of the duodenum, and to the effect of hydrolysis of 
nutrients on CCK release. 
Chapter 1 gives a short introductary background to our present knowlegde of 
cholecystokinin, bombesin, gallbladder motility, bile salts, and pancreatic function. 
Chapter 2 describes the effect of bile salt binding or inactivation of protease 
activity on bombesin-stimulated plasma CCK concentrations and gallbladder 
contraction in healthy volunteers. For this purpose, bombesin was infused intra-
venously and plasma cholecystokinin and gallbladder volumes were measured at 
regular time intervals. After an initial rise, plasma CCK drops to values somewhat 
higher than basal values despite continuous infusion of bombesin. Plasma CCK 
levels and gallbladder contraction in response to bombesin were markedly enhanced 
by bile salt precipitation, no matter whether colestipol or cholestyramine was used 
as precipitant. Inactivation of protease activity in the lumen of the proximal small 
intestine had no effects on bombesin-stimulated CCK release and gallbladder 
motility. These studies demonstrate that in acute experiments, bile salts but not 
proteases regulate the release of CCK in response to intravenous stimulation with 
bombesin. 
Chapter 3 deals with the effect of bile salt sequestration on amino acid 
stimulated plasma CCK release, pancreatic emzyme secretion and gallbladder 
motility in healthy volunteers. In this study, intraduodenally administered amino 
acids were used as stimulant to avoid bias on CCK release by gastric emptying or 
maldigestion of nutrients. Bile salt precipitation by cholestyramine markedly 
enhanced amino acid stimulated CCK release, amylase output, and gallbladder 
contraction. This demonstrates that in acute experiments, cholestyramine not only 
enhances CCK release and the effects of CCK in response to intravenous bombesin, 
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but also in response to nutrients. The present study also shows, that the effect of 
cholestyramine on nutrient stimulated CCK release is not related to alterations in 
gastric emptying or digestion of nutrients. 
In Chapter 4, we describe the role of introduodenal protease activity on 
plasma CCK and pancreaticobiliairy responses to protein and amino acids in 
healthy subjects. For this purpose, saline was perfused intraduodenally for 3 hours 
either with or without the synthetic protease inhibitor camostate. During the last 
hour albumin or amino acids, in the same molecular composition as albumin, were 
also perfused. Perfusion with camostate, in concentrations that abolished intra-
duodenal proteolytic activity, had no effect on unstimulated plasma CCK concen-
trations or gallbladder emptying, but markedly enhanced unstimulated pancreatic 
enzyme output. Perfusion with protein distinctly stimulated CCK release, gallblad-
der emptying and pancreatic enzyme output. Camostate significantly reduced 
protein stimulated CCK release, gallbladder contraction and pancreatic enzyme 
output. Perfusion with amino acids also stimulated CCK release, gallbladder 
emptying and pancreatic enzyme output. These effects were not influenced by 
camostate, suggesting that appropriate digestion of protein is required to stimulate 
plasma CCK release, gallbladder empting and pancreatic enzyme output in humans. 
From these studies it can also be derived that under basal conditions protease 
activity in the lumen of the small intestinal tract mediates pancreatic enzyme 
secretion, but that this effect is not mediated by CCK. 
Chapter 5 deals with the effect of duodenal perfusion with chenodeoxycholic 
acid on BBS- or CCK-stimulated pancreaticobiliary function and plasma CCK 
levels in healthy volunteers. We performed this study to investigate if the 
regulatory role of bile acids on CCK release and pancreaticobiliary functions is 
dependent on the presence of nutrients in the lumen of the gut. The study demon-
strated that chenodeoxycholate, in concentrations within the physiological range, 
inhibits bombesin stimulated gallbladder emptying and pancreatic function, whereas 
plasma CCK levels were enhanced. Thus, the inhibiting effect of chenodeoxycholic 
acid on pancreaticobiliary functions in the absence of nutrients in the gut is 
probably explained by diminished sensitivity to cholecystokinin. 
In Chapter 6 the role of the cholinergic system in the regulation of basal and 
bombesin stimulated plasma CCK release and gallblader motility was studied. 
Infusion of atropine increased basal gallbladder volume and inhibited bombesin-
stimulated gallbladder motility without significantly affecting plasma CCK release. 
This suggests that not only during the interdigestive or early phase of digestion but 
also during stimulated conditions, the cholinergic system co-regulates gallbladder 
motility. Furthermore, these results suggest a direct stimulatory effect of the 
cholinergic system on gallbladder motility. 
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Chapter 7 shows the effect of the opioid receptor agonist loperamide on 
amino acid stimulated pancreatic enzyme secretion, gallbladder motility and CCK 
release We performed this study in order to investigate whether opioid receptors 
are involved in meal stimulated pancreaticobiliary functions and CCK release The 
study demonstrated that loperamide inhibits basal as well as amino acid stimulated 
gallbladder motility and intraduodenal output of bilirubin and amylase, but enhan-
ces postprandial CCK release The data suggest that activation of peripheral opioid 
receptors have direct inhibitory effects on gallbladder emptying and pancreatic 
enzyme secretion, and that postprandial CCK release is subsequently enhanced due 
to a reduced concentration of pancreaticobiliary products in the lumen of the 
proximal small intestine 
In Chapter 8 a dose response study with increasing doses of BBS on plasma 
CCK release and gallbladder contraction in patients with coeliac disease is 
described Previous studies have demonstrated that postprandial CCK release and 
gallbladder contraction are decreased in patients with coeliac disease and a flat 
jejunal mucosa Controversy exists as to whether this decreased CCK release is the 
result of impaired production of CCK or of an impaired capacity of the ïnflammed 
intestinal mucosa to release the hormone m response to a meal We therefore have 
tried to stimulate CCK by an intravenously applied stimulus for the release of CCK 
and not by an intestinal stimulus We have found that CCK release and gallbladder 
contraction in response to intravenously administered bombesin are not significantly 
different between coeliac patients with a flat jejunal mucosa, coeliac patients with a 
normal mucosa while on a gluten free diet and healthy subjects, suggesting that the 
low postprandial CCK-responses in coeliacs with a flat jejunal mucosa are not the 
result of an impaired CCK producing capacity of the inflammed intestinal mucosa, 
but to a disturbance of CCK release in response to a luminal meal stimulus 
Furthermore, the study also demonstrates that there is no decreased sensitivity of 
the gallbladder for endogenous CCK m coeliac disease 
CONCLUSION AND CONSIDERATIONS 
Feedback regulation of pancreatic enzyme secretion, gallbladder emptying 
and CCK release is a complex mechanism in humans 
Under basal conditions, pancreatic enzyme secretion is enhanced by inac-
tivation of proteases in the lumen of the small intestine This effect is not mediated 
by CCK Basal gallbladder volumes are not affected by inactivation of proteases 
Under meal-stimulated conditions, protease activity facilitates the release of 
CCK, gallbladder emptying and pancreatic enzyme secretion by conversion of 
undigested protein into amino acids Only digested nutrients stimulate the release of 
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CCK, gallbladder emptying and pancreatic enzyme output. Inactivation of proteases 
virtually abolishes the release of CCK, gallbladder emptying, and pancreatic 
enzyme output in response to intact protein. 
Precipitation of bile salts under meal-stimulated, but not under basal 
conditions, strongly enhances the release of CCK, gallbladder emptying and 
pancreatic enzyme output, demonstrating that in the acute experiment, bile acids 
suppress meal-stimulated CCK release, gallbladder emptying, and pancreatic 
enzyme output. 
Thus, in humans, feedback regulation of CCK release, pancreatic enzyme 
output and gallbladder emptying is different under basal and meal-stimulated 
conditions. Under basal conditions a protease mediated feedback control operates 
that is not dependent on CCK. Under stimulated conditions a bile acid mediated 
feedback control operates that is dependent on CCK. This is different from rats, 
where both under basal and under meal-stimulated conditions a CCK mediated and 
protease dependent feedback mechanism exists. Furthermore, hydrolysed nutrients, 
but not undigested nutrients stimulate the release of CCK, gallbladder emptying and 
pancreatic enzyme secretion in humans, whereas in rats undigested nutrients are 
more potent stimulants for CCK than digested nutrients. 
These studies are in conflict with an important role for CCK in feedback 
regulation of pancreatic exocrine secretion in humans and cast doubt on the concept 
of a protease mediated feedback mechanism of CCK release that is believed to be 
involved in the induction of pain in chronic pancreatitis. 
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SAMENVATTING 
Het eten van vast en/of vloeibaar voedsel brengt in het maag-darm stelsel 
een reeks van reacties op gang die samen het verteringsproces bepalen. Dat 
verteringsproces begint al bij het zien, proeven of ruiken van, of denken aan 
voedsel. Dan worden in de mond en de maag al stoffen gemaakt (enzymen) die de 
vertering van het voedsel op gang brengen. Nadat het voedsel in de maag door de 
maagsappen gesplitst is in kleinere brokstukken wordt het verder vervoerd richting 
dunne darm, waar de verdere voedselvertering op gang komt. 
In de dunne darm leidt de aankomst van voedsel tot een hele reeks aan 
reacties zoals het vrijkomen van enzymen en vocht (bicarbonaat) uit de alvleesklier 
(pancreas), het samentrekken van de galblaas en dus de uitstoot van gal in de darm. 
Merkwaardig is, dat voedsel in de darm in staat is om effecten elders in hel 
lichaam te veroorzaken. Dit verschijnsel wordt echter snel aannemelijk als we 
bedenken dat er in het lichaam stoffen aanwezig zijn, die zorgen voor het overbren-
gen van een signaal naar de betreffende organen op afstand. Deze stoffen staan 
bekend onder de noemer hormonen. Dit zijn stoffen die via vervoer in het bloed 
effect kunnen hebben op organen elders in het lichaam. 
Eén van die hormonen is cholecystokinine of kortweg CCK. Eerder onder-
zoek heeft aangetoond dat CCK van belang is bij de werking van galblaas en 
alvleesklier. Zo is ondermeer bekend, dat CCK de galblaas doet samentrekken en 
dal zo galzuren in de darm komen. Deze galzuren werken in op de afbraakproduc-
ten van vet met als doel, opname van deze afbraakproducten in het bloed te 
vergemakkelijken. Ook activeert CCK de alvleesklier tot de afgifte van onder 
andere amylase, trypsine en chymotrypsine, enzymen in de darm, die koolhydraten 
en eiwitten daar splitsen in suiker (glucose, fructose) en aminozuren. 
Het op gang brengen van het verteringsproces is op deze manier goed 
voorstelbaar en middels onderzoek bevestigd. Een logisch gevolg van het op gang 
brengen van een proces, is echter ook de rem ervan zodat het niet doorschiet. Met 
andere woorden, er voor zorgen dat de enzymen en galzuren nadat ze hun werk 
hebben gedaan, niet beginnen aan de afbraak van b.v. de darm of alvleesklier zelf. 
Dit kan voorkomen worden door het op gang brengen van een terugkoppelingssys-
teem ("feedback regulation"), dat werkzaam is in het maag-darm stelsel. 
In dit proefschrift wordt de het terugkoppelingssysteem (feedbacksysteem) 
dat werkt op CCK, de galblaas en de alvleesklier nader bestudeerd. De aanleiding 
hiervoor komt voort uit tot nu toe verricht onderzoek naar de werking van dit 
feedbacksysteem. De algemene conclusie hieruit is dat alvleesklierenzymen de 
bepalende factor zijn in het feedbacksysteem dat werkt op CCK, galblaas en 
alvleesklier. Tevens wordt gedacht, dat bij mensen met een verminderde alvlees-
klierfunctie (pancreas-insufficièntie) of chronische alvleesklierontsteking 
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(chronische pancreatitis), door verminderde aanwezigheid van alvleesklierenzymen, 
een extra aanzet tot de productie van CCK wordt gegeven Dit zou leiden tot extra 
aanzet van productie van alvleesklierenzymen en zou daarmee een verklaring 
vormen voor de pijnkJachten bij deze patiënten 
Een van de beperkingen van tot nu toe verricht onderzoek is dat het meestal 
uitgevoerd is bij dieren, voornamelijk bij de rat In het lichaam van de rat 
ontbreekt echter de galblaas Dit alleen al zorgt voor terughoudendheid, als men 
het terugkoppelingssysteem op CCK, galblaas en alvleesklier bij de rat als model 
voor dat van de mens gebruikt 
Het doel van dit proefschrift is derhalve het feedbackmechanisme, 
werkzaam op CCK, galblaas en alvleesklier bij de mens nader in kaart te bren-
gen. Hiertoe zijn een aantal onderzoeken verricht bij gezonde mensen. Extra 
nadruk bij deze onderzoeken wordt gelegd op de rol van alvleesklierenzymen en 
galzuren in het terugkoppelingsmechanisme en het effect van voedselvertering op 
het vrijkomen van CCK. 
In hoofdstuk 1 wordt de bestaande kennis over CCK, de galblaas en de 
alvleesklier beschreven 
In hoofdstuk 2 wordt het effect beschreven van het stopzetten van de 
werking van galzuren in de darm middels cholestyramine (een galzout bindende 
hars), op het vrijkomen van CCK in het bloed (plasma) en de galblaassamentrek 
king (contractie) Ook wordt het effect bestudeerd van het stopzetten van de 
activiteit van alvleesklierenzymen Voor het op gang brengen van het maag-darm 
stelsel wordt m plaats van een maaltijd bombesine (BBS) via een ader toegediend 
BBS is een stof die ook in het lichaam aanwezig is en waarvan bekend is dat hij de 
galblaas en alvleesklier kan stimuleren Deze studie toont aan dat wegvangen van 
galzuren zorgt voor een extra stimulering van CCK-release en galblaascontractie 
Het inactiveren van alvleesklierenzymen tijdens stimulering met BBS heeft hierop 
geen effect Dit is m tegenspraak met tot nu toe verricht onderzoek 
Hoofdstuk 3 beschrijft een studie naar het effect van cholestyramine op 
CCK, de galblaas en de alvleesklier na stimulatie middels het toedienen van 
aminozuren in de darm Door het geven van aminozuren rechtstreeks in de darm 
wordt een eventueel effect van cholestyramine op maagontlediging en voedsel 
vertering omzeild Deze studie toont aan dat wegvangen van galzuren een extra 
stimulus voor CCK, galblaas en alvleesklier vormt, ook tijdens stimulatie met 
aminozuren Tevens wordt hiermee aangetoond dat het effect van cholestyramine 
niet het gevolg is van inwerking op voedselvertering of maagontlediging 
In hoofdstuk 4 wordt een studie naar het effect van eiwitsphtsende enzymen 
(proteasen) beschreven Hierbij wordt gebruik gemaakt van camostate, een slof die 
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in staat is alvleesklierenzymen te remmen in hun werking. Als stimulus wordt 
albumine in ongesplitste en gesplitste vorm (aminozuren) gegeven. Deze studie 
toont aan dat splitsing van eiwit nodig is voordat het maag-darm stelsel op gang 
kan worden gebracht. Dit in tegenstelling tot de rat waar eiwitten effectief zijn en 
aminozuren niet. Tevens komt uit deze studie naar voren dat in de fase tussen de 
maaltijden, proteasen de werking van de alvleesklier regelen en dat dit effect 
onafhankelijk is van CCK. Ook deze resultaten zijn in tegenspraak met tot nu toe 
geldende opvattingen over het feedback systeem werkzaam op CCK. 
In hoofdstuk 5 wordt het effect van het galzuur chenodeoxycholzuur 
(CDCA), één van de in het lichaam voorkomende galzuren, in de darm nader 
bestudeerd. Als stimulus voor CCK, galblaas en alvleesklier wordt BBS of CCK in 
plaats van een maaltijd gebruikt. Zo kan hel effect van galzuren bij afwezigheid 
van voedsel in de darm bestudeerd worden. Deze studie brengt naar voren dat dit 
galzuur een remmende werking heeft op de galblaas en de alvleesklier, 
waarschijnlijk doordat deze organen minder gevoelig worden voor CCK. 
In hoofdstuk 6 wordt de invloed van het zenuwstelsel op de werking van de 
galblaas en alvleesklier bekeken. Aangenomen wordt dat het zenuwstelsel alleen in 
de fase tussen de maaltijden in, en alleen bij het begin van een maaltijd effect heeft 
op de galblaas. Tijdens toedienen van atropine, een medicijn dat een remmende 
werking heeft op het zenuwstelsel, blijkt dat de galblaas zich ontspant. Als daama 
BBS wordt gegeven, reageert de galblaas minder hierop (minder samentrekking). In 
deze studie wordt dus duidelijk dal het zenuwstelsel niet alleen bij het begin, maar 
ook tijdens de gestimuleerde fase van het verteringsproces een belangrijke rol 
speelt bij de werking van de galblaas. 
Hoofdstuk 7 beschrijft het effect van loperamide (Imodium*), een medicijn 
dat gebruikt wordt tegen diarree, op alvleeskliersecretie, galblaascontractie en 
plasma CCK spiegels. Doel van dit onderzoek is vast te stellen of loperamide naast 
een remmende werking op de darmsamentrekking ook van invloed is op het 
verteringsproces door beïnvloeding van alvleesklier en galblaas. Deze studie toont 
aan dat loperamide in staat is de galblaas en alvleesklier te remmen in hun werking 
tijdens stimulering met aminozuren, ondanks het feit dat het medicijn het vrijkomen 
van CCK in het bloed stimuleert. Blijkbaar heeft loperamide een direct effect op 
beide organen. De verminderde aanwezigheid van galzuren in de darm tijdens 
aminozuur toediening bij hoge plasma CCK spiegels, toont nogmaals aan dat 
galzuren betrokken zijn in een negatief feedback systeem dat werkzaam is op het 
vrijkomen van CCK in het bloed. 
Tenslotte wordt in hoofdstuk 8 een studie beschreven naar de werking van 
de galblaas bij mensen met voor gluten overgevoelige spruw (Coeliakie). Bij 
mensen met deze ziekte bestaat er een overgevoeligheid van het darmslijmvlies 
voor stoffen (gluten) die aanwezig zijn in verschillende graansoorten. Hel gevolg 
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hiervan is onder andere het optreden van langdurige diarree met als gevolg sterke 
vermagering. Eerder verricht onderzoek toonde aan dat bij deze mensen de plasma 
CCK release en galblaascontractie na een maaltijd verminderd zijn. Onduidelijk is 
echter of het verminderde vrijkomen van CCK na een maaltijd een gevolg is van 
verlaagde productie van het hormoon, of van de verminderde mogelijkheid van de 
ontstoken darm het hormoon vrij te maken na een maaltijd. Door de CCK produc-
tie te stimuleren met BBS wordt in deze studie aangetoond dat mensen met spruw 
een normale CCK producerende activiteit hebben. 
SAMENGEVAT 
Het feedback systeem op plasma CCK, de galblaas en de alvleesklier bij de 
mens is een complex geheel. Dit feedback systeem werkt verschillend onder 
ongestimuleerde (basale) omstandigheden en tijdens de voedselvertering. In de 
ongestimuleerde fase (tussen de maaltijden) regelen proteasen (alvleesklierenzymen) 
dit systeem onafhankelijk van CCK. Echter, tijdens het verteringsproces regelen 
galzuren dit feedback mechanisme via het vrijkomen van CCK. Dit is anders bij de 
rat waar zowel onder basale als gestimuleerde omstandigheden proteasen dit 
systeem regelen door het vrijmaken van CCK. 
Tevens is vertering van voedsel bij de mens noodzakelijk voordat de galblaas 
en alvleesklier hun werk kunnen doen. Ook dit is anders bij de rat. 
De in dil proefschrift beschreven studies zijn in tegenspraak met de eerder 
vermelde rol van CCK als veroorzaker van pijnklachten bij mensen met alvleesklier 
ontsteking. Verder onderzoek is nodig naar de oorzaak van pijnklachten bij deze 
mensen. Tevens toont dit proefschrift aan, dat het gebruiken van een diermodel 
voor het verklaren van de werking van het menselijk lichaam, beperkt moet worden 
tot het vormen van hypothesen over de werking ervan. 
166 
DANKWOORD 
Op de voorkant van een proefschrift staat meestal slechts de naam van één 
auteur vermeld Dat het dit keer toevallig mijn naam is, vind ik èrg prettig Dat de 
voorkant van elk proefschrift veel meer namen zou moeten laten zien, wil ik hier 
graag benadrukken 
Professor dr J В M J Jansen, beste Jan, er zijn in ieders leven enkele 
momenten aan te wijzen die, naar later blijkt, belangrijke vertrekpunten ui de 
goede richting vormen Vaak betreft dat het ontmoeten van iemand die je zijn 
vertrouwen kan, en vooral wil geven Iemand die je ergens kan brengen Boston, 
New Orleans (Tien hoog m een hotel aan de andere kant van Bourbon-Street, met 
niet te openen balkondeuren, "security, you know"), Barcelona (Las Ramblas) en 
San Diego, om maar eens enkele prachtige ervaringen op te noemen Dat je veel 
plezier in je werk kunt hebben en ook goed werk kunt leveren door op een open en 
ongedwongen manier met elkaar om te gaan, heb ik kunnen meemaken op jouw 
afdeling Dank je wel Jan, dat ik éen van die mensen mocht zijn, jouw naam zou in 
dit geval twee voorkanten nodig hebben 
Dr W Ρ M Hopman, beste Wim, een onderzoeker dient elk station ал een 
onderzoeksplan te passeren Niet alleen dat, vaak moet de trein zelfs twee keer zo 
hard achteruit als vooruit Als geen ander heb ik van jou geleerd secuur en rustig te 
werken Nogal eens werd de trein door mij gemist' Een morgen of middag (en 
vaak avond) bemoeienis van jouw kant bracht mij steeds weer op het goede 
onderzoekspoor terug Dank je wel, voor de prima begeleider die je was en voor je 
geduld 
"Lab Gastro" vormde een pracht decor voor het bedrijven van de weten­
schap Naast een prima uitgerust research lab was er ook aandacht voor andere 
zaken Vooral tijdens de pauzes was er volop gelegenheid om onderzoeksstoom af 
te blazen Uniek was het rikuurtje, vaste prik tussen de middag, vaak tot schrik van 
een poli dokter, die nogal eens aan een patient uit moest leggen dat de verbouwing 
van het ziekenhuis nu wel heel dicht bij de poli in de buurt was Minstens even 
succesvol waren de verschillende pools die steeds tot grote hilariteit leidden Dank 
je wel voor jullie gastvrijheid, belangstelling en vriendelijkheid 
Prof Dr G Rosenbusch dank ik voor het beschikbaar stellen van een 
onderzoeksruimte en echo-apparaat op de afdeling Radiologie van hel St Radboud 
ziekenhuis Ook zijn oprechte belangstelling voor de vorderingen van het onder 
zoek waren een prettige ervaring voor deze onderzoeker De rontgenlaboranten en 
in het bijzonder Marijke Eijkemans dank ik voor hun medewerking tijdens de 
onderzoeken (Vooral wanneer "de dokter' weer eens geen galblaas tevoorschijn 
kon toveren, zorgde het aanzetten van het echoapparaat door iemand van jullie al 
voor voldoende hilariteit) 
De medewerkers van het CKCL, en vooral Mw Kohier, dhr Siem en dhr 
Hermans, onder leiding van Dr H Willems vormden een belangrijke schakel in de 
uitgevoerde onderzoeken De talloze figuren in dit proefschrift over bilirubine, 
amylase en trypsine zijn grotendeels tot stand gekomen dankzij hun inzet 
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Prof. Dr. F. Trijbels ben ik zeer erkentelijk voor zijn expertise op het 
gebied van aminozuur bepalingen. Met name bepalingen verricht in darmsap door 
Mw. Kwast en Mw. Van Oppenraaij-Emmerzaal vormden de "finishing touch" 
voor hoofdstuk 3 en 4. 
De 5 keuzevak-studenten die tijdens de afgelopen 4 jaar de revue passeerden 
betroffen steeds goed te motiveren personen. Vooral de spontane en langdurige 
medewerking van Pim Sloots en Rolf van Roermund was zeer prettig. Ook vond ik 
het plezierig Edith Klappe, Abdel Loualidi en Wilfried Roeloffzen te begeleiden bij 
het uitvoeren van hun wetenschappelijke stage. 
De medewerkers van de Audio-visuele dienst, te weten de heren P. Pijnap-
pels, N. van Uden en G. Bosgoed zorgden voor aanvoer van de t.v.- en videotoes-
tellen, die nodig waren om de proefpersonen "rustig" te houden. Zelfs als een 
videotoestel de videoband weigerde terug te geven wisten hun schroevedraaiers 
daar raad mee. 
Dr. R. Woestenborghs van de afdeling Drug, Metabolism and Pharmaco-
kinetics van Janssen Pharmaceutica in Beerse, België dank ik voor het bepalen van 
loperamide spiegels in plasma. 
Alle andere medewerkers van de afdeling Maag-, darm- en leverziekten 
dank ik voor de prettige samenwerking en hun belangstelling voor mijn onderzoek. 
Alle andere mensen die aan de totstandkoming van dit proefschrift hebben 
bijgedragen ben ik zeer erkentelijk. 
Lieve Saskia, een hele lijst aan medewerkers bij het maken van dit proef-
schrift is een prachtig bezit. Die lijst kan nog zo uitgebreid zijn, als de onderzoeker 
niet kan terugvallen op iemand die er altijd voor hem is, die hem van tijd tot tijd 
bijeen kan rapen, is al het werk zinloos. Dank je wel voor de "over all promotor" 
die je voor mij bent. 
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CURRICULUM VITAE 
De auteur van dit proefschrift werd geboren op 8 oktober 1965 te 
Maastricht. In 1984 behaalde hij het diploma Atheneum-B aan het Sint Maar-
tenscollege te Maastricht. Vanaf 1984 studeerde hij geneeskunde aan de Katholieke 
Universiteit te Nijmegen. In 1988 werd het doctoraal examen afgelegd. Het 
artsexamen werd afgelegd in 1991. 
Van september 1991 tot maart 1992 was hij werkzaam als arts-assistent op 
de afdelingen cardiologie en interne geneeskunde van het Slingeland Ziekenhuis te 
Doetinchem. 
Van maart 1992 tot maart 1996 was hij werkzaam als assistent in opleiding 
op de afdeling Maag-, Darm- en Leverziekten van het Academisch Ziekenhuis St. 
Radboud te Nijmegen (hoofd: Prof. Dr. J.B.M.J. Jansen) waar het onderzoek werd 
verricht dat tot dit proefschrift heeft geleid. 
Sinds 1 maart 1996 volgt hij de opleiding Interne Geneeskunde in het St. 
Maarlensgasthuis te Venlo (opleider: Dr. J.J.J. Mattousch). De opleiding zal vanaf 
april 1997 worden voortgezet op de afdeling Interne Geneeskunde van het 
Academisch Ziekenhuis St. Radboud te Nijmegen (opleider: Prof. Dr. J.W.M, van 
der Meer). Aansluitend volgt de opleiding Gastroenterologie op de afdeling Maag-, 
Darm- en Leverziekten van hetzelfde ziekenhuis. 
Hij is getrouwd met Saskia Gorissen. 
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PHYSIOLOGICAL ASPECTS OF GALLBLADDER MOTILITY 
AND PANCREATIC ENZYME SECRETION IN HUMANS; 
studies on plasma cholecystokinin, intraduodenal bile salts, protease 
activity, and nerve-gut interaction. 
Stellingen 
P.W.L. Thimister, 30 januari 1997 
I Bij de mens is splitsing van voedingseiwit nodig om in de dann de secretie 
van cholecystokinine, de galblaascontractie en de pancreasenzymsecretie te 
stimuleren 
- dit proefschrift -
2 Ti|dens de maaltijd spelen galzouten een belangrijke rol bij het terugkop-
pel ingsmechanisme op galblaas en alvleesklier 
- dit proefschrift -
3 De cholecystokinine producerende capaciteit van de darmmucosa is ook bij 
mensen met coehakie ongestoord 
dit proefschrift -
4 I operamide heeil, naast een remmende werking op de darmmotiliteit, ook 
een temmende werking op de afgifte van gal en pancreasenzymen 
- dit proefschrift -
5 In de interdigestievc fase beïnvloeden porteasen de secretie van de 
alvleesklier onafhankelijk van cholecystokinine 
- dit proefschrift -
6 Met het aanstellen van "zorg-managers" is de voorlaatste fase van 
bureaucratisering in het ziekenhuis volmaakt Belangrijkste aandachtspunt 
voor de beleidsmakers vanaf nu is erop toezien dat ziektes zich manitesteren 
lussen "s morgens 9 en "s avonds 5 uur 
7 Tijdens een gesprek overschakelen op het dialect van de patient werkt ook 
rustgevend voor de dokter 
8 Godsdienstconflicten doen afbreuk aan de geloofwaardigheid van een geloof 
9 Het médicaliserai van alledaagse begrippen voor b ν "overgewicht" heeft 
een grens In dit kader is het handiger bij een -uit de kluiten gewassen 
"Quetelet-index" te spreken van een "kotelet-index" 
10 De speelwijze geelt inzicht in de persoonlijkheid van de nkkei 
- een zelfverzekerde nkker -
11 " Niemand weet hoe laat het is Daarom moeten we dansen en moeten we 
vrijen, moeten we lachen en drinken vol vuur 
- Youp van 't Hek -
12 Beter een trap van het paard dan een kJap van de molen 
een doortrapte amazone 
13 Als mijn beroep een roeping was zou ik van mijn geloot vallen 



